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Summary  
It is increasingly evident that alternative pre- mRNA splicing events (AS) play a profound 
role in tumor progression and metastasis, frequently via the activation of cellular 
processes that can trigger epithelial-to-mesenchymal transition (EMT) program in the 
cells. Alterations in mRNA splicing pattern can arise from altered expression of splicing 
factors as well as interactions with cancer-related signal transductions. 
This study investigated the potential role of key hormones, estrogen and CRH in the 
regulation of pre-mRNA splicing mechanism, and the molecular pathways mediating CRH 
actions in promoting EMT in ER (+) MCF7 and ER (-) SKBR3 breast cancer cell line. 
Estrogen signaling has been reported to be involved in the alternative splicing of specific 
set of genes, and this study found that estrogen can induce the phosphorylation and 
nuclear translocation of a key splicing kinase, SRPK1 via Akt dependent pathway, and 
thus triggers the production of CD44s splice variant.  
Additionally, CRH regulates numerous protein kinases including Akt, therefore the 
effects of CRH on SRPK1 status was also investigated. In this study, CRH was shown to 
modulate SRPK1 activity via similar pathway as E2 did in MCF7 cells, resulted in the 
accumulation of CD44v6 mRNA isoform. Apparently, while this effect of CRH on SRPK1 
was not seen in SKBR3 cells, increased expression of CD44v6 mRNA was detected, 
suggesting that CRH exerted its effects via different pathways in SKBR3 cells. 
Furthermore, increased level of CD44 splice variant, particularly CD44v6 in the 
stimulated cells positively correlated with EMT gene expression Twist/Snail as well as 
the migration and invasion properties of the cells.  
Additionally, EMT gene profiling analysis revealed that in addition to Twist and Snail, 
CRH was able to drive the transcription of several other prominent EMT markers such as 
VIM, TGFB1/2, NOTCH1, MMP9 and Wnt5A when either Akt or SRPK1 kinase was 
inhibited in the cells, thus signifying the potential convergence of CRH signaling pathway 
in the MCF7 cells. Given that the role and the mechanism of E2 and CRH actions in the 
progression of breast cancer are still not fully elucidated, the link between these two key 
12 
 
hormones with alternative splicing events and the activation of EMT in ER+ cells 
demonstrated in this project may contribute considerably to the current understanding 
of breast cancer development and progression.  
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CHAPTER 1  
Introduction  
1.1 The pathogenesis of cancer 
There are more than one hundred different kinds of human cancers that have been 
identified and classified to date. These cancers are categorized into three main groups, 
namely carcinomas, sarcomas and lymphomas/leukemia and further classified according 
to tissue of origin such as lung, breast and colon. Approximately 80% of human cancers 
are shown to belong to carcinomas, a type of cancer which arise from epithelial cells (1). 
Unlike normal cells whose growth is strictly regulated in the organism, cancer cells 
replicate continuously and capable of invading surrounding tissues (malignant/invasive) 
as well as spreading to distant sites (metastasis) through the circulatory system.  
In fact, studies of cancer cells in culture reveal some of the distinct differences in 
the growth requirements and behaviors of cancer cells as compared to normal cells 
under controlled conditions. For examples, normal cells show density-dependent of cell 
growth, whereas tumor cells continue growing regardless of cell densities. In addition, 
cancer cells display reduced dependence on serum growth factors, they can grow 
without attachment to surface (anchorage independence), have the capacity to grow 
indefinitely and to be sub-cultured continuously as well as they can display no contact 
inhibition of movement in a culture dish (2,3). These features suggest that cancer cells 
reprogram their metabolism to promote growth, survival and proliferation, such as by 
displaying an increased rate of glucose uptake (Warburg Effect) to maintain tumors 
growth and viability [reviewed in (4)]. Following this observation, it was later 
demonstrated that the abovementioned abnormalities appeared to be attributed to 
aberrations in the regulatory system which were stably inherited at the cellular level 
18 
 
hence suggesting the involvement of genetic changes and progressive series of 
alteration in the process of tumor development (2,5).  
 
1.1.1 Biology of human cancers 
 
Cancer cells often differ from normal cells in several biochemical properties such as 
secretion of growth factors, increased glycolysis, and secretion of proteases, decreased 
levels of cell surface proteins and disorganization of cytoskeleton. These differences 
might be directly associated with the abnormal growth properties of cancer cells; 
however, it is not clear whether these altered biochemical properties are the causes or 
the consequences of the transformed state of the cells. Therefore, rather than 
comparing the phenotypes of cancer cells and normal cells, many researches have 
focused on understanding the molecular basis of cancers by identifying and studying the 
function of specific genes that can potentially induce cell transformation and abnormal 
cell proliferation, which are also known as oncogenes. These oncogenes are frequently 
found amplified or mutated in cancer cells where in some cases oncogene amplification 
is closely correlated with increased malignancy in tumors (6). This is supported by tumor 
genome sequencing analysis in which more than 10,00 tumor genomes have been 
sequenced and the information generated reveals thousands of mutations and other 
genomic alterations identified in cancer cells (6).  
Apart from increased oncogene expression due mutations or alternative splicing, 
loss of function of a class of genes that function as negative regulators in cancer biology 
can also lead to tumor development. These genes which are commonly called as tumor 
suppressor genes are frequently found inactivated in cancer cells and demonstrated to 
play critical role in the pathogenesis of various human cancers. Studies have revealed a 
growing list of tumor suppressor genes responsible for many inherited cancers, with one 
of the well-studied is p53 gene which is found mutated in nearly 50% of human cancers. 
Apparently, further investigation has shown that both oncogenes and tumor suppressor 
genes could encode for; 1) growth factors such as platelet-derived growth factor (PDGF), 
19 
 
fibroblast growth factors (FGFs), epidermal growth factor (EGF) & transforming growth 
factors (TGF), Wnt family and Interleukin-2/-3 and 2) protein-tyrosine kinases and the 
related cell surface receptors (e.g. EGFR, FGFR),  that are important in signal 
transduction pathways that regulate cell growth as well as allow cells to respond to 
extracellular stimuli (2). Consistently, many studies have reported the role of TGF, 
PDGF and FGF2 as key mediators of activated fibroblast recruitment in many cancers 
which consequently resulting in the increased proliferation of fibroblasts and positively 
correlates with cancer progression [reviewed in (7)]. Nevertheless, non-receptor 
protein-tyrosine kinases (e.g. Src, Jak) and non-tyrosine kinase receptors that can also 
act as oncogenes and propagate signals from growth factors by coupling with 
intracellular targets mediated by family of guanine nucleotide binding proteins (G 
proteins) hence inducing cell growth and proliferation.  
Another molecular alteration found in cancer cells is changes in microRNA 
(miRNA) expression, a small noncoding RNA that negatively regulate protein expression. 
Studies on miRNA expression in tumors have demonstrated global changes in miRNA 
expression in various malignant cancers as compared to their normal counterparts in 
which some of these miRNAs have been identified as either oncogenes (e.g. miR-15, 
miR-17-5p) or tumor suppressor genes (e.g. miR-34, miR-15a) (8,9). miRNA inhibits gene 
expression at the post-transcriptional level by binding to specific messenger RNA 
(mRNA) at specific sequences and forms miRNA/mRNA duplex which then inhibits mRNA 
translation or increases the rate of mRNA degradation in the cells [reviewed in (10)]. In 
vitro studies have shown that upregulation of miR-296 through VEGF and EGF promotes 
angiogenesis and increases migration of endothelial cells, whereas another study in 
murine breast and lung cancer models demonstrates that VEGF triggers the expression 
of miR-10b and miR-196b, both of which are identified as key molecules in angiogenesis 
and tumor progression in these cancers (11).   
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1.2 Breast Cancer 
Population studies show that death cases in developed countries are primarily caused by 
cancer and this trend is slowly followed by developing countries where cancer has now 
become the second leading cause of death (12,13). Globally, it is estimated that breast 
cancer causes more than 400,000 deaths every year and is the second leading cause of 
cancer-related death in women after lung cancer (14,15). Among women in the United 
States only, breast cancer accounts for 1 in 3 cancer cases diagnosed in patients and 
once the tumor has metastasized, the 5-year survival of the patient is approximately 
27% (12,16). Breast cancer begins as local disease but later can acquire the ability to 
metastasize to the lymph nodes and distant sites. Its progression to become metastatic 
is often marked by genomic alterations such as acquired genomic aberrations, changes 
in gene expression, splicing patterns and protein functionality (17,18).  
Although screening technology for diagnosing breast cancer has been improved, 
it can only reduce the mortality rate by offering early treatment to the patient. It is 
generally agreed that chemotherapy has been the most effective treatment for breast 
cancer. However, population studies and meta-analysis show that some tumor cells 
become resistant to chemotherapy and therefore survive the treatment (19). This 
subsequently leads to cancer recurrence and like many other cancers; the main cause of 
deaths in breast cancer cases is linked to metastatic spread of the tumor cells.  
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1.2.1 Pathogenesis of breast cancer 
 
The breast is composed of specialized glandular tissue which includes the ducts 
which terminate peripherally into terminal duct lobular units and supporting connective 
tissue. The epithelial compartment of glandular tissue is bound by a thin basement 
membrane and has two-layer structure with the luminal cells as an inner layer and 
myoepithelial cells as an outer layer. There are several risk factors that have been 
associated with the development of breast cancer in women, which include age, 
lifestyle, family history, reproductive history, endogenous estrogen level, exogenous 
hormone exposure and mutations of tumor suppressor genes such as BRCA1 BRCA2, p53 
and PTEN (20,21). At present, various lines of treatments are used to treat cancer such 
as surgery, radiation therapy, chemotherapy, targeted therapy and hormonal therapy 
(22). 
Currently there are more than 18 subtypes of breast cancers that have been 
identified, in which most breast cancers are carcinoma (epithelial origin) arises from cells 
lining the terminal duct lobular unit of the glandular breast tissue (23). Clinical signs and 
symptoms of breast cancer include mastalgia (breast pain), a change in breast shape, 
dimpling of the skin, nipple discharge and a lump in the breast (24,25). Furthermore, 
there are two important phases in breast carcinoma; in situ phase, which is restricted 
within epithelial compartment thus can be cured by excision, and invasive phase, where 
cells can breach the barrier of the epithelium, infiltrate within the breast connective 
tissues and have the potential to spread and establish at distant sites (metastasis) (26).  
In addition, the ability of breast glandular tissue to increase the number of epithelial 
cells (hyperplasia) in response to physiological stimuli has in some cases contributed to 
the formation of lesions of the breast including benign breast lesion and carcinoma in 
situ. Although there is no evidence about the progression of benign hyperplasia to 
carcinoma in situ, it is crucial to distinguish between hyperplasia associated with benign 
lesions from the ones associated with carcinoma as the progression from in situ to 
invasive carcinoma is already widely accepted (26). In addition to this, carcinoma in situ 
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can be further divided into two types; ductal carcinoma in situ (DCIS) and lobular 
carcinoma in situ (LCIS), with DCIS is more commonly associated with invasive carcinoma 
ductal type and LCIS is associated with invasive carcinoma of lobular type (26). 
 
1.2.2 Molecular subtypes of breast cancer 
 
Generally, breast cancer can be categorized according to the pattern of gene expression 
which defines each of the breast cancer types with distinct biological and clinical 
characteristics. Hormones bind to the receptors on the breast cancer cells surface or in 
their cytoplasm and nucleus resulting in the changes in the cells. Therefore, breast 
cancers are often classified according to the status of human growth factor-neu receptor 
(HER2) and hormone receptors (HR) such as estrogen receptors (ER) and progesterone 
receptors (PR). There are four molecular subtypes of breast cancer; Luminal A (HR+, 
HER2-), Luminal B (HR+, HER2+), HER2+ and triple negative (ER-, PR-, HER2-)(27–31). 
Although triple negative cancers do not express any of these receptors, they often 
express receptors for other hormones such as androgen and prolactin [reviewed in (32)].  
The status of ER and PR is usually assessed by immunohistochemistry, in which 
at least 1% of tumors cells needs to show positive nuclear staining to be interpreted as 
ER or PR positive, and if the tumor staining result shows less than 1%, it is considered as 
receptor negative (33). The cutoff of 1% is chosen to define receptor positivity because 
hormonal therapy can be benefited by the patient with even 1% of ER/PR- positive 
tumors (21). Meanwhile, approximately 10% to 34% of invasive breast cancer show 
overexpression or amplification of HER2, a proto- oncogene responsible for the 
production of transmembrane tyrosine kinase growth receptor and is found involved in 
various regulatory pathways related to proliferation, survival, motility and invasion in 
breast (21). HER2 overexpression is also associated with the increased translation of 
fatty acid synthase (FASN), which subsequently increases EGFR and HER2 signaling hence 
resulting in cell growth and poor prognosis in HER2-amplified breast cancer cells (34). 
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Meanwhile, annual reports on the status of cancer in the united states shows that 
HR+/HER2- breast cancer subtypes is the most common subtype, representing 72.6% of 
all cases, nearly six times higher than triple-negative (TN), seven times higher than 
HR+/HER2+ and 16 times higher than HR-/HER2+ breast cancer rate (35).  
 
1.2.3 Triple Negative (TN) breast cancer 
 
Triple negative breast cancer accounts for approximately 15% of all invasive breast 
cancers and is defined as tumors that do not express estrogen receptor (ER), 
progesterone receptor (PR) and HER2. As this type of breast cancer lacks the 
abovementioned receptors, patients with triple negative tumors often show worse 
prognosis as compared to luminal breast cancers. Since endocrine therapy or HER2- 
targeted therapy cannot be prescribed on them, therefore there is no standard form of 
chemotherapy for the treatment of triple negative breast cancer at present [reviewed in 
(36)]. It is reported that more than 75% of women carrying breast-cancer susceptibility 
gene mutation, BRCA1 are showing triple-negative breast cancer phenotype (37,38). In 
addition, analysis of triple negative breast cancer cells profile demonstrates that these 
cancer cells have high expression of aldehyde dehydrogenase 1 (ALDH1A1) and the cells 
also display cell surface marker CD44high CD24low  (CD44+CD24-), which is used to 
characterize breast-cancer stem cells (39). Apart from that, triple negative tumors also 
have high rate of tumor suppressor, p53 gene mutations which further contributes to 
their enormous aggressiveness (40). Currently, one of the promising treatment to treat 
triple negative tumors is the poly-ADP ribosepolymerase-1 (PARP-1) inhibitors, which 
together with the defect of BRCA1 DNA repair gene in these tumors would lead to cell 
death due to accumulation of breaks in the double- stranded DNA.  
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1.2.4 HER2+ breast cancer 
 
Human epidermal growth factor receptor (HER) family is located at the cell membrane 
and consists of four members; HER1 (epidermal growth factor receptor, EGFR/erbB1), 
HER2 (neu, c-erbB2), HER and HER4 with all these receptors have intracellular tyrosine 
kinase domain except HER3. To date, natural ligand for HER2 is not yet known but there 
are several ligands identified for HER1, HER3 and HER4 such as transforming growth 
factor-a (TGFa) and epidermal growth factor (EGF) [reviewed in (41)]. The binding of 
ligand to HERs causes auto-phosphorylation of specific tyrosine residues within the 
catalytic kinase domain of these receptors which in turn serves as docking site for 
phosphotyrosine-binding domain- and src-homology 2-containing proteins, linking ErbB 
receptors to MAPK and PI3K pathways (42–44).  
As compared to hormone-positive breast cancer, HER2+ breast cancer cells tend 
to be more aggressive and the treatment for HER2+ metastatic breast cancer is reported 
to be challenging as studies show that approximately 50% of patients develop brain 
metastasis [reviewed in (45)]. HER2 overexpression which is characterized by HER2 gene 
amplification (located in the 17q12 chromosome) and other genes associated with the 
HER2 pathway, accounts for 18-20% of all breast cancers is often used as a marker to 
select patients for anti-HER2 therapy such as trastuzumab for HER2+ metastatic breast 
cancer (33,46,47). In addition, more than 40% of HER2+ tumors show mutation in one of 
the prominent tumor suppressor gene, p53 (48).    
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1.2.5 Hormone- sensitive breast cancer 
 
Endocrine responsiveness in most of the hormone-sensitive breast cancers is 
predominantly dependent on the presence of a functional estrogen receptor (ER), a 
protein that regulates hormone-dependent growth of hormone receptor positive (HR+) 
breast tumors and is detected in approximately 50%-80% of all breast tumors (49). 
Studies in animal models have demonstrated the role of estrogen as a key hormone in 
breast cancer development as administration of estradiol (E2) in animal models induces 
breast cancer. This is parallel with other reports in which the level of estrogen has been 
shown to positively correlate with the increasing risk of breast cancer in women (50,51).  
Mutations are more commonly reported in hormone responsive breast cancer 
cell. This is shown by accumulating evidences that the resistance of ER+ breast cancer 
cells with PIK3CA-mutated tumors to therapy such as aromatase therapy is associated 
with mutations in ESR1, gene that encodes for estrogen receptor alpha (ER) (52), 
mutations that recently have also been reported in metastatic ER+ breast cancer tissues 
(53).  Furthermore, apart from receptor mediated-effects that cause cell proliferation- 
induced mutations triggered by estrogen, estrogens can act as mutagenic agents to 
breast tissue via mechanisms independent of ER, by causing estrogen-induced mutations 
which subsequently result in the development of breast cancer (Figure 1.1).  
Meanwhile in another study, it is demonstrated that the ratio between ER/ER 
in breast cancer cells affects the pattern of pre-mRNA maturation and the splicing of 
biologically active estrogen-dependent genes which regulate apoptosis, cell signaling, 
protein ubiquitination and mRNA maturation and translation (54). Several variants of 
ERs which include truncated isoforms of ERs (ER66, ER46, ER36) have been 
identified in breast cancer which are implicated in the development of endocrine 
therapy in ER+ tumors [Reviewed in (55)]. Studies in ER+ MCF7 breast cancer cells show 
that overexpression of ER66 leads to cell proliferation and can potentially contribute to 
cancer development and progression thus highlighting the role of aberrant splicing 
which tends to occur in ER+ breast cancer [Reviewed in (56)]. Furthermore, the 
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complexity of estrogen receptor signaling is suggested to be attributed to the interplay 
of kinase networks involved in pathways associated with cancer hallmarks in ER+ breast 
cancers [reviewed in (57)].  
 
 
Figure 1.1 Diagrammatic representation of the effects of estrogen to breast tissue that 
can give rise to breast cancer via ER- dependent pathway (Left) such as through cell 
proliferation-induced mutations triggered by estrogen, and de novo cancer formation 
via non-genomic pathway that leads to estrogen-induced mutations (Right) [Adapted 
from Yue et al, 2013 (58)]. 
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1.2.5.1 Steroid Hormones  
 
Steroid hormones are derived from cholesterol and thus are structurally similar to it 
(Figure 1.2). Steroid hormones are produced in three endocrine organs that are 
specialized in steroid hormone production: adrenal cortex, ovary and testis, and during 
pregnancy, placenta also serves as additional major source of steroid hormones.  
Generally, steroid hormones are divided into five groups; mineralocorticoids, 
glucocorticoids, estrogens, progestins and androgens. They are distinguished by their 
physiological behavior and actions on specific steroid hormone receptors which are 
intracellular transcription factors, and subsequently regulate transcription of target 
genes and protein synthesis (59). In addition, second messengers such as cAMP, induced 
by peptide agonists have been shown to be able to modulate steroid-induced nuclear 
transcription by an intracellular cross-talk (60). In fact, studies have also shown that this 
cross-talk can take place without the presence of steroid ligand, for instance, estrogen 
receptor (ER)  can be activated by epidermal growth factors (EGF) via MAPK pathway 
(61). In addition to genomic steroid actions, rapid nongenomic effects of steroid 
hormones via membrane receptors involving second messenger cascades such as 
protein kinase C (PKC) have also been described in many studies [reviewed in (62)]. 
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Figure 1.2 An illustration of steroid hormones structure. As cholesterol is the parent 
compound from which steroids are derived, their structures are similar to cholesterol 
with four fused rings as core structure. Adapted from (63). 
 
1.2.5.2 Estrogen Biosynthesis  
 
Estrogen is a female sexual hormone and a drug of choice in treating menopausal 
symptoms in women. This steroid hormone is a key regulator of growth and 
differentiation in various target tissues such as in the male and female reproductive 
tracts, mammary gland, skeletal and cardiovascular systems. Although estrogens are 
primarily produced in the ovaries, they can also be produced by other organs such as 
heart, skin, liver and brain (64). While E2, or 17- estradiol is the major product from 
estrogen biosynthesis process, there are two other forms of estrogen; estrone (E1) 
which plays role mostly after menopause, and estriol (E3), the least potent estrogen that 
plays a larger role during pregnancy. The synthesis of estrogen in the body is regulated 
by aromatase, an enzyme that is responsible for the last step in the E2 synthesis and in 
which its expression in tissue relies on three major factors; alternative splicing 
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mechanisms, different transcription factors and tissue-specific promoters (65–67). In 
addition, the synthesis of estrogen is different in reproductive women and non-
reproductive women. Estrogen synthesized in extragonadal sites such as kidney and 
adipose tissue mostly functions as paracrine/intracrine factor and act locally to maintain 
tissue specific functions (68). Whereas, ovarian-synthesized estrogen in reproductive 
women is released into the bloodstream where its level is dependent upon the 
reproductive status of the individual.  
 
1.2.5.3 Estrogen Signaling 
 
The physiological actions of estrogen involve complex cellular/molecular mechanisms 
that can be classified into two different pathways; genomic signaling (ligand-dependent, 
ligand-independent, DNA response elements ERE- independent) which leads to the 
transcription of downstream target genes and non-genomic signaling (cell-surface ER 
forms) which does not involve any transcriptional activity in the nucleus (69,70). 
 In the ligand-dependent pathway, estrogen exerts its effects predominantly 
through two distinct intracellular receptors, estrogen receptor alpha (ER) and estrogen 
receptor beta (ER), that show a high degree of homology specifically at the DNA-
binding domain (97%) and ligand binding domain (60%) (Figure 1.3) (69,71). As for the 
ligand- independent pathway, the function of ER can be modulated by extracellular 
stimuli such as epidermal growth factor (EGF) and insulin-like growth factor 1 (IGF-1), in 
the absence of estrogen and eventually elevate the expression of ER target genes (72). 
Meanwhile, in the ERE-independent action of estrogen, estrogen-ER binding alters 
transcription of genes through the interaction with other DNA-bound transcription 
factors (Fos/Jun) and AP-1 binding site of the target genes (69) (Figure 1.4). 
 On the other hand, the non-genomic effects of estrogen can be mediated 
through membrane-associated binding site, possibly a form of ER that is linked to 
intracellular signal transduction proteins such as tyrosine-kinase protein which is 
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associated with MAPK signaling pathway activation that may promote proliferative and 
anti-apoptotic effect of estrogen in the target cells (69,73–75). In addition, estrogen is 
also reported to activate phosphoinositide 3-kinase (PI3K) signaling, a major pathway in 
the regulation of aerobic glycosylation in proliferating cells (76,77). While the tumor -
promoting role of estrogen has been demonstrated to be mediated predominantly by 
ER, recent studies have reported the substantial role of ER in promoting cell 
proliferation and invasion independently of estradiol in ER-negative (MDA-MB-435 
cells), in vitro. In addition to this, in vivo studies in ER+ MDA-MB-435 cells also showed 
that as compared to control cells, the growth rate of these ER+ cells were higher with 
more pulmonary metastasis detected (78). This finding indicates the importance of 
ER/ERratio in cells for the ER to exert its effect in breast cancer development.  
 
 
 
Figure 1.3 Comparison of ER and ER structures and homology. There are three major 
modular domains of ERs; an A/B domain, a DNA binding domain (DBD) and a ligand 
binding domain (LBD). While ERcontains more amino acids (595) than ER(530), their 
DNA binding domains show almost perfect homology whereas their least identical 
domain is at the A/B and LBD which contains Activation Function, AF-1 and AF-2 binding 
domain respectively which are responsible for regulating gene transcription. [Adapted 
from Leitman et al, 2010 (71)]. 
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Figure 1.4 Proposed model of estrogen actions through genomic and non-genomic 
pathway. Genomic pathways (highlighted in yellow) lead to the transcription of target 
genes whereas non-genomic pathway (in red) causes rapid effects through cell surface 
receptor and triggers responses in target tissues [Adapted from Hall et al, 2001 (69)].  
 
Emerging evidence also suggests the involvement of a G protein-coupled 
receptor, G protein-coupled estrogen receptor (GPER/GPR30) has been reported in 
breast cancer development as it is demonstrated to mediate both genomic and non-
genomic effects of estrogen (79,80). The upregulation of GPER expression in breast 
cancer cells has been shown to cause the activation of yes-associated protein 1 (YAP) 
and transcriptional coactivator with a PDZ-binding domain (TAZ), both of which are 
required for GPER-induced gene transcription, cell proliferation and migration in breast 
cancer (81). In addition, TAZ is often found overexpressed in metastatic breast cancer 
and is shown to play role in the self-renewal and tumor initiation capabilities of breast 
cancer stem cells (82). In addition, accumulating evidence suggests that mutations in the 
gene encoding for ER, ESR1 is one of the contributing factors in the development of 
endocrine therapy- resistance in ER- positive breast tumors. These mutations, which 
are frequently identified in metastatic breast tumors, enable tumor cells to evade 
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hormonal treatments by inducing activation of estrogen receptor in the absence of 
hormone (55).  
 
1.2.6 Breast cancer signaling pathways 
 
Research on signaling pathways governing the process of tumors formation has allowed 
better understanding on cancer biology which in turn provides valuable information for 
the development of new targeted therapies. The study on molecular biology of breast 
cancer reveals interconnection of multiple signaling pathways which include PI3K/AKT, 
MAP kinase signaling, p8 kinase, JNK kinase, JAK/STAT signaling pathway, transforming 
growth factor beta (TGF), Notch, Wnt and NF- signaling. However, a plethora of 
studies has shown that cellular transformation, tumorigenesis, cancer progression and 
drug resistance in breast cancer are frequently associated with alterations in 
phosphoinositide 3-kinase (PI3K/AKT) pathway [Reviewed in (83)]. In addition, 
alterations in this signaling pathway are found to be particularly common in ER-positive 
breast cancer (45% in luminal A, 30% in luminal B)(84).  
 
1.2.6.1 PI3K/AKT 
 
Among all the classes in PI3K families, class IA PI3Ks is the predominant class implicated 
in cancer. Class IA PI3Ks consist of a p85 regulatory subunit and a p110 catalytic subunit 
which are responsible in mediating signals from growth factor receptor tyrosine kinases 
(RTKs) such as EGFRs, HER2, IGF-IR and FGFR. The binding of these growth factors results 
in the recruitment of p85-p110 complex to the lipid phosphatidylinositol PIP2 at the 
plasma membrane, followed by phosphorylation of phosphatidylinositol-3,4,5-
trisphospate (PIP3) by PI3K (p110) (85). PI3K signaling is negatively regulated when PIP3 is 
dephosphorylated by PTEN and INPP4B, whereas  the signaling pathway will lead to 
protein synthesis, RNA translation, cell growth and autophagy when proteins such as 
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AKT and PDK1 bind to PIP3 leading to phosphorylation of AKT involving PDK1 and 
mTOR/Rictor complex [reviewed in (86)].  
The highly proliferative property of cancer cells demonstrates that there is 
dysregulation in the cellular metabolism, cytoskeletal rearrangement, survival and 
growth control (87). One of the pathways that control these cellular processes is the 
PI3K/AKT pathway, one of the most frequently altered signaling pathways in human 
cancer (Figure 1.5). These alterations include the loss of lipid phosphatases PTEN and 
INPP4B and mutation/amplification of genes encoding the PI3K catalytic subunits (e.g. 
p110a/PI3KCA), the PI3K regulatory subunits (e.g. p85a/PI3R1) and the PI3K effectors 
(e.g. AKT1, AKT2, AKT3 and PDK1) [reviewed in (88)]. Mutations in PI3K pathway are also 
reported in 20-25% of the breast cancers studied with ER+ breast cancer shows the 
highest percentage of nearly 35% (89). PI3K is also demonstrated to directly and 
indirectly interact with estrogen receptor (ER) leading to the phosphorylation of ER and 
thus increasing the ligand-independent ER transcription in breast cancer cells (86). In 
addition, uncontrolled activation of PI3K pathway is thought to be responsible for the 
cells resistance to anti-estrogen treatment in ER+ breast cancer cells and the mutations 
in this pathway is also associated with resistance to anti-HER2 drugs (90,91). 
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Figure 1.5 PI3K/AKT signaling pathway. Signals from receptor tyrosine kinases (RTKs) 
such as EGFR, HER2, IGF-IR and FGFR are mediated by p85 and p110 regulatory subunit 
of PI3K. Mechanisms of altered PI3K/AKT activation include the loss of PTEN and INPP4B 
lipid phosphatases and mutation or overexpression of p85 and p110 subunits and PI3K 
effectors, AKT1/2/3 which can result in increased protein synthesis, proliferation and cell 
survival. [Adapted from Mayer and Arteaga, 2016 (86)]. 
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1.3 Corticotropin- Releasing Hormone (CRH) & CRH-related 
peptides 
 
Corticotropin-releasing hormone (CRH) family peptides are 41-amino acid residues 
encoded by CRH gene that involve in the stress response and functions primarily in the 
stimulation of pituitary adrenocorticotropic hormone (ACTH) in hypothalamic-pituitary-
adrenal axis (HPA) (92). CRH sequence homology between human, mouse, rat and 
others are approximately 76-95% with its mRNA distributed mainly in the brain and also 
detected in other organs such as the retina, stomach, intestine, spleen, lung and gonads 
(93). CRH family peptides consist of CRH, Urocortin (Ucn), Urocortin 2 (Ucn2) and 
Urocortin 3 (Ucn3), and their actions are mediated by specific seven transmembrane 
domain (7 TMD) G-protein-coupled receptor (GPCRs). While CRH is responsible for 
initiating stress response to stress, urocortins play substantial role in the recovery 
response to stress.  
In the anterior pituitary, CRH stimulates the synthesis and processing of 
proopiomelanocortin (POMC) to generate adenocorticotropin hormone (ACTH) and its 
secretion into the systemic circulation which in turn stimulates the synthesis and the 
release of glucocorticoids (94). Apart from that, CRH also has several other physiological 
functions such as suppression of food intake, regulation of body temperature, growth, 
metabolism and reproduction. Recent findings demonstrate that peripheral CRH-related 
peptides can act as pro-inflammatory factors (95). In addition, studies on CRH effects in 
human and mice have also reported that abnormal elevation of CRH and modification to 
CRH system are often associated with human stress-related disorders such as anxiety, 
sleep disruption, depression and adverse changes in cardiovascular, metabolic and 
immune function (96–98). Peptides of the CRH family and their receptors have been 
detected in several cancer cells such as human renal carcinoma (99), tumorous 
adrenocortical cells (100), human endometrial, prostate, ovarian and breast cancer cells 
(101–105) and several lines of evidence have suggested that CRH has dual roles 
depending on tissue types. CRH and Ucn 1 have been demonstrated to inhibit the 
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human endometrial adenocarcinoma growth (101), and hepatocellular carcinoma 
growth and angiogenesis (106), respectively. On the other hand, dermal fibroblasts 
deficient of CRH has shown higher proliferation and migration rates as compared to the 
wild type cells (CRH+/+) (107).  
 
1.3.1 CRH Receptors 
 
Three types of CRH receptors have been identified; type- 1 (CRHR1) and type- 2 (CRHR2) 
which share 70% homology at the amino acid level (108,109) are present in mammals, 
chicken, xenopus and teleost, whilst type-3 (CRHR3) is found in catfish (93). In mammals, 
gene coding for CRHR1 consists of 13 exons and 12 introns whereas CRHR2 gene consists 
of 12 exons and 12 introns, and three splice variants (CRHR2, 2 and 2) (93). Both 
CRH and Urocortin 1 bind to CRHR1 with higher affinity while CRHR2 exhibits low affinity 
to CRH but high affinity to other CRH-related peptides such as Urocortin1, Urocortin 2 & 
3 (92). In addition, the actions of CRH-like peptides have been shown to be modulated 
by a CRH-binding protein (CRH-BP), which circulates in blood and is detected in the brain 
of some species (110) (Figure 1.6).  
These CRH receptors belong to the class B1 subfamily of seven transmembrane 
(TMD7), secretin type G protein-coupled receptors (GPCRs). GPCR is activated when an 
agonist binds to and promotes interaction with heterotrimeric G protein (G) hence 
triggering guanine nucleotide exchange and separation of G subunit from G subunits 
(111), followed by initiation of downstream responses upon the interaction between G 
protein subunits and variety of effectors and second messenger pathways such as 
enzymes and ion channels (112). G protein signaling is strictly controlled by the family of 
regulator of G protein signaling (RGS) proteins that function as GTPase activating 
proteins (GAPs) on the  subunits of the Gi and Gq subfamilies of heterotrimeric G 
proteins to facilitate the termination of downstream signaling by the G and G 
subunits [reviewed in (113)]. In addition, the activation of G protein is terminated by 
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desensitization mechanism such as phosphorylation of receptors by GPCR kinases (GRKs) 
followed by recruitment of - arrestins (arrs) to the phosphorylated receptor (114), 
which engages the phosphorylated C-tail and transmembrane core of the receptor, an 
interaction that leads to overlapping with the G protein-binding site and thus prevent 
further G protein activation (115–117).  
 
 
Figure 1.6 Corticotropin-releasing hormone (CRH) system showing CRHR1 and CRHR2 
receptors and their splice variants. CRH binds with high affinity to CRHR1 but with low 
affinity to CRHR2. Urocortin 1 can bind to both receptors and Urocortin 2 & 3 bind to 
only CRHR2. [Adapted from Im, 2014 (118)].  
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Upon the binding of CRH to the CRHRs, the structural confirmation of these 
receptors would change and thus resulting in the signals being transduced across the cell 
membrane (109). The stimulation of CRHRs by CRH and CRH-related peptides induces 
activation of adenylyl cyclase via Gs protein-coupled with CRHRs, which increases cAMP 
levels (119,120). Increased production of cAMP activates protein kinase A (PKA) which in 
turn phosphorylates downstream effectors in cytosol and nucleus such as CREB, c-fos 
and Nur77, thus inducing POMC gene transcription. Even so, this activation of adenylyl 
cyclase signaling pathway is believed to be tissue-specific as this pathway activation is 
not seen in certain tissues, instead CRH is shown to activate alternative signaling 
cascades suggesting that CRH and CRH-like peptides can trigger different responses in 
target tissues (121,122). CRH has been shown to activate extracellular signal-regulated 
kinase (ERK1/2) via a PKA CamKII- dependent pathway that activates Nur77 
transcriptional activity (123) (Figure 1.7).   
 
39 
 
 
Figure 1.7 CRH binds to CRHR1 and activates PKA which subsequently triggers two main 
transduction pathways; (1) Calcium-independent pathway. (2) Calcium-
dependent/CAMKII pathway. MAPK pathway can be activated via calcium-dependent 
and – independent which involves Rap-1, Raf, MEK and ERK1/2 that can lead to 
increased transcriptional activity of transcription factor Nur77. In addition, PKA can 
activate CREB thus eventually regulate the expression of POMC. [Adapted from Refojo & 
Holboer, 2009 (124)]. 
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1.3.2 CRH and Cancer 
 
Variations of the CRHR1 gene have been reported as one of the risk factors for 
depression after childhood maltreatments (125,125,126) and CRHR1 polymorphism is 
associated with recurrence in major depressive disorder (MDD) and is found to mediate 
irritable bowel syndrome (IBS) (127,128). Whereas, polymorphism and gene variation in 
CRHR2 can attenuate stress response thus reducing symptoms of PTSD disorder in 
women (129). In addition to this, several studies have demonstrated the potential of 
CRH receptors in modulating various intracellular protein kinases such as protein kinase 
A (PKA), protein kinase B (PKB/Akt) and p42/p44 and p38 mitogen activated protein 
kinases (MAPKs) [reviewed in (109)]. As one hypothalamic factors mediating behavioral 
and neuroendocrine responses to stresses, CRH has been detected in a stress 
environment such as in tumor microenvironment, thus influencing cancer progression.  
The presence of CRH family peptides and their two corresponding CRHR1 and 
CRHR2 in various human cancers, for examples malignant melanomas and small-cell lung 
cancers as well as in endocrine-related cancers such as breast cancer and prostate 
cancer has also been previously reported (130–135). Besides, genomic studies have 
reported approximately 20% of human cancers show mutations in GPCRs suggesting the 
important role of GPCR in cancer biology (136). At present, CRH has been shown to play 
both promoting and inhibitory roles in tumorigenesis. CRH receptors have been shown 
to modulate inflammation and tumor growth, for example in mouse model of colitis-
associated cancer (CAC), CRHR1 has been demonstrated to induce tumorigenesis and 
regulate colon cells survival and proliferation through NFB and STAT3 signaling 
pathways (137).  In addition, CRH and Ucn2 has been shown to induce migration of RM-1 
prostate cancer cells through CRHR1 and CRHR2 (138). The role of CRH and Fas ligand 
(FasL), a protein that plays significant role in promoting tumor cells’ counter attack 
towards immune cells thus favoring tumor survival and progression, has been shown in 
ovarian carcinoma (105). Furthermore, studies also showed that CRH upregulated 
MMP2 and MMP9 levels in Ishikawa cells hence enhancing migration and invasion 
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properties of the cells (139). In addition, its tumor-promoting effects has been reported 
in hormone-responsive MCF7 breast cancer cell line where it was shown to promote cell 
motility and invasiveness (104).  
On the other hand, inhibitory roles of CRH have also been reported in various 
tumors. The anti-proliferative effect of CRH has been previously reported in human 
endometrial adenocarcinoma and human mammary cancer cells (101,140). In addition, 
it has also been demonstrated that CRH, via CRHR1 inhibits human breast cancer cell 
growth and invasion in a concentration-dependent manner (103), and that the biological 
activity of CRH may be regulated by estrogen in which estrogen was shown to increase 
the abundance of CRHR2 and CRHR1 splice variant, CRHR1 (∆12) mRNA which 
subsequently prevents the inhibitory effect of CRHR1 on cell invasion in ER+ breast 
cancer cells (141). Furthermore, CRH was also shown to promote apoptosis in ER+ breast 
cancer cell line, MCF7 (134), and inhibit TGF1 – mediated MCF-7 cell migration via 
CRHR1/R2, and the inhibition in MDA-MB-2331 was demonstrated via CRHR2 (142).  
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1.4 Alternative Splicing (AS) 
In the mature mRNAs, introns are excised from the pre-mRNAs transcript by the process 
of alternative splicing (AS). This splicing event regulates gene expression mechanism to 
generate greater protein diversity from a single gene and is tightly regulated by splicing 
regulatory proteins in a cell- or tissue- specific manner, and at different developmental 
stages (143–145). Splicing regulatory proteins which are also known as spliceosomes 
comprise of five types of small nuclear ribonucleoprotein (snRNP; U1, U2, U4, U5 and 
U6) and at least 150 of additional proteins that control the process of intron excision and 
exon joining in pre-mRNA splicing process (146). AS commonly consists of either 
included or skipped of single cassette exon in the spliced mRNAs which can potentially 
produce protein isoforms with diverse functions such as in protein-protein interactions 
and post-translational modifications [reviewed in (147)]. However, there are other types 
of AS which include alternative 5’ or 3’ splice sites that produces short or long forms of 
an exon, mutually exclusive exons and intron retention (Figure 1.8).  
The mechanism of actions of two main regions in pre-mRNA transcript; exonic 
splicing silencer (ESE) and intronic splicing enhancer (ISE) involve the binding of 
regulatory proteins such as SR proteins (serine/arginine-rich proteins) or heterogeneous 
nuclear ribonucleoproteins (hnRNPs). In addition, certain splicing silencers form a pre-
mRNA secondary structure that blocks the activity of SR proteins in recognizing the 
splicing enhancer sequence on pre-mRNA transcript (148).  
Recently, mutations have been revealed to play roles in the disruption of 
canonical splice sites or abolishment the splicing enhancers and silencers function 
leading to the production of aberrantly spliced mRNA or failure to a functional protein 
resulting in the pathogenesis of diseases such in tumor development and progression. 
Mutations in splicing elements of susceptible genes such as LKB1, KIT, CDH17, KLF6, 
BRCA1 and alterations in splicing regulators that affect Ron, RAC1 and CD44 gene 
expression have been detected in cancers (148).      
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Figure 1.8 Different types of alternative splicing generate several combinations of exons 
in mature mRNA transcripts. Green boxes indicate constitutive exon sequences, blue 
arrow indicates alternative regions and red arrows indicate alternative splice patterns 
that can take place. [Adapted from Srebrow & Kornblihtt, 2006 (148)]. 
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1.4.1 Alternative splicing in cancer 
 
Although there are several other regulatory checkpoints in the gene expression pathway 
such as polyadenylation of mRNA precursor and translation, alteration in alternative 
splicing (AS) can cause the most profound impacts of all. Given that approximately 90% 
of human genes undergo AS, its deregulation can influence the downstream profile of 
various genes important in cell developmental programs and consequently causes 
diseases including cancer.  
 Alternative splicing in cancer usually can contribute to tumor survival, 
proliferation, invasion and metastasis due to aberrant expression of mRNA transcripts. 
An example of this is the alternative splicing of 5’ splice sites of exon 2 in the BCL-X gene 
that produces two variants that oppositely regulate cell death (149). In addition, studies 
in human breast, colon carcinoma and colorectal adenocarcinoma cells have shown that 
accumulation and overexpression of alternatively spliced protein isoforms such as ∆Ron 
and Rac1b are sufficient to transform cells in culture (150,151). In fact, ∆Ron which 
skipped the exon 11 of the original pre-mRNA transcript has also been identified to 
induce invasive phenotype of human gastric carcinoma (152).  
Furthermore, dysregulation of cancer-related signal transductions such as the 
Ras-PI3K-AKT pathway can also contribute to alterations of splicing patterns in cells 
(Figure 1.9). This pathway has been reported to trigger changes in the activity of SR 
proteins, particularly SF2/ASF and 9G8 as AKT has been demonstrated to phosphorylate 
these SR proteins in vitro (153,154). In addition, the activity of another SR protein, 
SRp40 can be affected by the induction of this pathway by insulin, resulting in the 
inclusion of alternative exon in protein kinase C (PKC) II pre-mRNA (155,156). Besides, 
Ras- dependent pathway is also implicated in the regulation of CD44 (157), one of the 
most studied alternatively spliced genes in cancer, whose splice variants correlate with 
tumor development and metastasis (158,159). The regulation of exon 5 alternative 
splicing in CD44 is shown to be dependent on the activity of nuclear RNA-binding 
protein, Sam68 which is phosphorylated by ERK after the induction by phorbol-ester in 
T-lymphoma cells. Furthermore, another Ras-dependent co- activator SRm160, a factor 
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that promotes cell invasiveness has also been identified to trigger inclusion of exon 5 in 
CD44 in HeLa and 293T cells (160).  
 
   
 
Figure 1.9 Mutations and Activation/Deregulation of signaling pathways such as Ras-
PI3K-AKT can lead to changes in the activity of splicing factors thus causing alterations in 
the splicing of oncogenes such as Ron, Rac1, BRCA1 and CD44 hence promoting 
tumorigenesis and cancer metastasis. [Adapted from Srebrow and Kornblihtt, 2006 
(148)].  
 
 
A number splicing alteration that promote cell growth and survival has been 
identified in ER+ and ER- breast cancers, which among the well- studied genes are ER, 
HER2 and CD44. Aberrant splicing of ER1 locus leads to the generation of a splice variant, 
ERa36 that regulates non-genomic estrogen signaling pathways and subsequently 
resulting in 4-hydroxytamoxifen resistance in breast cancer cells (161). In addition, 
∆16HER2 which lacks exon 20 of HER2 has been identified in 9% of HER2-amplified 
breast cancer and shown to confer endocrine therapy- resistance in HER2 positive breast 
cancer (162,163). Whereas, alternative splicing of CD44 gene can produce several 
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isoforms such as CD44s and CD44v, in which although both have been implicated in the 
development of breast cancer, CD44v is found to be more associated towards better 
prognosis in hormone-responsive breast cancer, while CD44s is more commonly found 
in HER2+ or metastatic breast cancer cells (164).  
 
1.4.2 Serine-Arginine Protein Kinase 1 (SRPK1) 
 
There are three classes of splicing kinases in human which include the serine-arginine 
protein kinases (SRPK1/2/3), the CDC-like kinases (CLK1/2/3/4) and the pre-mRNA 
processing factor 4 kinases (PRP4K) with each has distinct cellular localization based on 
their different roles in splicing regulation (165). The PRP4K is a lesser-known splicing 
kinase and shown to regulate spliceosome assembly through the phosphorylation of 
splicing factors PRP6 and PRP31, whilst CLK1 and Serine-Arginine protein kinases (SRPKs) 
family are responsible for the phosphorylation of serine residues in SR protein.  
SRPKs family comprises of more than 50 members that have been detected in 
the genomes of mammals, fungi, insects, nematode and plants (166). Most of the 
functional studies on mammalian SRPKs were based on SRPK1, which is one of the first 
protein kinases to be studied in literature, followed by SRPK2 and SRPK3 which were 
identified based on sequence homology with SRPK1 (167). While the functions of SRPK1 
and SRPK2 are in the regulation of SR proteins distribution through phosphorylation, 
SRPK3 has been identified to be involved in normal muscle growth and homeostasis 
(167,168).  
SRPK1 is a 92kDa SR protein kinase found in the cytoplasm of most cell types and 
tissues that act as downstream AKT target for transducing growth signal from cell 
surface to the nucleus (169). It is anchored in the cytoplasm by networking with 
chaperones and is thought to be the key splicing regulator in the alternative splicing 
mechanism (170). Zhong et al demonstrated that SRPK1 binds to the co-chaperones 
Hsp40/DNAjc8 and Aha before interacts with major molecular chaperones Hsp70 and 
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Hsp90 in the cytoplasm (171). Following this, SRPK1 dissociates from these chaperone 
complexes which can be triggered by many factors such as stress signal, and translocates 
to the nucleus and initiate SR proteins phosphorylation and alter the splice site of target 
mRNA (171).  
Cytoplasmic SRPK1 phosphorylates RS domain of serine arginine-rich (SR) 
proteins that induces them to relocate back to the nucleus where they can influence 
splice site usage for alternative splicing (172–174). Studies show that additional 
phosphorylation is required to recruit the already phosphorylated SR proteins in the 
nucleus to nascent pre-mRNA transcript and this second phosphorylation is mediated by 
CLK1 (175). These sequential phosphorylation events are proposed to be regulated by 
two factors; distinct cellular localization of the kinases (SRPK1 can be found in both 
cytoplasm and nucleus, CLK1 in nucleus only) and substrate specificity of the splicing 
kinases. For example, cytoplasmic SRPK1 phosphorylates the Arg-Ser repeats (RS1) at N-
terminal of splicing protein SRSF1, whereas CLK1 phosphorylates Ser-Pro repeats (RS2) 
at C- terminal of SRSF1 (Figure 1.10) (173,176). Recently, studies have suggested that 
after binding to SR proteins to phosphorylate them, CLKs may require a release factor 
that can unleash them from the phosphorylated SR proteins to make it fully functional 
and SRPK1 is shown to function as release factor for CLK1 (Figure 1.11) (177,178).  This 
therefore indicates that SRPK1 and CLK1 interact and work synergistically, rather that 
competitively, in phosphorylating RS domain of SR proteins and thus promoting 
spliceosome assembly in the nucleus (179).  
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Figure 1.10 SRPK1 phosphorylates SR proteins in the cytoplasm hence induces SR 
proteins shuttling into the nucleus. CLK1 mediates additional SR proteins 
phosphorylation and promotes theirs release from splicing speckles to nascent pre-
mRNA transcript. Once splicing completed, SR proteins bound to mRNA are 
dephosphorylated by nuclear phosphatases (PP1/PP2A), resulting in the recycling of the 
SR to the cytoplasm for the translation regulation or re-phosphorylated by SRPKs for the 
next round of splicing. [Adapted from Corkery et al, 2015 (165)]. 
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Figure 1.11 SRPK1 and CLK1 works in a cooperative manner in the nucleus of cells, where 
in addition to phosphorylating SR proteins, SRPK1 acts as release factor that remove 
CLK1 from tightly bound SR proteins and promotes U1 binding to pre-mRNA transcript 
thus stimulating mRNA splicing. [Adapted from Aubol et al, 2016 (179)].  
 
Furthermore, in mammalian central nervous system, SRPK1, through the 
phosphorylation of SR proteins, has been shown to regulate alternative splicing events 
leading to the production of neuron-specific protein isoforms important in neuronal 
development, learning, memory and cell communication (180,181). For example, SRPK1 
was demonstrated to phosphorylate SRp38 that led to the alternative splicing of 
glutamate receptor subunit 2 (GluR2) by promoting inclusion of flip exon in GluR2 pre-
mRNA transcript (182). In addition, SRPK1 also plays role in the splicing of exon 10 in Tau 
protein which is implicated in the pathogenesis of Frontotemporal Dementia as well as 
Alzheimer disease (183). Studies also show that by decreasing the SRPK1 expression in 
cell will result in the decrease of phosphorylated SR proteins such as SRp20, SRp30c, 
9G8, SRp40, SRp55 SRp75, Tra21 and ASF/SF2, in a dose-dependent manner 
(165,170,184,185). This data suggests that since phosphorylation of SR proteins by 
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SRPK1 would determine the pattern of splicing, the level of SRPK1 in cells is crucial to 
ensure balanced level of phosphorylated and dephosphorylated SR proteins.  
Although SRPK1 activity is important for regulation of various cellular functions 
as shown by studies in which SRPK1 knockout mice demonstrated severe aberrations of 
cells functioning (186), its overexpression at both protein and mRNA has been shown to 
promote breast and colonic tumorigenesis (172,187,188). In fact, recent data from The 
Cancer Genome Atlas (TCGA) reveals that the expression of SRPKs are frequently altered 
in cancers as shown in Table 1.1, in which high expression of SRPK1 positively correlates 
with tumor progression (189).  
In cancer cells, SRPK1-SR proteins activity has been demonstrated to contribute 
to the splicing regulation of various target genes splicing such as MAP2K2 and Rac1b. 
Depletion of SRPK1 kinase in breast, colon and pancreatic cancer cells resulting in 
reduced phosphorylation of SR proteins including SRSF3, SRSF4 and SRSF6 leading to 
altered splicing of MAP2K2 mRNA causing it unable to phosphorylate its targets, MAPK1 
and MAPK3 which eventually leading to the induction of apoptosis (170,172). It has also 
been shown that nuclear translocation of SRPK1 in cancer cells can be induced by 
upstream signals such as growth factors, that can lead to activation of signaling 
pathways involved in various cellular events. This is demonstrated in studies by which 
EGF was shown to induce cytoplasmic SRPKs translocation into the nucleus via the 
activation of AKT, a protein kinase that plays substantial role in cell survival, and thus 
triggers splicing events mediated by AKT-SRPK-SR network (190).  
In addition, SRPK1 has been shown to target RBM4 in myeloid leukemia cells, 
thus inhibiting RBM4 binding to MCL1, a gene member of BCL2 family that regulates 
apoptosis in cells. This subsequently leads to exon 2 exclusion from the final mRNA 
transcript hence producing anti-apoptotic gene isoform in cells (165). Furthermore, 
increased level of MCL1 gene isoform, MCL1L has been shown to positively correlate 
with SRPK1-RBM4 network, where elevated level of SRPK1 causes increased 
accumulation of RBM4 in the cytoplasm and thus interfere with MCL1 alternative 
splicing, leading to the production of anti-apoptotic protein isoform in MCF7 and MDA-
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MB-231 breast cancer cells (191,192). Consistently, SRPK1 has also been identified as 
one of the determinants in metastatic breast cancer as it was shown to facilitate tumor 
cell migration in breast cancer (193). 
As studies have repeatedly identified alterations that affect splicing in diverse 
cancer types such as mutations in splice-site sequences and mutations in genes encoding 
splicing factors, manipulation of splicing might provide therapeutic benefits in cancer. 
For examples, splicing might be modulated by using spectrum of compounds that 
modulate spliceosome assembly for examples by inhibiting SF3B1 which plays essential 
role in initiating assembly of spliceosome components or by inhibiting the 
phosphorylation of SR proteins through the inhibition of CLKs and SRPKs (194).  
 
Table 1.1 The roles of splicing kinases in cancers (195). 
 
 
 
 
 
52 
 
1.5 Epithelial- to- Mesenchymal Transition (EMT)  
There are three different subtypes of EMT; type 1 is associated with implantation, 
embryo formation and organ development which does not contribute to fibrosis or 
invasive phenotype. For example, EMT is important during embryogenesis to facilitate 
proper anchoring of the placenta and allowing it to function in nutrient and gas 
exchange (196,197). The formation of primitive streak where epithelial cells in this tissue 
express E-cadherin, is considered the first sign of gastrulation which subsequently leads 
to the formation of three germ layers that generate all tissue types of the body (198). At 
the molecular level, canonical Wnt signaling has been shown to orchestrate the EMT 
process during gastrulation and this process cannot be initiated in the embryos deficient 
in Wnt3 (199).  
Meanwhile, type 2 is related with wound healing, tissue regeneration and organ 
fibrosis following trauma and inflammatory injury. Inflammatory cells and fibroblasts 
mediate organ fibrosis by releasing various inflammatory signals and components such 
as collagens, laminins and elastin. This fibrosis- associated EMTs can be found in kidney, 
liver, lung and intestine (198). In addition, studies in 133 kidney fibrosis patients using 
double labelling of the tubular epithelial cells with cytokeratin, vimentin, -SMA or zona 
occludens 1 (ZO-1) showed that EMT was evident in a number of samples, suggesting 
that organ fibrosis can be reversed if novel therapeutic interventions can be developed 
to suppress EMTs (200).   
Whereas, type 3 EMTs has been described in cancer cells that have undergone 
genetic changes affecting oncogenes and tumor suppressor genes which favor the 
development of localized tumors. Type 3 EMTs may induce invasive properties in 
carcinoma cells thus enabling the cells to metastasize and facilitating life-threatening 
cancer progression (198). The underlying biochemical mechanisms in the acquisition of 
invasiveness by primary epithelial cancers is proposed by many studies to be due to 
activation of EMT program (201). EMT is often associated with the loss of cell-cell 
contact and disruption of intracellular tight junction which eventually causes cells to 
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acquire motile mesenchymal characteristic (202). Moreover, carcinoma cells that have 
acquired mesenchymal phenotype usually express mesenchymal markers such as 
vimentin, and are considered to be the cells that enter into subsequent steps of the 
invasion- metastasis cascade, namely intravasation, transport through the circulation, 
extravasation, formation of micrometastases, and eventually colonization of new sites 
(Figure 1.12) (203,204) .  
 
 
Figure 1.12 Three types of EMTs in human. [Adapted from Kalluri and Weinberg, 2009 
(198)]. 
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It has been reported that the activation of EMT- inducing transcription factors, 
notably Snail, Slug, Twist and FOXC2 in cancer cells are emanated from EMT- associated 
signals such as EGF, PDGF and TGF-which is also depending on series of intracellular 
signaling networks including ERK, MAPK, PI3K, Akt, Smads, RhoB, -catenin and Ras 
(198,205). Overexpression of these transcription factors can lead to the down-regulation 
of E-cadherin expression in epithelial cells causing the cells to detach from their 
surroundings, and eventually gaining access to the lymphatic or blood vessels (Figure 
1.13) (206,207). In fact, cells that have undergone EMT often re-program their metabolic 
and oncogenic pathways, which is also a hallmark of cancer, in order to survive the new 
target site (208). Some other signatures of EMT are the increased presence of N-
cadherin and vimentin, nuclear localization of -catenin and increased production of 
mesenchymal-specific transcription factors such as ZEB1/2, apart from Snail, Slug, Twist 
(144,209).  
 
 
Figure 1.13 Cancer cells transform from epithelial-like to mesenchymal-like due to 
epithelial markers suppression and mesenchymal markers upregulation, which 
eventually lead to cancer metastasis. [Adapted from Shih and Yang, 2001 (210)].  
 
55 
 
Recent evidence suggests that EMT is also partly responsible for the emergence 
of cancer stem cells (CSCs), a subset of cell population among heterogeneous tumor cells 
that exhibit stem cell-like features. For examples, the induction of EMT by TGF- 
treatment or forced suppression of E-cadherin expression in mammary epithelial cells 
gives rise to CD44high CD24low cells, one of the known markers of breast CSCs (211). In 
addition, the emergence of EMT- associated CSCs in breast cancers is also reported to 
take place after an immune response, as CD8+ T-cells can trigger dedifferentiation of 
breast cancer cells, leading to the formation of CD44high CD24low stem cell-like cells (212). 
In a clinical setting, it is possible to trace EMT process by examining Circulating Cancer 
Cells (CTCs). Studies on these CTCs from patients with metastatic breast tumors revealed 
that mesenchymal markers were enriched in clusters CTCs rather than single migratory 
cell which might propose that either EMT causes single cell to form cluster cells or 
mesenchymal transformation happens in pre-existing cluster of CTCs in the blood stream 
(213,214).  
These findings provide evidence that EMT involved in the breast cancer 
metastatic process and is a critical phenomenon that is believed to contribute to 
chemotherapy-resistance of various cancer cells.   
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1.5.1 Molecular mechanisms of EMT in cancer cells 
 
Understanding the regulation of EMT is of utmost important to find effective and 
specific therapies for the treatment of metastatic cancer. The complex process of EMT 
involving crosstalks between multiple pathways and the activation distinct EMT-
associated transcription factors, miRNAs and IncRNAs makes the onset of EMT in cancer 
cells does not rely on additional genetic alterations (213,215).  
Studies in breast cancers found that association between lung metastasis 
relapse and TGF expression can only be seen in ER-negative primary breast tumors but 
not in ER+ breast tumors (216). In addition, overexpression of HER2 using heregulin 
(HRG) in breast cancer cells has resulted in increased expression of EMT signature, Slug 
but not Snail or Twist, with concurrent phosphorylation of Akt and heat shock factor 1 
(HSF-1) (217). Meanwhile, ER-positive breast cancer model, MCF7 has been 
demonstrated to undergo EMT changes after the treatment with estrogen and the cell 
adhesion molecules L1 (218,219). Furthermore, another subtype of breast cancer, Triple 
negative (TN) cells have been shown to express high levels stem cells and EMT markers, 
CD44high CD24low and Twist, respectively, as compared to hormone-sensitive or HER2-
positive breast cancers (220). However, although some EMT signatures can be detected 
or induced in breast cancer subtypes, co-expression of epithelial and mesenchymal 
markers can still be predominantly observed in all cell subtypes, hence suggesting that 
‘partial’ EMT, rather than complete EMT, might represent a state with higher cell 
plasticity between breast cancer groups (215).  
Generally, it is known that the activation and expression of the EMT- associated 
transcription factors take place as a response to various signaling pathways. Previous 
studies have revealed that EMT is controlled by family of transcription factors which 
include Twist, Snail, Slug, ZEB1 and ZEB2 that act by binding to the promoter region of 
genes responsible for cell-cell adhesion in epithelial cells such as E-cadherin (CDH1) and 
repressing their expression (145,221). Some of the well-recognized signaling pathways in 
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inducing EMT are TGF-B (Transforming Growth Factor B), Wnt /- catenin and Notch 
(family of transmembrane proteins) (145,222,223).  
 
1.5.1.1 Transforming growth factor-B 
 
Amongst all the pathways involving in tumor invasion and metastasis such as NF-kB, 
MAPK/ERK and PI3K/AKT, TGF- signaling pathway has been known as the major inducer 
of EMT in vitro and acts through various intracellular messengers. Typically, there are 
three isoforms of TGF (TGF-1, 2, and 3) and the EMT event observed in cancer is 
commonly regulated by TGF-1 (224). The TGF- effect is enough to initiate the 
formation of motile cancer stem cells (CSCs) by upregulating the oct4, Nanog, N-
cadherin, Vimentin, Slug, Snail and suppressing E-cadherin (significant signature of EMT) 
and Ck18 (213,225). It has been reported that TGF- induces breast cancer cell invasion 
via Smad3- and Smad4- dependent manner (226). In addition, analysis of circulating 
tumor cells (CTC) of metastatic breast cancer reveals that these CTC express known EMT 
regulators, including TGF-pathway components which support the role of this pathway 
in EMT-associated blood-borne dissemination of human breast cancer (227). 
The Smad pathway involves activation of the TGF Type II receptor (TGFR2) by 
TGF, followed by phosphorylation of the Type I receptor (TGFR1) which in turn causes 
the activation of Smad complex. This complex then translocates to the nucleus and 
triggers EMT by binding to the SNAIL1/2 and ZEB1/2 promoters, inducing their 
transcription and suppressing expression  of E-cadherin and occludin (Figure 1.14) 
(213,228,229). Ji et al. reported that high abundance of Snail1 in the nucleus correlates 
with the reduction of E-cadherin in breast cancer cell (230).  Consequently, this whole 
cascade leads to tumor development, invasion and metastasis of cancer cells (231,232) . 
Additionally in non-Smad pathway, TGF- induces EMT and cancer cell invasion by 
activating mTOR signaling through the activation of phosphatidylinositol 3-kinase (PI3K) 
as well as through the activation of mTOR complex 2 (mTOR2) which promotes 
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cytoskeleton changes and elevates the EMT-associated protein expression in cancer cells 
(233).  
 
 
 
Figure 1.14. TGF- signaling pathway in cancer invasion and metastasis. TGF- induces 
EMT, invasion and metastasis of cancer cells via Smad/non-Smad pathways that leads to 
the transcription of EMT regulators such as Snail and ZEB1/2, and subsequently resulting 
in the suppression of E-cadherin expression. Other pathways that also involve in tumor 
invasion and metastasis are PI3K/AKT, NF-kB, Hedgehog, MAPK/ERK, p38MAPK, Wnt/-
catenin signaling pathway. [Adapted from Li et al, 2015 (234)].  
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1.5.1.2 Wnt Signaling  
 
A plethora of studies confirmed that Wnt signaling is inappropriately active in 
several cancers such as in human liver cancer, colon cancer, ovaria cancer, and its signal 
transduction is associated with the loss of BRCA1, which is a hallmark for aggressive 
basal-like breast cancer (235). Even more, high expression of the EMT-related 
transcription factor Twist in mammary epithelial cell is also linked with Wnt signaling 
activation (236). The role of Wnt signaling in promoting EMT has also been 
demonstrated in which knocking down of Wnt3 reversed the nuclear accumulation of B-
catenin as well as reduced the expression of EMT markers (213).  
The Wnt pathway is activated once Wnt ligand binds to the transmembrane 
receptors of the Frizzled family and the signals then transduces across plasma 
membrane by low-density lipoprotein receptor-related protein (LRP) (Figure 1.15) 
(213,221,237). This binding causes -catenin to release from APC complex followed by -
catenin accumulation in the nucleus. In the nucleus, -catenin will then form -
catenin/TCF/LEF transcriptional complex to target genes associated with EMT (221,237). 
In addition, it has also been shown that the action of -catenin/TCF complex in 
activating EMT program in the breast cancer is mediated by Axin2, which in turn 
regulates GSK3, a nuclear kinase that is responsible for controlling the stability of 
transcription factor, Snail in the nucleus (230). This eventually leads to the activation of 
target genes such as OCT4, Nanog, Sox-2 which are crucial for cancer metastasis as well 
as for maintaining self- renewal ability of cancer stem cells. 
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Figure 1.15 Wnt protein is a ligand that transmit extracellular signal to intracellular 
signaling cascade by binding through frizzled receptor. In the presence of WNT ligand 
(on state), the binding to frizzled receptors results in b-catenin accumulation in the 
nucleus. In the absence of the Wnt ligand (off state), b-catenin is sequestered by 
complex molecules such as Axin1 and APC (destruction complex). Ubiquitination and 
degradation process will take place because of b-catenin phosphorylation within this 
complex. [Adapted from Vaz et al, 2014  (238)]. 
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1.5.1.3 Notch   
 
It has been reported that Notch signaling pathway is involved in the developmental 
process such as cell proliferation, survival, apoptosis and differentiation. It is also shown 
to be involved in the acquisition of EMT in cancer cells.  Elevated expression of Notch-1 
and its ligand Jagged-1 was observed to be linked with poor prognosis of various cancers 
for example breast cancer, bladder cancer, leukaemia and prostate cancer (239–244). 
Figure 1.16 shows the mechanism of action of Notch signaling as well as the cross talks 
between Notch signaling and other signaling such as TGF, FGF and PDGF that can lead 
to the activation of intracellular notch and thus increasing the transcription of EMT 
regulators including Twist, Snail, Slug, and ZEB1/2 (245). 
In general, interaction of Notch receptor (NICD) which contains elements for 
nuclear localization, with the neighboring Notch receptor causes the NICD to be cleaved 
by enzymes and thus translocate to the nucleus (221,246,247). In the nucleus, the NICD 
activate the expression of genes that promote tumor development such as NF-kB, Akt 
and p21 by binding to transcription repressor complexes (247–249). Furthermore, Snail 
can be upregulated directly by Notch by recruiting the intracellular domain of the Notch 
(ICN) to the Snail-1 promoter. This will cause over-expression of Snail which will in turn 
down regulate the expression of E-cadherin and consequently trigger the EMT process in 
the cells (250).  
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Figure 1.16 Diagram showing mechanism of Notch signaling and the cross-talks with 
other signaling pathways, in promoting EMT. [Adapted from Wang et.al, 2010 ((245)]. 
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1.5.2 Link between Alternative Splicing (AS) and Epithelial-
mesenchymal Transition (EMT) 
 
There are also several ways alternative splicing can play a role in EMT particularly 
through the regulation of EMT-associated signaling pathways. Shapiro et al suggested 
that the occurrence of alternative splicing in EMT is controlled by one or more members 
of splicing factors such as RBFOX, MBNL, CELF, hnRNP and ESRP (251). The connection 
between AS and EMT was first established when  specific CD44 splice variants were 
detected in metastatic pancreatic cancer cells that was not present in the primary tumor 
(252).  
CD44 is a transmembrane glycoprotein where its pre-mRNA transcript is subject 
to intricate alternative splicing (AS) including ten adjacent exons (Figure 1.17) that can 
be included in combination or single and its altered splicing has been reported to be 
linked with the signaling pathways associated with cell growth (253,254). Some of the 
pathways that can be influenced by CD44 in cancer cells are Wnt/-catenin pathway, 
TGF, Notch and PI3K pathway (Figure 1.18) (255). Previously, it was demonstrated that 
the alternatively spliced CD44 gene (CD44v4-7 and CD44 v6-7) were highly expressed 
particularly in metastatic pancreatic carcinoma as opposed to the parental tumor (256). 
In addition, studies on CD44v6 also demonstrate that this variant is crucial for the 
formation of a complex with the receptor tyrosine kinase Met and hepatocyte growth 
factor (HGF), an crucial step for the acquisition of metastatic features by cancer cells 
(257,258).  
In 2011, Brown et al revealed that a switch or shift in CD44 expression from 
variant isoforms (CD44v) to standard isoform (CD44s) was required to accelerate EMT 
and breast cancer progression and was demonstrated to be negatively controlled by 
epithelial specific splicing factor, ERSP1 (145). In this study, it was found that CD44v was 
predominantly expressed in epithelial cells, and the induction of EMT by TGF in the 
breast cancer cells has resulted in the exclusive expression of CD44s, increased ratio of 
CD44s/CD44v mRNA, and this increased CD44s expression was also positively correlated 
with the expression of mesenchymal cell marker, N-cadherin, thus indicating that CD44 
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isoform switching occurs during EMT and CD44s is essential for EMT (145). In addition, 
studies on primary breast tumors revealed that except CD44s, mRNA and proteins 
expression of all analyzed CD44 isoform correlated with cancer stem cells (CSC) 
phenotype CD44+/CD24-(164). Following this, further analysis showed that CD44s 
isoform was positively correlated with ALDH1, another biomarker of malignant stem 
cells (164,259). Consistently, CD44s has also been shown to activate EMT signature, 
ZEB1 and maintain mesenchymal phenotype of breast cancer cells via TGFsignaling 
pathway (260). Recently, ERK/Ras signaling which is substantial for cell cycle progression 
has been shown to induce CD44v6 splicing (261). Furthermore, collaboration between 
Wnt signaling, specifically Wnt- target gene, Met and CD44v6 was also observed in 
colorectal cancer and is required in colorectal cancer progression (262).  
Besides CD44, studies have also identified other gene targets with alternative 
isoforms affecting EMT and correlating with invasive phenotypes in cancer cells. For 
example, mis-regulated splicing of tyrosine kinase receptor, Ron in breast and colorectal 
tumors is the most widely known example of the link between alternative splicing (AS) 
and the activation of EMT. The skipping of exon 11 results in the production of Ron 
spliced variant, ∆Ron and its over-expression stimulates EMT and confers increased cell 
motility and matrix invasion (151).  It has been observed that the expression level of 
splicing factor, ASF/SF2 critically determines the generation of ∆Ron which is found to 
play significant roles in tumor progression (263). 
Notably, the role of estrogen signaling in AS and EMT have been reported in 
several studies. For example, the induction of EMT by TGF in prostate cancer cell line 
that endogenously expresses both ER and ER shows that EMT was negatively 
correlated with the presence of ER while ERa was not affected, suggesting that loss of 
ER promotes EMT in prostate cancer (264). In addition, studies in breast epithelial cells 
induced with estrogen (E2) reveals that estrogen can cause genomic aberrations such as 
changes in gene expression resulting in disrupted integrin signaling and apoptosis 
pathway, and EMT by reducing the expression of epithelial marker, E-cadherin and 
increasing mesenchymal markers such as n-cadherin and vimentin (265). Estrogen 
signaling has been previously studied to be implicated in the alterative splicing of several 
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target genes such as CRHR1 in breast cancer (141) and Fibulin-1 in ovarian cancer that 
produces Fibulin-1C isoform which may be involved in ovarian carcinogenesis (266). In 
addition, estrogen receptor- gene (ESR1) has been shown to cooperate with homeobox 
transcription factor (BARX2) in MCF7 breast cancer cells, where both proteins bind to 
different ESR1 gene promoters and regulate the expression of ESR1 protein isoforms 
(66kDa and 46kDa). The upregulated expression of ESR1 promotes the survival, cell 
growth and invasion property in breast cancer by promoting increased expression of 
active matrix metalloproteinase-9 (MMP9) and the expression of tissue inhibitor of 
metalloproteinase (TIMP 1 & 2) genes (267) .  
This finding as well as several other studies provides evidence that modification 
of constitutive splicing events can induce EMT-related phenotype change as a result of 
gene isoform produced which promotes and supports transformation of cells from 
epithelial to mesenchymal state (144).  
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Figure 1.17 CD44 gene contains 20 exons and alternative splicing typically produces two 
main type of isoforms; CD44s (short/standard) and CD44v (variant). [Adapted from 
Chanmee et al, 2015 (268)]. 
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Figure 1.18 Illustration of signaling pathways stimulated by CD44. [Adapted from Xu et al, 
2015 (269)]. 
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1.6 Cancer Stem Cells (CSCs) 
Cellular heterogeneity and plasticity within tumors has been one of the greatest 
challenges in cancer therapeutics. Many solid tumors contain a small population of 
highly tumorigenic CSCs, which contribute significantly to tumor initiation and 
metastasis. Generally, cancer initiation and development is proposed to follow two 
models; through accumulation of mutations which promote the loss or gain of specific 
proteins, where each cancer cell has similar potential to grow a tumor, and/or the 
existence of cancer stem cells (CSCs), a small population of stem-like cells that are 
responsible for the generation of highly proliferative, therapy resistant progeny cells as 
well as the development of the disease (270). Notably, accurate distinction between 
CSCs and normal stem cells is needed as they share numerous properties apart from 
their ability to renew themselves, such as both are demonstrated to express surface 
markers including CD44 or the enzyme aldehyde dehydrogenase (ALDH), and the 
activation of EMT- associated signaling pathways such as Wnt and Notch (271). In 
addition to these markers, studies in tumor-initiating population from hepatocellular 
carcinoma show another cell surface marker, epithelial cell adhesion molecule (EpCAM), 
which is expressed in normal epithelial progenitor cells (272).  
 Furthermore, several studies in various tumor types such as osteosarcoma, 
glioblastoma, breast cancer, lung cancer, ovarian cancer and colon cancer demonstrate 
that glucose uptake, glycolytic enzyme expression, lactate production and ATP content 
in CSCs are markedly increased as compared to other differentiated cancer cells in vitro 
and in vivo (270). However, growing evidence reveals that CSCs are less glycolytic and 
have preference for mitochondrial oxidative metabolism, in which CSCs show an 
increased oxygen consumption rates and higher mitochondrial ROS than differentiated 
cancer cells (273,274). These discrepancies in CSCs metabolism are suggested to be 
possibly due to metabolic adaptability of CSCs which might allow CSCs to survive in 
unfavorable circumstances during tumor progression, such as at metastatic sites 
(275,276). For example, in-vitro CSCs studies that have non-physiological high glucose 
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and oxygen concentration may favor a glycolytic phenotype of CSCs as opposed to 
oxidative phosphorylation (OXPHOS) phenotype (276).  
Heterogeneity within tumors such as breast cancer has been well-demonstrated, 
in which it comprises of cells that can be subdivided into clinical subtypes based on 
cellular marker expression, and with molecular alterations across the subtypes of breast 
cancer, such as mutational activation of PI3K signaling in luminal breast cancers, TP53 
and BRCA1 mutations in triple negative breast cancer (TN) and PTEN deletions in HER2-
positive breast cancers, that have been shown to increase CSCs frequency in patient 
samples and pre-clinical models (277). Recently, breast cancer stem cells have been 
shown to maintain their plasticity while transitioning between two different phenotype 
states; a more proliferative epithelial-like state identified by the expression of CSC 
marker ALDH, and a more invasive, mesenchymal-like state characterized by the 
expression of CD44+/CD24-. These transitions are mediated by epigenetic alterations 
regulated by cytokine and chemokine signaling and/or transcriptional regulation, a 
concept that supports the link between CSCs and the process of EMT as proposed in 
previous studies (211,278,279). Differences in the CSC types have also been reported 
across these breast cancer subtypes. Notably, TN breast cancer contains high proportion 
of CD44+/CD24- and ALDH1- expressing CSCs, HER2-positive breast cancer contains high 
proportion of ALDH1-expressing CSCs, and hormone-positive (HR+) breast cancer is 
characterized by a low proportion of cells expressing CSC markers (277,280,281).  
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1.6.1 Relationship between CSC, EMT and gene splicing in cancer 
 
The EMT process which is often found to promote tumor metastasis and cancer cells 
dissemination has also been proposed to impart a self-renewal capability to these 
disseminating cancer cells. This is supported by studies in which cells that have 
undergone EMT show similar behavior to stem cells isolated from normal or neoplastic 
cell population (211). Furthermore, studies in head and neck squamous cell carcinoma 
(HNSCC) show that Snail- induced EMT promotes the maintenance of CSC-like 
phenotype of the cells as well as enhances their sphere-forming capability, chemo- 
resistance and invasive ability (282). The molecular links between EMTs and the 
acquisition of stem-cell traits have also been elucidate, which among them is through 
the regulation of microRNAs that function as stemness suppressors such as miR-200 
family, whose expression are negatively regulated ZEB1 transcription factor (283). In 
addition, the role of TGF- through Type 1 TGF- receptor (TR1) in modulating EMT 
and ‘stemness’ of cells has been revealed, in which this cytokine activates effector 
Smads 2/3/Smad4 complexes and associate with transcription factors such as ZEB1 and 
Zeb2/SIP1, thus resulting in the suppression of E-cadherin expression during EMT (284). 
Of note, SIP1 is important in the activin-mediated maintenance of human embryonic 
stem cells, which further suggests the connection between TGF- signaling, EMT and 
stemness of cells (285). 
Furthermore, the process of EMT and the reverse process, mesenchymal-
epithelial transition (MET) have been implicated in the plasticity between CSCs types and 
their connection with the molecular subtypes of breast cancer with previous studies 
have revealed that overexpression of EMT-associated transcription factors such as Snail 
and Twist can lead to increased CSCs population in tumors, whereas MET ensures that 
metastatic cells can return to their highly proliferative state and causes tumor relapse at 
new sites (286). Experimental evidence have also suggested that differentiated 
populations of normal mammary epithelial cells can be transformed to mammary 
epithelial stem-like cells through the induction of EMT (211). In line with this, it has been 
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shown that cells derived from human mammary epithelial cells can acquire both stem 
and tumorigenic characteristics of CSCs through EMT-induced Ras-MAPK pathway 
activation (287). Consistently, gene expression profiling in MCF7 cell line demonstrated 
high expression of EMT-associated genes such as Vimentin, ZEB1, ZEB2, -catenin and 
MMP1 in the cells enriched with CD44+/CD24- marker (279). In addition, the significant 
role of specific genes and proteins in the maintenance of breast cancer cells 
differentiation and proliferation was further evaluated. Studies have found that the loss 
of WISP2 expression in breast cancer cells in vitro has caused the induction of EMT and 
increased the stemness of the cells (288). In addition, EMT gene Wnt1 was found to be 
differentially expressed in cancer cells grown in sphere culture where those cells with 
suppressed Wnt1 expression showed lack of stem cell- like properties such as reduced 
sphere forming ability and decreased ALDH activity (289).  
The role of alternative splicing has also been observed in the generation of CSCs, 
as the analysis in CD44+/CD24- population of breast cancer cells show that the fate of 
breast CSCs is determined by regulated splicing of 6 Integrin. It was observed that 
these CSCs contain distinct epithelial and mesenchymal population and with the 
expression of 6A  and 6B integrin subunits was especially detected on epithelial and 
mesenchymal population, respectively (290). In fact, Olsson et al. has demonstrated that 
tumors with high expression of ALDH1 (CSC marker) also has marked level of CD44 splice 
variant, CD44s expression, which is also a widely established marker for EMT (164). 
Furthermore, analysis of CD44+ population in HNSCC cells shows that cells with a high 
level of CD44 splice isoform, CD44v and low level of EGFR expression display both EMT 
and CSC- like phenotypes and exhibit resistance to radiotherapy treatment (282). 
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 Aims & Objectives 
In mammary cancer, growing evidence show that estrogen signaling plays critical roles in 
the regulation of target genes that may affect various cellular processes that lead to 
tumorigeneses. Notably, alterations in signaling pathways though mutations or post-
translational modifications such as alternative pre-mRNA splicing are more frequently 
found in hormone responsive breast cancer. More importantly, alternative splicing (AS) 
was suggested to be responsible for the widespread changes in the mRNA isoform 
during the epithelial-to-mesenchymal transition (EMT) event, a process that marks the 
early event of cancer metastasis. Studies in ER+ MCF7 cells have revealed the 
involvement of estrogen receptors (ERs) in many oncogenic signaling pathways, whilst 
corticotropin-releasing hormone, (CRH) a hypothalamic hormone involved in adaption to 
stress has also been demonstrated to play roles in the development of various human 
cancers (291). However, the molecular mechanism through which both hormones can 
potentially promote oncogenesis needs to be further elucidated. Therefore, using MCF7 
and SKBR breast cancer cell lines as ER+ and ER- cellular model respectively, this study 
explored the potential role of estrogen and corticotropin-releasing hormone (CRH) in 
influencing cancer progression through the regulation of alternative pre-mRNA splicing 
mechanism. The link between alternative splicing and EMT was assessed by studying the 
effects of altered splicing factors activity on the transcription of various EMT-associated 
genes. It was hypothesized that estrogen (E2) as well as CRH can cause changes in the 
global protein expression in hormone-responsive breast cancer cells leading to 
upregulation of oncogenic proteins and activation of signaling networks that can 
potentially trigger biological processes associated with cancer metastasis. In detail, the 
aims of this project were: 
1. Proteomic analysis of MCF7 breast cancer cell line (ER+ cells) exposed to 
estrogen (17-estradiol). 
 
2. Isolation of MCF7 breast cancer stem cell subpopulation. 
 
3. Identification of potential role of Estrogen and CRH in promoting cancer through 
the regulation of alternative splicing (AS) mechanism. 
 
 
4. To study the relationship between increased production of CD44 splice isoforms 
with epithelial-to-mesenchymal transition (EMT) event. 
 
5. Profiling of CRH-induced transcriptional activation of EMT- associated gene 
expression in MCF7 cells and their effects on cellular behaviours. 
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CHAPTER 2  
Material and Methods 
2.1 Cell culture  
Human breast cancer cell lines (MCF-7 and SKBR3) were purchased from American Type 
Culture collection (ATCC, USA). MCF-7 cells were maintained in Dulbecco’s Modified 
Eagle Media, DMEM (Lonza) supplemented with 10% FBS (v/v) and 1% Penicillin 
Streptomycin (v/v).  
 SKBR3 cells were cultured in RPMI 1640 media (Sigma Aldrich, UK) 
supplemented with 10% (v/v) fetal bovine serum (FBS),1% sodium bicarbonate (v/v) and 
1% Penicillin Streptomycin (v/v) and incubated at 37oC with 5% CO2. 
 
2.1.1 MCF-7 cell culture 
MCF-7 cells vial was removed from liquid nitrogen and warmed in 37oC water bath for 1-
2 min. The thawed cells were then transferred into 15mL tube, diluted with fresh 
complete DMEM and centrifuged at 1000 rpm for 5 min. The supernatant was removed, 
and cells were resuspended in DMEM and transferred into tissue culture flask. The flask 
was kept in 37oC, 5% CO2 incubator for 3-4 days before cell passage.  
 For MCF-7 cell passage, medium from cell culture flask was aspirated and the 
cells were washed once with PBS followed by 1-2 min incubation with Trypsin-EDTA 
(Sigma Aldrich, UK) in the incubator. Warmed complete DMEM was added into the flask, 
and the cell suspension was mixed several times. Then, 1/5 of the cell suspension was 
transferred to a new sterile cell culture flask incubated for 3-4 days. The media was 
changed every 4 days and experiments were performed on cells that were 70-80% 
confluent and with cells less than 30 passages.  
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 For cell freezing, confluent cells were trypsinized as described above and 
centrifuged at 1000 rpm for 5 min. The supernatant was removed, and cells were 
resuspended with 5ml freezing medium (4.5ml complete DMEM + 0.5ml DMSO). Cell 
suspension was then aliquoted into 1ml cryovial and placed in a cryofreezing container 
in -80oC freezer overnight, before transferring them into liquid nitrogen. 
  
2.1.2 SKBR-3 cell culture 
Vial containing SKBR-3 cells (ATCC R HTB-30TM) was thawed in a 37oC water bath for 1-2 
min. The thawed cells were then transferred into 15mL tube, diluted with fresh 
complete RPMI 1640 media and centrifuged at 1000 rpm for 5 min. The supernatant was 
removed, and cells were resuspended in RPMI 1640 media and transferred into tissue 
culture flask. The flask was kept in 37oC, 5% CO2 incubator for 6-7 days and the media 
was changed every 3 days before cell passage.  
 For SKBR-3 cell passage, the old medium from cell culture flask was aspirated 
and the cells washed once with PBS followed by 1-2 min incubation with Trypsin-EDTA 
(Sigma Aldrich, UK) in the incubator. Warmed complete RPMI 1640 media was added 
into the flask, and the cell suspension was mixed several times. Then, 1/3 of the cell 
suspension was transferred to a new sterile cell culture flask incubated for 3-4 days. The 
media was changed every 3 days and experiments were performed on cells that were 
70-80% confluent and with cells less than 30 passages.  
 For cell freezing, confluent cells were trypsinized as described above and 
centrifuged at 1000 rpm for 5 min. The supernatant was removed, and cells were 
resuspended with 5ml freezing medium (4.5ml complete RPMI 1640 + 0.5ml DMSO). 
Cells suspension was then aliquoted into 1ml cryovial and placed in a cryofreezing 
container in -80oC freezer overnight, before transferring them into liquid nitrogen. 
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2.2 Breast Cancer Stem Cells (CSCs), CD44+CD24- isolation 
2.2.1 Removal of CD24+ cells 
 
MCF7 cells were grown in T25 flask and trypsinized once the cells reached 80% 
confluent. Cells were resuspended in cold 1x MagCellect Plus buffer provided in the 
MagCellect Human CD24-CD44+Breast Cancer Stem Cells Isolation Kit (R&D Biosystems). 
Then, 0.5ml of these cells containing 5x 106 cells were added into the round bottom 
tube, followed by 25 l Biotinylated CD24 antibody (biotinylated mouse anti-human 
CD24 antibody), and incubated at 2-8oC for 15 min. The samples were then washed and 
resuspended in cold 1x MagCellect Plus Buffer, before incubated with 50 l of 
MagCellect Streptavidin Ferrofluid (a solution containing BSA and preservative) at 4oC 
for 15 min. Following this, 3 ml of the cold buffer was added to the tube, centrifuged at 
300 x g for 8 min, resuspended in cold buffer and finally the tubes were placed in the 
MagCellect magnet for 6 min at room temperature. The CD24- cells in the supernatant 
were collected and placed into a new tube.  
 
2.2.2 Isolation of CD44+ cells 
 
The collected CD24- cells from previous step was centrifuged at 300x g for 8 min, 
resuspended in the cold MagCellect plus buffer, and incubated with 10 l of Biotinylated 
CD44 antibody (biotinylated mouse anti-human CD44 antibody) for 15 min at 4oC. Then, 
cells were washed with 3 ml cold buffer followed by centrifugation at 300 x g for 8 min 
and the cell pellet was resuspended again with cold buffer. 50l of MagCellect 
Streptavidin Ferrofluid was added in the tube and incubated at 4oC for 15 min, before 
placed in the MagCellect magnet for 6 min. The unwanted cells (CD44-) were removed 
by aspirating the supernatant, and the ones left at the bottom of the tubes are cells with 
CD44+CD24- properties. These cells were then transferred into sterile ultra-low 
attachment plate for at least 7 days to allow the formation of clusters/mammosphere to 
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take place. Additionally, in different tubes the collected cells were mixed again with 
100l cold buffer and incubated with 10 l of PE- and APC- conjugated Human CD24 
(APC-conjugated mouse anti-human CD24 antibody) and CD44 Detection Antibodies (PE-
conjugated mouse anti-human CD44 antibody). The tagged cells were then analysed 
using standard flow cytometry procedures to confirm the presence of the breast cancer 
stem cells (CSC) marker.   
 
2.3 Cell Treatments  
Cells were serum-starved overnight prior to treatments with various 
agonists/antagonists/inhibitors. There were no vehicle controls used in each 
experiment, however, untreated cells were used as controls and referred as ‘untreated’ 
in all experiments.  
 
17-Estradiol (Estrogen, Sigma Aldrich UK) Treatment 
For all experiments, Estrogen dissolved in 100% Ethanol was used at a final 
concentration of 10nM. MCF-7 cells were treated with 10nM of estrogen for various 
time points depending on the type of experiments. This concentration was used 
following series of preliminary experiments by other members of the group. 
 
CRH Treatment 
CRH (Abcam) in distilled sterile water was used at a final concentration of 100nM. MCF-7 
and SKBR-3 cells were treated with 100nM CRH for various time points according to 
experimental protocol and these time points and concentration were used following 
series of preliminary experiments by other members of the group. 
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Kinase Inhibitor Treatment 
SRPIN340 (SRPK1 inhibitor, Tocris Bioscience UK) dissolved in 100% ethanol was used at 
a final concentration of 10M, whereas AKT inhibitor, MK2206 (Seleckchem) dissolved in 
DMSO was used at a final concentration of 5M. MCF-7 and SKBR-3 cells were treated 
for 2hr with 10M of SRPK1 inhibitor and with 5M of AKT inhibitor. These 
concentrations were chosen based on recommendation by supplier and by previous 
studies done by (292).      
 
 
2.4 Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) 
Real- time PCR is a technique that allows amplification of specific target sequences in a 
sample, and at the same time permits the analysis of the products while reaction is still 
in progress. This is achieved by using fluorescent dyes which react with the amplified 
product and emit fluorescent signals that can be measured by an RT-PCR instrument 
thus allowing kinetic measurements of product accumulation.  
 For all my RT-qPCR experiments, sample preparation started from cell growing, 
isolation of RNA, quantification of RNA content, reverse transcription of RNAs (cDNA 
synthesis) and finally quantitative PCR reactions were performed using SYBR Green- 
based fluorescent dye. 
 
2.4.1 RNA Isolation 
Total RNA was isolated according to the manufacturer’s instruction (Sigma GenElute 
Mammalian Total RNA Kit, Sigma Aldrich UK). For the RNA extraction from cultured cells, 
the cells were grown until 60-70% confluent in 6-well plates. In the case of hormones or 
inhibitor treatment, cells were treated in serum-free media for 24h prior to RNA 
isolation. The cells were then washed with ice-cold phosphate buffered saline (PBS) and 
lysed by adding 250l or 500l QIAzol lysis buffer containing 1% of 2-mercaptoethanol 
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(v/v), depending on the density of cells in each well. The cell lysate was then transferred 
into filtration column to separate the RNA from cell debris, followed by mixing with 70% 
ethanol for the precipitation stage. This mixture was loaded into binding column and 
washed several times with Wash Buffer 1 and 2. Finally, 50-80l of elution buffer was 
added to elute the isolated RNA to be used in the next step. 
 
2.4.2 RNA Quantification (Nanodrop) 
The integrity of the isolated RNA was quantified by measuring the absorbance value at 
260nm using NanoDrop 1000 UV-Vis spectrophotometer (Nanodrop Technologies). The 
ratio obtained from A260/A280 and A260/A230 were used to select samples with best 
RNA quality.  
 
2.4.3 cDNA Synthesis/Reverse Transcription PCR 
Prior to the reverse transcription step, RNA was treated with RNase-free DNase 1 
(Invitrogen) to remove any genomic DNA contamination. Following the DNase 
treatment, cDNA synthesis was performed on 1g RNA samples using High Capacity 
RNA-to- cDNA kit (Applied Biosystems). Briefly, template RNA was mixed with reaction 
mixture containing 20X RT Enzyme Mix (MuLV and RNase inhibitor protein), 2X RT Buffer 
(includes dNTPs, random octamers and oligo dT-16) and nuclease-free water with the 
final volume of 20L in 0.5ml PCR tubes. The reverse transcription was started by 
incubating the tubes at 37oC for 60 min followed by 95oC for 5 min and finally was hold 
at 4oC before the cDNA tubes were stored at 2-8oC for short term storage and -15 to -
25oC for long term storage.  
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2.4.4 SYBR® Green-based quantitative RT-qPCR 
RNA expression of target genes was quantitatively examined using SYBR® Green-based 
method. 1l/well of cDNA was used as a template and 19l of PCR mixture reactions 
was added to each well of ABI 96-well plate. The mixture components contained 2x SYBR 
Green PCR Master Mix SensiFast Lo-Rox (Bioline) (10l/well), Reverse Primer (1l/well, 
10M), Forward Primer (1l/well, 10M) and 7l nuclease-free water (Invitrogen). The 
plate was then centrifuged at 300xg for 3 min before loaded into ABI 7500 fast real-time 
PCR system. The program settings used to perform the PCR reaction was as followed:  
Pre-PCR stage: 60oC, 1 min. 
Holding stage: 95oC, 20s 
Cycling stage: 95oc, 3 s (denature) & 60oC, 30 s 
(extend) 
Melt curve stage: 95oC, 15 s & 60oC 1 min 
Post-PCR stage: 60oC, 1 min 
 
Each of the gene expression level was determined using comparative CT method and 
normalized to the expression level of GAPDH which served as endogenous control. 
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2.5 Human Epithelial to Mesenchymal Transition (EMT) RT2 Profiler 
PCR Array  
The human EMT RT2 profiler array (Qiagen) allows the analysis of expression profiles of 
84 key genes that change their expression during EMT process. As EMT and the 
reciprocal mesenchymal to epithelial transition (MET) are key processes implicated in 
both tumour metastasis and stem cell development, this array includes cell surface 
receptor, extracellular matrix, and cytoskeletal genes mediating cell adhesion, migration, 
motility and morphogenesis. Genes controlling cell differentiation, development, 
growth, proliferation and signal transduction and transcription factor genes that 
involved in EMT are also included.  
 Similar to quantitative RT-PCR, sample preparation for this experiment involves 
cDNA synthesis using the provided kit, RT2 First Strand cDNA Synthesis followed by the 
quantitative gene expression analysis using SYBR Green-based dye, performed on 
Applied Biosystem 7000 Real-Time PCR System. The relative expression of each gene 
was determined using the ∆∆CT method. 
 
2.5.1 RT2 First Strand cDNA Synthesis 
 
Genomic DNA Elimination 
The same amount of RNA isolated from method described in 2.4 were used to prepare 
the cDNA for EMT array experiment. Briefly, the reagents of the RT2 First Strand kit 
(Qiagen) were thawed and genomic DNA elimination mix for each RNA sample was 
prepared as described in Table 2.1.  
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Table 2.1 Genomic DNA elimination mix. 
Component  Amount  
RNA 25ng-5g 
Buffer GE 2l 
RNase-free water Variable 
Total volume 10l 
 
The mixture was then incubated for 5 min at 42oC then immediately kept on ice for 1 
min before proceeded to the next step. 
 
Reverse Transcription 
Reverse transcription mix was prepared as in Table 2.2. 10l of reverse- transcription 
mix was added into the tube containing 10l of genomic DNA elimination mixture from 
the previous step. The mixture was mixed well by pipetting up and down followed by 
incubation at 42oC for exactly 15 min before the reaction was immediately stopped by 
heating at 95oC for 5 min. In the final step, 91l of RNase-free water was added to the 
tube, mixed well and placed on ice before proceeding with the real-time PCR protocol. 
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Table 2.2. Reverse-transcription mix 
Component  Volume for 1 reaction  
5x Buffer BC3 4l 
Control P2 1l 
RE3 Reverse Transcriptase Mix 2l 
RNase-free water 3l 
Total Volume 10l 
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2.5.2 RT2 Profiler Real-Time PCR Array 
The EMT RT2 Profiler PCR Array plate format C (PAHS-090) was used for this experiment. 
The plate and gene layout are as shown in Figure 2.1 and Table 2.3, respectively. 
 
 
Figure 2.1 RT2 EMT Profiler Array plate layout. 
 
 
 
 
 
 
 
 
 
 
84 
 
Table 2.3. Each well in this plate measures the expression of a transcript related to a 
pathway in epithelial to mesenchymal transition. 
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ZEB1 
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ZEB2 
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ACTB 
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RTC 
H08 
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PPC 
H11 
PPC 
H12 
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The PCR component mix (Table 2.4) was prepared in a 5ml tube and subsequently 
dispensed into the RT2 Profiler PCR Array plate.  
Table 2.4. PCR component mix. 
Component  96-well Array Format C 
2x RT2 SRBYR Green Master mix 1350 l 
cDNA synthesis reaction 102 l 
RNase-free water 1248 l 
Total volume  2700 l 
 
The plate was then centrifuged to precipitate the mixture and remove bubbles at 1000 g 
at room temperature for 1 min. the plate was then placed in real-time cycler (ABI 7000) 
which was programmed as below: 
Table 2.5. Cycling conditions for ABI cycler. 
Cycles  Duration  Temperature  
1 10 min 95oC 
40 15s 95oC 
1 min 60oC 
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2.6 Immunofluorescence 
Preparation of coverslips 
Circular No.1 microscope coverslips (VWR UK) were sterilized by immersing in absolute 
ethanol for 30 min and allowed to air dry in the cell culture hood before being placed in 
a sterile 8-well plate, one in each well. Then, cells were seeded on the glass coverslips at 
a density 1x105 cells/well. 2ml of growth media containing fetal bovine serum (FBS) and 
Penicillin/Streptomycin was added into each well and the plate was kept in the 
incubator at 37oC until it reached 80% confluence. For treatments, cells were treated at 
60-70% confluent and was left growing up to 80% confluent before proceeding to 
subsequent steps. 
 
Fixation 
Coverslips were removed, transferred to a new sterile well and washed three times with 
ice-cold Phosphate Buffer Saline (PBS). Then, cells were fixed with 4% paraformaldehyde 
(v/v) (VWR Chemical) (in PBS) for 10 min at room temperature followed by washing 
three times with ice-cold PBS. Cells were incubated in Wheat Germ Agglutinin (Alexa 
Fluor 488) for 10 min at room temperature for plasma membrane staining (optional).  
 
Permeabilization 
Cells were incubated in ice-cold PBS containing 0.2% Triton X-100 (v/v) (Fisher Scientific) 
and washed in PBS three times.  
Blocking & Immunostaining 
To minimize non- specific binding signal, cells were incubated with 5% BSA (w/v) (VWR 
UK) in PBS for 1 hour at room temperature prior to incubation with primary antibody 
diluted in 1% BSA (w/v), for 1 hour (room temperature) or overnight (4oC). Unattached 
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antibodies were removed three times with PBS followed by incubation with secondary 
antibody (in 1% BSA, 1:400) for 1 hour in the dark at room temperature.  
 
Counter staining 
Nuclear staining was done by adding 1g/ml DAPI for 5 min and fixed again with 4% 
paraformaldehyde (w/v) for 10 min. Fixation solution was removed by rinsing with PBS 
three times and air dried. 
 
Mounting   
A drop of mounting medium, DPX Mounting Medium (Fisher Scientific) was added 
directly onto the cells and coverslips were pressed gently onto glass slides and stored in 
the dark (wrapped with aluminium foil) at 2-8oC overnight before viewing them under 
the fluorescence microscope (ZEISS LSM 750)  
 
 
 
 
 
 
 
 
 
 
 
 
 
88 
 
2.7 Western Blot 
2.7.1 Sample Preparation 
 
Whole Cell Protein extraction 
Cell culture plate was placed on ice and cells were washed with ice-cold PBS. Then cells 
were lysed directly from the plate by adding 100l ice-cold RIPA lysis buffer (Insight 
Biotechnology Ltd) per 107 cells containing protease inhibitor and phosphatase inhibitor 
following 1:100 dilution. Adherent cells were scraped with plastic scraper and the cell 
lysate were transferred into a pre-cooled microcentrifuge tube followed by 
centrifugation at 12,000 x g for 15 min at 4oC. The supernatant was aspirated and placed 
in a fresh tube for protein quantification.  
 
Cytoplasmic & Nuclear Protein Extraction 
Nuclear and cytoplasmic proteins were extracted using NE-PER Nuclear and Cytoplasmic 
Extraction kit (Thermo Scientific) according to manufacturer’s instruction. Briefly, Cells 
were washed with ice-cold PBS and harvested with Trypsin-EDTA followed by 
centrifugation at 500x g for 5 min. Supernatant was removed and ice-cold CER 1 (with 
added protease & phosphatase inhibitor, Thermo Scientific) to the cell pellet according 
to table below: 
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Table 2.6. Reagent volumes for different packed cell volumes. For HeLa cells, 2x106 cells 
is equivalent to 20 L packed cell volume. 
Packed cell 
volume (L) 
CER I (L) CER II (L) NER (L) 
10 100 5.5 50 
20 200 11 100 
50 500 27.5 250 
100 1000 55 500 
 
The tubes were then vortex at maximum speed for 5s followed by incubation on ice for 
10 min. Ice- cold CER II was then added to the tube, vortexed on the highest setting for 
5s and incubated on ice for 1 min. Next, the tube was vortexed again for 5s on highest 
setting and centrifuged for 5 min in a microfuge tube at 16,000x g (11570 rpm). 
Immediately the supernatant (cytoplasmic extract) was transferred to a clean pre-chilled 
tube and stored in -80oC until use. 
 For nuclear protein extraction, pellets produced from previous step was 
resuspended with ice-cold NER (containing protease & phosphatase inhibitor), vortexed 
for 15s and placed on ice for 10 min. This step was repeated for every 10 min, for a total 
of 40 min. Finally, the tube was centrifuged at maximum speed (16,000xg) for 10min and 
the supernatant was transferred to a clean pre-chilled tube. All samples were kept on ice 
for protein quantification step or stored in -80oC until use. 
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2.7.2 Protein Quantification 
The protein content from each sample was measured in duplicates using BCA Protein 
Assay Kit (Thermo Scientific) according to manufacturer’s instructions. Briefly, 10 l of 
BSA standard and protein samples was added into each well in the 96-well plate 
followed by the addition of 200 l of working reagent. The plate was then incubated in 
37oC incubator for 30 min before protein samples were measured using a plate reader 
(GENioS, Tecan) at the absorbance of 570nm. The content of protein in each sample was 
calculated using linear equation from BSA standard curve. A representative of BSA 
standard curve is shown in Figure 2.2. 
Once the amount of protein to be loaded was determined, samples were mixed 
with equal volume of 2x Laemmli buffer (Sigma Aldrich UK) and denatured at 95oC for 7 
min before processed for gel electrophoresis or stored at -20oC for future use. 
 
 
Figure 2.2 Serial dilution of BSA standard was prepared according to manufacturer’s 
protocol and concentration ranged between 0-2mg/ml. 
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2.7.3 SDS-PAGE Gel Electrophoresis 
 
Gel Preparation 
10% resolving and 10% stacking gel with 0.75mm thickness for electrophoresis was 
casted according to Table 2.7.  
Table 2.7. Reagents and chemical for resolving and stacking gels.  
10% Resolving Gel (v/v) 
Distilled H2O 4.48 ml 
1.5M Tris pH 8.8 3.0 ml 
ProtoGel 30% (v/v), GENEFLOW Ltd UK. 4.0 ml 
10% SDS (w/v) 120 l 
Ammonium Persulphate (APS), Sigma 
Aldrich UK 
40 l 
TEMED, Sigma Aldrich UK 10 l 
10% Stacking Gel (v/v) 
Distilled H2O 5.8 ml 
0.5M Tris pH 6.8 2.5 ml 
ProtoGel 30%, (v/v) 1.5 ml 
10% SDS, (w/v) 100l 
Ammonium Persulphate (APS) 100l 
TEMED 10l 
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Electrophoresis 
Equal amounts of protein samples in Laemmli buffer (10-20g) were loaded into each 
well alongside with the PageRuler Pre-stained protein ladder (Thermo Scientific). The gel 
was run in 1x SDS Running Buffer containing 25 mM Tris, 192 mM glycine and 0.1% SDS 
(w/v), for 30 min at 20 Amp (A) and the power was increased to 40 Amp for another 30 
min. 
 
2.7.4 Protein Transfer/Blotting 
Proteins from the gel were transferred to nitrocellulose membranes (Amersham UK) for 
one hour at 100 V. The transfer buffer was prepared by mixing ice-cold 10% of 10x Tris-
glycine, (v/v) (Fisher Scientific), 10% of methanol, (v/v) and 80% of filtered water.  
 
2.7.5 Blocking and Antibody Staining 
Nitrocellulose membrane was incubated with Odyssey Blocking Buffer (LICOR 
Biosciences) at room temperature with consistent shaking for one hour. The membrane 
was then incubated with primary antibody diluted at 1:1000 in the 5% BSA (w/v) (VWR 
Chemical) overnight at 4oC, followed by three washes with TBST, 20 min each. Next, the 
membranes were incubated with secondary antibody (700CW conjugated goat anti-
mouse or 800CW conjugated goat anti-rabbit, LICOR Biosciences), at the dilution of 
1:5000 at room temperature for one hour with consistent shaking before washing with 
two times TBST and final wash with TBS for 15 min.  
 
2.7.6 Visualization of Proteins 
Protein bands were visualized with Odyssey Infrared Imaging System and bands were 
quantified based on OD value with the Odyssey software. For the detection of 
endogenous control protein, membranes were stripped using the LICOR Stripping Buffer 
(LICOR Biosciences) for 20 min, washed with TBST, followed by incubation with Odyssey 
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Blocking Buffer for 1 hr before proceeding to the primary and secondary antibodies 
incubation steps.  
 
2.8 Co-Immunoprecipitation (Co-IP) 
Experiments were performed following manufacturer’s instructions. Briefly, 200g of 
protein sample was mixed with 1-10 l of primary antibody and incubated on rotating 
shaker at 4oC overnight. Then, the samples were incubated on rotating shaker at 4oC 
overnight in PBS containing 20l of Protein A/G Plus Beads (Santa Cruz), a genetically-
engineered protein that combines binding profiles of Protein A and Protein G, that 
provides binding for all species of antibody and IgG subclasses recognized by either 
Protein A or Protein G. Immunoprecipitants were collected by centrifugation at 4000 x g 
for 5min at 4oC and washed three times by resuspension and centrifugation (5min at 
4000 x g) in PBS. The samples were eluted into 40l of Laemmli buffer, boiled for 2-3 
min at 95oC, and analysed by SDS-PAGE/Western Blot (Method 2.7). Unused samples 
were stored at -20oC until use. A schematic diagram of the protocol is as depicted in 
Figure 2.3. 
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Figure 2.3. Schematic diagram of standard co-immunoprecipitation procedures 
(www.thermofisher.com). 
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2.9 Filter-Aided Sample Preparation (FASP)/ Proteomics Analysis 
Filter-aided sample preparation (FASP) method is a commonly used for proteomics 
analysis as it allows processing of essentially any class of protein, irrespective of their 
subcellular location. In general, proteins are extracted using sodium dodecyl sulfate-DTT 
buffer (SDS-DTT), followed by detergent removal with 8M urea on standard filtration 
device. As the 10,000k filter has been shown to efficiently retain small proteins (5-
10kDa) and efficiently elute peptides up to 5,000 Da, this filter was used for the entire 
experiments. Pure peptides are eluted after trypsin digestion, making them suitable to 
be used for single-run proteome analysis.  
 
Sample preparation for mass spectrometry 
2.9.1 Protein extraction 
Attached cells were washed with ice-cold PBS and lysed directly from the plate by adding 
100l of 0.1-1 % SDS-DTT (SDT)-lysis buffer (w/v), followed by incubation for 5 min at 
95oC. The proteins were solubilized by a quick sonication to reduce the viscosity of the 
lysates before centrifugation at 13,000 rpm for 15 min. 
 
2.9.2 Detergent removal and trypsin digestion  
Aliquot of lysates corresponding to 100g of proteins was mixed with 400l of 8M urea 
in 0.1M Tris/HCI pH 8.8 (Sigma, U5128) in an Eppendorf tube, vortexed and transferred 
to filter units of the 10k NMWCO spin columns. The filter unit was then centrifuged at 
14,000 x g for up to 30 min at room temperature and the collected flow-through was 
discarded. This whole step was repeated twice. Then, 400l of 0.05 M iodoacetamide in 
8M urea in 0.1 M Tris/HCI pH 8.8 were added to the concentrate followed by 
centrifugation at 600 rpm for 1 min and incubation for 5 min (without mixing) possibly in 
the dark, and finally centrifuged at 14,000 x g for 30 min.  
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Next, 400 l of 8M urea in 0.1 M Tris/HCI pH 8.0 (Sigma, U5128) was added to 
the filter unit and centrifuged at 14,000 x g for 20 min. This step was repeated twice 
with 400 l of 100mM ammonium bicarbonate (NH4HCO3). Following this, 120l of 
trypsin solubilized in NH4HCO3 was added, mixed at 600 rpm for 1 min and incubated in 
water bath overnight at 37oC. The next day, the filter units were transferred to fresh 
collection tubes and centrifuged at 14,000 x g for 40 min before adding 50 l of 0.5M 
NaCI for further centrifugation at 14,000 x g for 20 min. Finally, the sample was acidified 
and purified with 1 l of 5% Trifluoroacetic acid, TFA (v/v) to promote peptide binding to 
the resin of a C18 column. 
 
2.9.3 Desalination of peptides samples 
The ZipTip was rinsed ten times with 10l 100% Acetonitrile, ACN (v/v) and acidified 
peptides were loaded onto the tip by pipetting through 10l of the sample for at least 
ten times. For salt removal, the tip was immersed in 10l 0.1% TFA (v/v) by pipetting for 
at least ten times followed by rinsing with 10l of 50% ACN/0.1% TFA (v/v) for ten times 
to elute the peptides. The peptides samples were then centrifuged for 3 min to remove 
organic solvents and samples were subsequently applied to the high-performance liquid 
chromatography column and were run for 2hrs for each sample. Raw MS files were 
processed with a freely available software, MaxQuant and peak list files produced were 
searched by the MASCOT search engine against human database. 
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2.10 xCELLigence® Real-Time Cell Analysis (RTCA) 
Continuous monitoring of cell viability, which is mediated by internal and external 
factors, provides better understanding of molecular and biochemical pathways 
mediating cell viability. RTCA instruments utilize gold microelectrodes embedded in the 
bottom of microtiter well, to non-invasively monitor cell status in real-time without 
generating potential artefacts. This label-free impedance measurement given as cell 
index (CI), allows detection of changes in cell number, adherence, morphology and 
viability, with enhanced sensitivity without the need for over-expression of reporter and 
target proteins.  
 
2.10.1 Xcelligence proliferation assay protocol 
 
The experiments were performed following manufacturer’s instructions. Briefly, 100l of 
media was added into each well of E-Plate 16 (ACEA Biosciences, USA), a specially 
designed 16-well plate with micro-electrode configuration that covers 80% of each well 
bottom’s surface area. The real-time measurement of impedance across the electrodes 
provides a sensitive immediate detection of the cellular condition and response from 
low cell numbers to confluency. Prior to adding the cells, the plates were placed in the 
RTCA analyser and baseline measurement was taken every 1 min for 5 mins. Then, 100l 
of cells (approx. 3000 cells) to each well and the plates were left at room temperature 
for 30 min, before loading into the analyser for real-time measurement for 24hrs. After 
24hrs, 5 l of stimulating compound/ treatment was added into the respective wells.   
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2.10.2 Invasion/Migration Assay  
 
Invasion Assay 
The experiments were performed according to manufacturer’s instructions. For the 
invasion and migration experiment, CIM-plate was used instead of E-plate 16. CIM-plate 
(ACEA Biosciences, USA) is a modified- Boyden chamber designed with a removable top 
and bottom chamber, featuring the same micro-electrode configuration for the bottom 
chamber of a microporous polyethylene terephthalate (PET) membrane with the median 
pore size of this membrane is 8m (Figure 2.4). 
Prior to experiment, Matrigel (Corning) was diluted to 1:10 or 1:20 with cold 
serum free media and 30l of this was carefully added to the middle of the upper 
chamber well without introducing any bubbles. Then, the plates were left in the hood 
for 4hrs to ensure that the Matrigel was completely solidified. Following this, 160ml of 
pre- warmed media was added to the lower chamber well before upper chamber was 
locked on top of the lower chamber. Next, 30l of serum free media was then added to 
the top chamber wells and the plate was loaded into the analyser for 1 hour for the 
plate to equilibrate inside the chamber. Afterward, baseline measurement was taken 
every 1 min for 5 mins, before 100 l of cells was added to the upper chamber. The plate 
was then left for 30 mins in the 37oC incubator to allow cells adherence, before 
measurement was taken at every 15 mins for at least 10 hrs. Only data from a 2-10 hour 
were analysed for migration and invasion studies the cells will begin to proliferate after 
10hours. 
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Migration Assay 
The experiments for migration assay were the same as the invasion assay described 
above, except that the upper chamber of the plates was not coated with Matrigel prior 
to experiment. 
 
 
Figure 2.4 The diagram illustrates the view of upper and lower chambers for a single 
well. The bottom surface of the upper chamber chamber was composed of mircoporous 
memrane that cells can migrate through. Gold electrodes on the underside of this 
membrane detect the presence of the adherent cells. 
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 Statistical analysis 
 
Statistical analysis (Student t-test and 1-way ANOVA) for all experiments were 
performed using GraphPad software. All the results shown were the mean of standard 
error of means (SEM) of at least three independent experiments, where significance was 
assumed when p-value < 0.05.  
For the qRT-PCR assays, relative target gene expression was normalized against 
endogenous control, GAPDH using the ∆∆Ct method.  
As for the RT2 EMT profiler array, gene expression was analyzed using the web-based 
Qiagen data integration and visualization tool (https://www.qiagen.com/gb/shop/genes-
and-pathways/data-analysis-center).  
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CHAPTER 3 
Analysis of the effects of estrogen (E2) on 
the proteome profile of MCF7 breast 
cancer cell line  
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Introduction  
Estrogen (E2) has been shown to induce various physiological effects, in which, their 
actions are not only required for normal development growth of reproductive tissues in 
female but are also implicated in tumorigenesis arise from these tissues. Studies show 
that E2 can exert proliferative effects in breast cancer and act as a survival agent such as 
by promoting the expression of anti-apoptotic protein Bcl-2 (293). Although E2 has been 
demonstrated to play critical role in breast cancer progression, primarily in hormone-
responsive breast cancer, the molecular basis of this association is not yet fully studied.  
 
Previous studies have used various methods to identify protein targets of E2 
actions, for example by using 2-D-PAGE, however, this method provides limited 
coverage of the protein profile. Therefore, in this experiment, mass spectrometry was 
used to identify changes in global proteome profile by estrogen in hormone-responsive 
breast cancer cells MCF7. Through this method, greater protein coverage (generally 
>2000 proteins) can be obtained and highly quantitative proteome analysis can be done 
to elucidate sets of proteins regulated by E2 and their association with signaling 
networks or biological events leading to breast cancer progression and metastasis. 
Additionally, numerous studies have suggested that the presence of subpopulation of 
cells known as cancer stem cells (CSCs) within breast cancer cells is one of the factor that 
contribute to cancer metastasis. Therefore, this chapter was also aimed to investigate 
the presence of CSCs within MCF7 cells and to elucidate protein markers that connect 
CSCs with cancer progression.  
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Results 
3.1 Estrogen (17-estradiol, E2) regulates the expression of a core 
splicing kinase, serine-arginine protein kinase 1 (SRPK1) protein in 
MCF7 breast cancer cells 
Approximately 50%-80% of all breast tumors have been found to express 
estrogen receptors (ERs), and studies have reported that breast cancer progression and 
hormonal therapy resistance in hormone- responsive breast cancer was frequently 
found to be associated with estrogen signaling in the cells (57). To investigate the effect 
of steroid hormone, 17-estradiol (E2) on the global protein expression in ER+ breast 
cancer, proteome analysis was performed in cellular model of ER+ breast cancer cell, 
MCF7 cell line. Following the concentration and treatment period used in other studies, 
cells were treated with 10nM for 24hr, and analyzed using LC-MS/MS in triplicates.  
It was demonstrated that of all 3000 proteins identified from the experiment, 
fold-change analysis measured against control samples (untreated) showed a total of 
157 proteins were found to have statistically significant changes (p<0.1) in expression, 
with 93 proteins were upregulated and 64 proteins were downregulated in response to 
E2 treatment (Figure 3.1A). Comparison in gene ontology analysis (Figure 3.1B) of both 
the upregulated and downregulated proteins showed that E2 signaling seemed to target 
proteins predominantly expressed in the cytosol, nucleus, mitochondrion and 
cytoskeleton of the cell.  
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Figure 3.1 (A) Venn diagram shows proteins identified from quantitative profile of 
control vs E2-treated samples. A total of 2610 protein were identified as having 
identical values (statistically insignificant) in both samples, whereas 63 proteins were 
found upregulated (downregulated by E2) and 93 proteins were upregulated in the 
stimulated cells. (B) Comparison of Gene Ontology (GO) analysis for cellular 
component between upregulated and downregulated proteins in response to E2. 
Changes are considered significant when p-value < 0.1 and the fold change is two and 
above. 
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At present, there are only a few studies on proteomic analysis of breast cancer, 
specifically on hormone- responsive MCF7 cells. One of the studies in which MCF7 cells 
were exposed to mitogenic concentration of estrogen has identified statistically 
significant changes in the expression of twelve proteins which include those that are 
already implicated in the progression of breast cancer such as stathmin (STMN1), 
calreticulin (CRTCC), heat shock 71kDa (HS7C) and alpha- enolase (ENOA) (294). In 
addition, other studies have also analyzed the pathways that participate in the 
differential response to estrogen and estrogen- induced proliferation and apoptosis in 
MCF7 cells and has identified 26 proteins associated with GPCRs, PI3K/AKT, Wnt and 
Notch signaling pathways such as PRPF6 (proteins involved in pre-mRNA splicing/co-
activator of androgen receptor), FAK1, Rap1GAP (GPCR signaling), BCL3 (Wnt signaling), 
TLE3 (Wnt/ Notch) (295).  
Notably, some of the identified proteins above such as STMN1, ENOA, and 
PRPF6 were also found upregulated in this study (Table 3.1). In addition to these three 
proteins, my study has unexpectedly identified serine-arginine protein kinase 1 (SRPK1), 
which is one of the well-established key kinases in regulating alternative splicing 
mechanism in cells, among the ER-signaling targets and found to be upregulated with as 
high as 7.7-fold as compared to that in control cells.  
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Table 3.1 List of 93 upregulated proteins in response to estrogen treatment in MCF7 
cells, as compared to control. Some of these are known proteins involved in the 
regulation of mRNA splicing mechanism and in the activation of oncogenic signaling 
pathways in cells (red font). 
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Furthermore, validation experiments by western blot and immunostaining 
experiment confirmed that SRPK1 protein expression was detected to be upregulated 
following estrogen treatment at 10nM for 24hr, as shown in Figure 3.2 and Figure 3.3, 
respectively. Previous studies have demonstrated that elevated level SRPK1 protein 
expression has been observed various cancers such as breast, pancreatic and colorectal 
(172). In addition, it has also been reported that the production of oncogenic protein 
isoforms is one of the factors contributing to the tumorigenesis , predominantly in ER+ 
breast cancer, in which this regulation of mRNA splicing mechanism involves SRPK1 
(17,296–298). 
  
 
 
 
 
Figure 3.2 Western blot results confirmed the upregulation of SRPK1 protein 
expression following estrogen treatment. *p <0.05 (n=4). 
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Figure 3.3 MCF7 cells were treated with 10nM of estrogen (17 -estradiol) for 24 hr 
before detection using anti- SRPK1 antibody. Secondary antibody used was FITC, 
shown in green. DAPI nuclear staining was shown in blue. Protein signal was 
measured by drawing shape around the cell as shown above, and intensity was 
measured using ImageJ. Representative images are shown. n=6, scale bar =10um. 
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Further analysis using STRING, a biological database and web resource of known 
and predicted protein-protein interactions, shows the interaction between SRPK1 and SR 
proteins such as SRSF1, SRSF2, SRSF3, SRSF4, SRSF5, SRSF6, SRSF7 and SRSF9 in human 
(Figure 3.4A). The role of SRPK1 kinase in the phosphorylation of serine-arginine (SR) 
splicing proteins has been well documented and studies show that differential level of 
phosphorylated SR proteins can affect splice site selection of pre-mRNA transcript during 
alternative splicing of target genes, which can subsequently lead to the production of 
oncogenic protein isoforms. For example, increased SRPK1 kinase activity in the nucleus 
has been demonstrated to induce differential phosphorylation of SRp30, SRp40, SRp55 
and SRp75 which in turn altered the splice site choice of EIA gene thus producing E1A-9S, 
E1A-13S and E1A-12S isoforms in cells (174). Therefore, upregulation of SRPK1 in the 
stimulated cells may suggest the potential role of estrogen in modulating splicing 
mechanism, which might subsequently trigger the activation of various oncogenic 
signaling networks in the cells. 
In addition to SRPK1, other targets of E2 actions such as DNAjc21, which belongs 
to Hsp40 heat-shock proteins family important in the formation of chaperone complex 
with Hsp70 and SRPK1 in the cytoplasm was also detected in the treated cells. Some of 
Hsp40 proteins family functions include protein translation, folding, unfolding, 
translocation and degradation through the interaction with Hsp70 proteins (299). 
Previous studies have demonstrated that SRPK1 binds to the co-chaperones 
Hsp40/DNAjc8 and Aha before interacts with major molecular chaperones Hsp70 and 
Hsp90 in the cytoplasm (171), and it dissociates from these chaperone complexes upon 
stress signals which triggers its translocation to the nucleus, and initiate SR proteins 
phosphorylation and alter the splice site of target mRNA (171). Furthermore, mutations 
in DNAjc21 has also been shown promote cancer-prone bone marrow failure (BMF) 
syndrome and the loss of its expression inhibits cell growth(300). In cytoplasm, DNAjc21 
interacts with 60S Ribosome maturation factors and recruits heat shock 70 kDA protein 
8 (HSPA8) to stimulate ATPase activity.  
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Another protein that showed increased expression following E2 treatment was 
the splicing factor SF35B, a non-snRNP multiprotein complex essential for spliceosome 
formation in which it ensures accurate excision of introns from pre-mRNA transcript by 
recognizing the branch site of pre-mRNA within the major and minor spliceosomes 
(301). In addition, HNRNPDL (JKTBP), a family of splicing repressor protein hnRNPs, was 
also found amplified under estrogen treatment. It acts as transcriptional regulator and 
functions primarily in mRNA biogenesis and mRNA metabolism. In epithelial cells, 
hnRNPDL expression was found highly elevated in response to pro-inflammatory 
cytokines such as interleukin-6 (IL-6), and was shown to regulate the expression level of 
NF-κB-repressing factor (NRF) by increasing the translation initiation of the NRF (302). 
NF- κB pathway is one of the signaling pathways implicated in oncogenesis, where its 
constitutive activation can lead to the dysregulation of genes involved in many cellular 
processes such as proliferation, migration and apoptosis.  Even more, hnRNPDL was also 
demonstrated to promote cell proliferation and stimulate the expression of EGFR in 
prostate cancer cells (303). Apart from that, consistent with STRING analysis (Figure 
3.4B), my finding was in line with the established interaction between hnRNPDL and 
Polypyrimidine tract-binding protein 1 (PTBP1), in which their expression was found to 
be negatively correlated in this study.  
Other than the abovementioned splicing- related proteins, there were other 
functional proteins whose expression were found to be amplified in response to 
estrogen, such as Ras-related protein Rab-2A (RAB2A), Growth factor receptor-bound 
protein 2 (GRB2) and Tumor protein D52 (TPD52). RAB2A is a member of Ras-oncogene 
family that activates ERK ½- MAPK (Figure 3.4C), and is required for the cell-surface 
targeting and GPCRs signaling (304). Consistently, as one of RAB2A targets, the 
expression of MAPK was found upregulated by 0.5-fold although not statistically 
significant, with borderline p-value of 0.14. It has also been shown to promote breast 
cancer stem cells (BCSCs) expansion and tumorigenesis by upregulating the activity of 
transcription factors Zeb1 and -catenin nuclear translocation resulting in the activation 
112 
 
of Wnt signaling, a prominent signaling pathway implicated in the epithelial-to-
mesenchymal transition (EMT) event in the cells (305).  
Meanwhile, GRB2 is a proto-oncogene and an adapter protein frequently found 
overexpressed in breast cancers and was involved in EGF-induced ERK and AKT 
activation and cell proliferation (Figure 3.4 D) (306). In addition to its role in positive 
signaling via the Ras/Erk pathway, GRB2 was also found to act as adaptor in Wnt 
signaling activation by FAK, through Grb2-rac-jnk-c-jun pathway (307). Whereas in lung 
cancer, GRB2 was demonstrated to be involved in pathway activation that leads to lung 
cancer invasion and metastasis (308). Furthermore, while tumor protein TPD52 
overexpression has been shown to promote lung squamous cell carcinoma 
aggressiveness (309), high level of TPD52 expression was found to be positively 
correlated with patient’s survival in ERBB2-amplified breast cancer cells (310). 
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On the other hand, there were a number of downregulated proteins that are 
related to splicing mechanism in cells such as DHX15 which is a functional partner of 
SRPK2 and splicing repressor,hnRNPA1, RUXG; a core component on spliceosomal, 
PTPB1; family of splicing repressor hnRNPs, and RAB21 which is required in the 
promotion of cancer cell invasion and migration as reported in previous studies 
(311,312).  
The differential expression of splicing molecules, as well as cancer-associated 
proteins following estrogen treatment suggests the complexity of E2 signaling in the 
cells which might involve interactions between various signaling pathways in the cells, as 
Figure 3.4 STRING analysis showing the protein-protein interaction network of 
selected proteins found upregulated in response to estrogen. (A) SRPK1, (B) HNRPDL, 
(C) RAB2A, and (D) GRB2.  
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well as it establishes the potential of E2 signaling in regulating SRPK1-driven molecular 
pathway in the mRNA splicing event in breast cancer cells. 
 
3.2 Analysis of breast cancer stem cells (CSCs) isolated from parent 
MCF7 cells.    
Following the finding that estrogen (E2) can modulate the activity of a core splicing 
kinase, SRPK1, it was hypothesized CSCs subpopulation in cancer cells could potentially 
promote cancer progression via alternative splicing event. This is supported by the fact 
that one of the hallmarks of CSCs is high CD44 expression, a cell surface protein whose 
splice variants have been demonstrated to accelerate cancer metastasis in various 
human cancers.  
The existence of cancer stem cells (CSCs) or circulating-tumor cells (CTCs) which 
has the characteristics of stem cells (e.g. to self-renew)) has been successfully 
demonstrated in breast cancer patients (313). Since CSCs was thought to play role in 
cancer metastasis and hormone therapy resistance, a magnetic separation method was 
used to test whether these cells could be isolated from MCF7 cell line. These CSCs are 
known to exhibit positivity for few markers such as CD44high/CD24low. This CSCs 
population was successfully isolated using various other methods in breast cancer cell 
lines such as SUM149,HCC194 and MCF7 (269).  
In fact, high counts of CTCs/CSCs have been used as indicator of bad prognosis in 
patients with metastatic breast cancer (314). However, since the percentage of CSCs is 
relatively low in MCF7 breast cancer cells, only a small fraction of them could be 
collected in this experiment and mammosphere-forming ability of the collected cells was 
observed for several days. This mammospheres-forming ability of is often used to isolate 
and identify CSCs, as unlike other cells, CSCs are not anchorage-dependent and are able 
to survive, proliferate and form multicellular spheroids (termed as ‘mammospheres’), in 
the absence of attachment (in suspension) (315). The ability of CSCs to form 
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mammospheres or clusters is also one of the factors that is shown to be associated with 
increased metastatic ability, with at most 50-fold of metastatic potential as opposed to 
single CSCs (316).  
Figure 3.5 shows the morphology of parent MCF7 cells grown in complete 
culture media, before CSCs was isolated from 5x106 of MCF7 cells suspension. Following 
the isolation of CSCs subpopulation, these single cell suspension of CSCs were seeded in 
ultra-low attachment plates, in the presence of 1% charcoal-stripped fetal bovine serum 
(CS-FBS) in the media and the plates were kept in the 37oC incubator for at least 7 days 
as CSCs have been known to have a slow population- doubling time (317), without 
changing the media throughout the incubation period. It was found that, single cells 
started to form small multicellular clusters after day 2, and the clusters appeared larger 
at day 6. The cells were kept growing in the plate up until day 15, before the cells started 
to die. The successful isolation of CSCs subpopulation from MCF7 cell line suggests that 
these cells indeed contain CSCs, and that the magnetic separation method can serve as 
another technique to separate the stem cells from their parent cells. In addition, this 
also shows that MCF7 cell line can be a suitable model to further study the biology of 
breast cancer stem cells. However, considering that these CSCs exist only in a very small 
number within breast cancer cell lines (approximately 1%), it can be an obstacle to 
obtain enough samples to conduct the study, without further enrichment method. 
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Figure 3.5 Mammosphere-forming experiment. The CSCs subpopulation were 
isolated from parent MCF7 cells using MagCellect CD44+CD44- breast CSC isolation 
kit following the manufacturer’s protocols, and single cells (Day 1) were seeded in 
ultra-low attachment plate. Single cells started to form multicellular clusters on Day 
2, and the spheres gradually expanding, as shown in Day 6. Pictures were taken using 
Nikon phase-contrast microscope at 10x objective. 
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To investigate the effects of estrogen on protein expression profile in CSCs, 
especially proteins involved in splicing mechanism and metastatic process as 
demonstrated in parent MCF7 cells, these CSCs were treated with 10nM E2 for 24 hr and 
quantitative proteomics analysis was carried out as described in Chapter Method 2.9. 
Results from the mass spectrometry analysis demonstrated that out of 2479 total 
proteins detected in the samples, 64 of them were highly expressed in stimulated cells 
as compared to control, and 136 were suppressed after the exposure with estrogen.  
Further analysis on gene ontology annotation of these differentially expressed 
proteins indicated that the downregulated proteins are mainly in cytoplasm and nucleus 
(Figure 3.6A). In addition, STAT6, a member of STAT transcription factor which play a key 
role in mediating interleukin 4 (IL4) biological response via JAK-STAT signaling pathway 
was found among the significantly reduced proteins (Figure 3.6B). The JAK-STAT 
pathway has been known to be involved in normal stem cell development, and recently 
it was demonstrated that this pathway was also found deregulated in breast cancer 
stem cells (318).  On the other hand, E2 significantly stimulated the expression of 
proteins that reside mainly in the cytoplasm and nucleus, and one of the protein 
identified among the upregulated protein was Cyclin D1 (CCND1), which is a known 
target of ER signaling that promotes hormonal therapy resistance breast tumors 
(319,320).  
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Figure 3.6 (A) GO annotation of proteins affected by estrogen treatment in cancer 
stem cells (CSCs) shows that most of the targets are the proteins found in cytoplasm, 
nucleus, ER and mitochondria. (B) One of the downregulated protein was STAT6, 
which is one of the key players in JAK-STAT pathway, a pathway that has been found 
deregulated in breast cancer stem cells. 
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Discussion  
The role of estrogen receptor signaling in the progression of one of breast cancer 
subtypes, ER positive tumours, has long been recognized where more than 80% of 
lymph node metastasis and approximately 65-70% of distant metastases retain ER 
expression [reviewed in (321)].  In addition, estrogen (E2) has been shown to facilitate 
metastatic process through rapid cytoskeletal remodelling resulting in the increased 
migration and invasion ability of the cells through G13/RhoA/ROCK/moesin cascade 
(322,323). Previous studies have shown that estrogen receptors (ERs) signaling can 
interact with multiple cytosolic kinases such as Src kinase, Akt, MAPK and PI3K in ER+ 
breast cancer (57,321).  
 
Changes in MCF7 protein expression profile by estrogen 
Proteome analysis conducted in this study demonstrated that E2 can positively 
modulate the expression of another protein kinase, Serine-Arginine Protein Kinase 1 
(SRPK1), a key regulator in pre- mRNA splicing event. Although proteomics studies on 
E2-stimulated ER+ MCF7 breast cancer cells have been reported before (294,295,324), 
as well as estrogen has been demonstrated to regulate the transcription of hundreds of 
genes implicated in breast cancer proliferation and survival, the potential effects of 
estrogen in modulating splicing related proteins are not yet fully explored. Validation 
experiments through the analysis of total SRPK1 protein expression and mRNA 
expression further confirmed that E2 can stimulate SRPK1 expression both at protein 
and mRNA level in MCF7 cells. Therefore, finding from this study reveals another target 
of E2 action in ER+ breast cancer cells, which may potentially trigger signaling networks 
that can influence various downstream molecular events such as alternative splicing, 
hence promoting cancer development and progression. This is because, elevation of 
SRPK1 activity has been extensively reported in various cancers undergoing EMT, which 
include prostate, ER (+) breast and non-small cell lung carcinoma (171,174,190,193).  
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Alongside SRPK1, the expression of other splicing related proteins was also 
detected to be differentially expressed, such as DNAjc21 (upregulated), which is 
important in the formation of chaperones complexes with SRPK1 and Hsp70 in the 
cytoplasm. Interestingly, the expression of splicing repressor PTPB1 (family of hnRNPs) 
and component of spliceosomal protein, RUXG were found downregulated in response 
to estrogen. Given the significant altered pre-mRNA splicing event in cancer progression, 
these results reveal that estrogen is most likely to influence breast cancer progression, 
one of the ways via the modulation of splicing proteins activity in the cells.  
 
Effects of estrogen on splicing-related protein expression in cancer stem cells (CSCs) 
The existence of CSCs which have the characteristics of stem cells such as self-
renewal ability, has been previously demonstrated in breast cancer patients (313). These 
cells, which exhibit markers such as high CD44/low CD24 (CD44+CD24-) marker on its cell 
surface, is suggested to be one of the factors that contribute to hormone therapy 
resistance and cancer recurrence and metastasis in patients. Furthermore, as splice 
variants of CD44 gene has also been shown to accelerate metastasis process in various 
cancers, the differential expression of splicing related proteins in response to estrogen 
was also investigated.  
Of note, while presence of cancer stem cells (CSCs) sub-population in MCF7 cell 
line was successfully demonstrated in this study, detailed analysis of the results showed 
that none of splicing related proteins were found affected by the treatment. However, 
estrogen was shown to downregulate STAT6, a member in JAK-STAT pathway, a pathway 
involves in inflammatory response and in normal stem cell pathway development. 
Recently, JAK-STAT pathway was also found to be deregulated in breast cancer stem 
cells (318). In addition, one of the E2 signaling target genes, Cyclin D1 (CCND1) that play 
roles in the processes promoting hormonal therapy resistance in breast cancer was 
found upregulated by the treatment.  
Furthermore, it has been reported in several studies that CSCs notably has 
different epithelial and mesenchymal characteristics among them, and this characteristic 
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is not necessarily homogenic as parent cells, for example, CSCs found in ER-positive 
metastatic breast cancer frequently lack estrogen receptor expression (325). Thorough 
search on markers specific for metastatic CSCs, such as the expression of tyrosine kinase 
receptor (c-MET)(326) was carried out, and it was not found among the upregulated 
proteins in the CSCs isolated from this study. Therefore, although the isolated CSCs were 
shown to have the properties associated with increased metastatic ability such as ability 
to form mammospheres, the criteria may not be enough to be considered as CSCs of 
mesenchymal/ metastatic type, thus may suggest that these CSCs might be from the 
epithelial type. In addition, since the detection method used was not a targeted 
proteomic study, in which protein abundance is a key determinant of detection, this 
could be a limiting factor and sample enrichment is needed before deeper analysis could 
be done. Therefore, further studies on CSCs were not continued in this project.  
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CHAPTER 4 
Role of estrogen (E2) and corticotrophin-
releasing hormone (CRH) in pre-mRNA 
alternative splicing (AS) in ER+ and ER- 
breast cancer cells  
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Introduction  
Alternative splicing (AS) takes place in nearly all the mammalian genes and is 
regulated by protein complex called spliceosome. It is an essential regulatory 
mechanism that regulates proper production and function of proteins. Numerous 
studies have demonstrated that aberrant splicing can lead to various human diseases 
through the production of protein isoforms that can trigger disease development or 
progression in human, or by modifying protein functions important in maintaining 
human health. The role of estrogen in the alternative splicing of several target genes has 
been previously demonstrated, such as PKM2, CRHR1, FAS/CD95 and FGFR2 in MCF7 
cells (327), which eventually contribute to breast carcinogenesis and development.  
In line with this finding, results from my previous chapter showed that estrogen 
(E2) can potentially regulate the expression of splicing kinase, SRPK1 in ER+ cells. This 
Serine-Arginine protein kinase acts downstream of protein kinase B (AKT), and can be 
found predominantly in the cytoplasm of most cell types (169). In the cytoplasm, SRPK1 
forms complex with major molecular chaperones HSP70 and HSP90 before leaving the 
complexes upon stress signal, and moves to the nucleus to phosphorylate serine-
arginine (SR) proteins and initiate pre-mRNA splicing in the nucleus (170,171).  
Furthermore, studies have shown that alterations in cellular immunity such as in 
cytokine production induced by stress signal may promote cancer progression (328–
331). Studies show that stress- induced alterations through the action of such as CRH 
can potentially increase disease susceptibility. This is supported by previous findings in 
which the nucleotide sequences in the POMC promoter, a CRH target gene, has been 
found in the genome of human diseases such as HIV-s, human MAT-1 breast cancer 
oncogenes and in proinflammatory molecules, for example interleukin-1b converting 
enzyme (332). This has led to the hypothesis that CRH may influence progression of 
certain endocrine-related diseases such as breast cancer. In addition, dual roles of CRH 
in promoting and inhibiting breast cancer progression have also been previously 
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reported (103,104), in which both effects were shown to be time- and cell types- 
dependent.  
Even more, physiological stress has been found to likely cause poor outcome in 
breast cancer patients, one of it by inducing poor response to therapy (333). The 
presence of stress molecules, corticotrophin-releasing hormone (CRH) and its related 
peptides in various cancers such as breast and prostate cancer further supports the 
notion that this hormone plays role in tumorigenesis (134,135). However, whilst reviews 
and meta-analysis have reported the association between stress and cancer, little is 
known about the underlying mechanism of actions of stress molecules in tumorigenesis.  
Therefore, in this chapter, various molecular biology techniques were used to 
investigate the downstream effects of estrogen- driven upregulation of SRPK1 activity on 
the pre-mRNA alternative splicing mechanism in ER+, as studies showed that altered 
splicing event occurred more predominantly in hormone-responsive breast cancer. 
Additionally, since CRH has also been demonstrated to regulate protein kinase B (AKT), a 
protein kinase known to regulate SRPK1 phosphorylation, CRH was also used as 
extracellular stimulus to examine its potential effect on SRPK1 as well as the role of CRH 
signaling in promoting cancer progression in ER+ and ER- cells through the regulation of 
alternative splicing mechanism. This was done by analysing the activity of serine-arginine 
(SR) splicing proteins after the treatment with both hormones. In addition, CD44 gene, 
whose splice variants, especially CD44s and CD44v have been implicated in 
tumorigenesis was selected to measure the consequence of altered activity of splicing 
proteins on the production of CD44 splice isoforms in both MCF7 (ER+) and SKBR3 (ER-) 
cell lines. 
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Results  
4.1 Detection of SRPK1 protein in co-chaperone complexes 
Estrogen- induced upregulation of SRPK1 protein expression found in the proteomic 
experiment has led to further investigations on the regulation of this splicing kinase 
activity and the alternative splicing (AS) mechanism mediated by this protein in the cells. 
Previous studies have shown that cellular distribution of SRPK1 is essential for its 
function in the regulation of serine-arginine proteins (SRps) phosphorylation, and SRPK1 
was demonstrated to interact with molecular cochaperone, Hsp70/Hsp90 complex in the 
cytoplasm, that facilitates folding of the kinase into active conformation for the kinase-
mediated signaling (171,334). The active form of SRPK1 proteins are then released from 
these cochaperone complexes, and it was also demonstrated that these active SRPK1 
kinases were capable to translocate to the nucleus for SR proteins phosphorylation upon 
dissociation from cochaperone complexes in the cytoplasm (171). 
The association between SRPK1 and the Hsp70/Hsp90 containing complexes was 
interrogated using co-immunoprecipitation (co-IP) method followed by western blot 
against SRPK1 protein, and indeed, SRPK1 protein was detected in the Hsp70/Hsp90 
cochaperone as shown in Figure 4.1. This finding is therefore consistent with current 
understanding that SRPK1 interacted directly and formed complexes with major heat-
shock protein Hsp70 as well as Hsp90 (190).  
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Figure 4.1 Detection of SRPK1 in Hsp70/Hsp90 co-chaperone complex confirms the 
association between SRPK1 with the major heat-shock complexes in the cells. The co-
chaperone complexes were immunoprecipitated by using anti- Hsp70, followed by 
western blot against SRPK1 protein.  
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4.2 Analysis of estrogen (E2)- induced SRPK1 phosphorylation and 
nuclear translocation 
 
4.2.1 Time-course determination of SRPK1 activity by E2 
 
As the protein discovery analysis showed that E2 can stimulate the expression of SRPK1 
in MCF7 cells, further investigation was performed to confirm this finding and to 
examine how E2 signaling regulates SRPK1 activity in the cells. The fundamental role of 
SRPK1 kinase in regulating alternative splicing mechanism in breast cancer has been 
reported in several studies, for example, it was reported that depletion of SRPK1 kinase 
in breast cancer cells resulted in reduced phosphorylation level of SR proteins, including 
SRSF3, SRSF4 and SRSF6, leading to altered splicing of MAP2K2 gene and inhibition of 
apoptosis in the cells (170,172). In addition, it is also known that catalytically active 
SRPK1 translocates to the nucleus upon phosphorylation by upstream kinases such as 
AKT, and dissociation form Hsp70/Hsp90 co-chaperone complexes and regulates the 
phosphorylation of SR proteins in the nucleus (171,335). In fact, the detection of SRPK1 
protein signal in stimulated cells by immunofluorescence in previous section (Figure 3.3) 
also displayed generally higher detection of SRPK1 protein in the nuclear compartment 
as compared to cytoplasm. 
Therefore, to determine whether E2 regulation of SRPK1 activity can also lead to 
its nuclear translocation, time-course experiment followed by western blot was 
performed in cytoplasmic and nuclear compartments of MCF7 cells, before and after E2 
stimulation. As E2 was shown to induce SRPK1 protein expression, it was hypothesized 
that it can also trigger SRPK1 nuclear translocation in the cells. Therefore, MCF7 cells 
were treated with 10nM estrogen at various time points; 0, 0.5, 1, 2, 24 hr, and 
cytoplasmic and nuclear proteins were extracted. Since dissociation of SRPK1 from co-
chaperone complexes releases active SRPK1 kinases, immunohistochemistry was 
performed against phopho-SRPK1 (Thr 601) in both cell compartments, and signal 
detection was normalized against total SRPK1 level. It was observed that in line with the 
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hypothesis, E2 indeed can stimulate SRPK1 nuclear translocation and both the cyto- nuc 
level of SRPK1 was found to be the highest at 24 hr after stimulation (Figure 4.2).  
 
 
    
 
 
 
Figure 4.2 MCF7 cells were treated with 10nM E2 at 0, 0.5, 1, 2, 24hr. Cytoplasmic 
and nuclear proteins were extracted and phospho-SRPK1 (Thr601) signals were 
detected in both cell compartments using anti-pSRPK1 antibody and results were 
normalized against total SRPK1 level.  Phosphorylation level was detected increased 
in both compartments after 24hrs of estrogen treatment. Representative blots are 
shown. 
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4.2.2 Analysis of phosphorylation and nuclear translocation of SRPK1 
protein by estrogen (E2)  
 
Following the time-course experiment, E2-driven SRPK1 phosphorylation and nuclear 
translocation were further examined, and SRPK1 mRNA expression was also 
investigated. Cells were treated with 10nM E2 at 24hr (this concentration and treatment 
period were used in all subsequent experiments) before proteins and RNA were 
extracted. The cyto-nuc level of phospho-SRPK1 (pSRPK1) were detected by western 
blot, whilst the expression of SRPK1 mRNA after estrogen stimulation was determined 
by real-time quantitative PCR (RT-qPCR). Figure 4.3A confirms that stimulated cells 
demonstrated statistically significant increase in the level of pSRPK1 in the cytoplasm 
and nucleus, as compared to unstimulated cells. Consistently, it was also found that the 
expression of SRPK1 mRNA was upregulated in the stimulated cells (Figure 4.3B).  
 
4.2.3 Effects of Akt kinase inhibition on E2- induced SRPK1 
phosphorylation 
 
Previous findings revealed that Akt regulates the phosphorylation of SRPK1 in the cells 
(190), therefore the role of Akt in this E2- driven SRPK1 phosphorylation was assessed by 
inhibiting Akt kinase activity in the stimulated cells. Stimulated MCF7 cells were pre-
treated with Akt kinase inhibitor (MK2206), at 5mM for 2hr before proteins and RNA 
were extracted. It was demonstrated that reduced Akt kinase did not affect much of 
basal phosphorylation of SRPK1, this kinase inhibition in stimulated cells showed 
markedly reduced pSRPK1 level (Figure 4.3A). This finding was also consistent with 
SRPK1 mRNA expression, in which, Akt kinase inhibition blocked E2- driven stimulation 
of SRPK1 mRNA expression in the cells (Figure 4.3B), suggesting that Akt plays role in E2 
signaling in the regulation of SRPK1 kinase in MCF7 cells.  
130 
 
 
 
 
 
 
Figure 4.3 (A) Western blot analysis of phospho-SRPK1 showed that estrogen (E2) 
stimulates basal phosphorylation of SRPK1 (pSRPK1) and its nuclear translocation. In 
addition, pre-treatment of the stimulated cells with Akt inhibitor (MK2206) has led to 
reduced pSRPK1 signal detection, although reduced level of Akt activity did not affect 
basal pSRPK1 level. As compared to Akt kinase inhibition alone, inhibition of Akt 
kinase in stimulated cells also showed significantly reduced signal of pSRPK1 in 
cytoplasm. (B) Similarly, this finding was also evident at mRNA level, in which E2 was 
found to upregulate SRPK1 mRNA expression. However, reduced Akt kinase inhibited 
this E2-driven induction of SRPK1 mRNA expression.  
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4.3 Analysis of Corticotrophin- releasing hormone (CRH)-induced 
SRPK1 phosphorylation and nuclear translocation 
There is growing evidence that stress may affect cancer progression, one of the ways 
through alterations in cellular immunity such as in cellular activation, cytokine 
production and cell trafficking (328–331). Previous studies suggest that physiological 
stress factors may also contribute to poor outcome in breast cancer patients which 
include poor response to therapy (333). In addition, one of the stress molecules, 
corticotrophin-releasing hormone (CRH) was thought to be implicated in tumorigenesis 
after studies reported the presence of CRH receptors and CRH family peptides in 
endocrine-related cancers such as breast and prostate cancer (134,135). Although 
reviews and meta-analysis have reported the association between stress and cancer, 
little is known about the underlying mechanism of actions of stress molecules in 
tumorigenesis.  
Therefore, this study was also aimed to examine the mechanism of stress-
induced changes in cancer, specifically by studying the effects of CRH and the functional 
consequences of CRH signaling in influencing cancer progression. CRH was used as 
extracellular stimulus to investigate its effects on SRPK1 status, as previous studies have 
reported that Akt is one of protein kinases regulated by CRH, and Akt has also been 
shown to regulate SRPK1 phosphorylation in the cells. Furthermore, the suitability of 
cellular model, estrogen receptor positive (ER+), MCF7 breast cancer cell line for 
studying the effects of CRH in the regulation of splicing molecules is described in this 
section.  
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4.3.1 Time-course determination of SRPK1 activity by CRH 
CRH through activation of G protein-coupled receptor (GPCR) exerts acute effects 
affecting the activity of intracellular pathways leading to transcriptional effects of its 
target genes. Therefore, following the final concentration of CRH used by previous 
student in this group, the effects of CRH on SRPK1 status were investigated. MCF7 cells 
were treated with 100nM CRH at various time points; 0, 0.5, 1, 2, 4, 24hr, and 
cytoplasmic and nuclear proteins were extracted, followed by western blot analysis 
against phospho-SRPK1 (Thr601). Interestingly, it was observed that CRH can 
significantly induce SRPK1 phosphorylation and nuclear translocation in MCF7 cells 24hrs 
after stimulation (Figure 4.4), suggesting that CRH may influence tumorigenesis via 
modulation of key protein kinase in the regulation of splicing mechanism, SRPK1 in ER+ 
MCF7 cells.  
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Figure 4.4 MCF7 cells were treated with 100nM CRH at 0, 0.5, 1, 2, 4, and 24hr. 
Cytoplasmic and nuclear proteins were extracted and phospho-SRPK1 (Thr601) signals 
were detected in both cell compartments by using anti-pSRPK1 antibody and results 
were normalized against total SRPK1. CRH was shown to significantly stimulate SRPK1 
phosphorylation and nuclear translocation after 24hrs of treatment.  Representative 
blots are shown. 
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4.3.2 Measurement of SRPK1 protein phosphorylation, nuclear 
translocation and mRNA expression in CRH-stimulated MCF7 
cells 
 
Following time-course experiment, MCF7 cells were treated with 100nM CRH for 24hrs 
before cytoplasmic and nuclear protein and RNA extraction, followed by western blot 
and RT-qPCR analysis of phospho-SRPK1 (pSRPK1) protein level and SRPK1 mRNA 
expression, respectively. As expected, Figure 4.5A shows that raised signal of pSRPK1 
was detected in stimulated cells, and cellular fractions analysis revealed that pSRPK1 
signal increased nearly two-fold as compared to untreated cells. Furthermore, CRH was 
also demonstrated to have transcriptional effects on SRPK1, as SRPK1 mRNA expression 
was shown upregulated by 50% as compared to untreated cells (Figure 4.5B). In 
addition, cellular distribution of pSRPK1 in stimulated cells was also observed by 
immunostaining, and consistent with western blot results, the overall pSRPK1 signal was 
detected higher in stimulated cells, and pSRPK1 signal in the nucleus of stimulated cells 
was slightly increased than that in unstimulated cells (Figure 4.6).  
 
4.3.3 Effects of Akt kinase inhibition on CRH-induced SRPK1 
phosphorylation 
 
As previous studies have demonstrated that CRH signaling through GPCR was shown to 
regulate Akt kinase, the effects of reduced Akt kinase on the regulation of CRH-driven 
SRPK1 phosphorylation was further assessed. Stimulated cells were pre-treated with Akt 
kinase inhibitor (MK2206) for 2hr, followed by western blot detection of pSRPK1 in 
cellular fractions. Results showed that basal level of pSRPK1 was increased in cytoplasm, 
but it did not seem to affect much of nuclear pSRPK1 level when Akt kinase was 
inhibited (Figure 4.5A). However, inhibition of Akt activity in stimulated cells has led to 
reduced SRPK1 phosphorylation and nuclear translocation, as shown by markedly 
decreased signal of pSRPK1 in cytoplasm and nuclear fractions. 
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Furthermore, mRNA expression analysis by RT-qPCR also revealed that while 
reduced Akt kinase in the cells did not lead to statistically significant change in basal 
SRPK1 mRNA expression, inhibition of this protein kinase activity in stimulated cells has 
abolished the transcriptional effects of CRH on SRPK1 (Figure 4.5B). Overall, these 
findings have so far demonstrated that CRH has two effects via Akt; increased mRNA 
transcription of SRPK1, and increased phosphorylation and nuclear translocation of the 
SRPK1, suggesting that CRH may influence cancer progression through the regulation of 
SRPK1-mediated splicing signaling pathway in the cells. 
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Figure 4.5 (A) Western blot analysis of phospho-SRPK1 in MCF7 showed that CRH can 
induce basal phosphorylation of SRPK1 (pSRPK1) in both cytoplasm and nuclear cells 
compartments. This CRH-driven stimulation was shown to be mediated by Akt kinase, 
as pre-treatment of the stimulated cells with Akt inhibitor (MK2206) has led to 
reduced pSRPK1 signal detection. Meanwhile, reduced level of Akt activity slightly 
affected basal pSRPK1 level in the cytoplasm only. In addition, as compared with Akt 
kinase inhibition alone, the inhibition of Akt kinase in stimulated cells also showed 
significantly reduced signal of pSRPK1 in cytoplasm. (B) Similar finding was also 
evident at mRNA level, in which, while CRH can induce SRPK1 mRNA expression, 
reduced Akt kinase was shown to inhibit this effect of CRH on SRPK1 mRNA 
expression. 
 
137 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 MCF7 cells were treated with 100nM of CRH for 24hrs before phospho-
SRPK1 (Thr601) was detected using anti-pSRPK1 antibody. Green fluorophore shows 
the signal for pSRPK1, whereas blue fluorophore (DAPI) was showing the cells’ 
nucleus. Overall, higher signal detection for pSRPK1 was observed in stimulated cells 
(white arrow), as compared to unstimulated cells.  Representative images are shown 
as above, n=6, scale bar =10um. 
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4.3.4 Effects of CRH on SRPK1 phosphorylation in ER- SKBR3 cells 
Following the demonstration that CRH can regulate SRPK1 phosphorylation, nuclear 
translocation and mRNA transcription in estrogen receptor positive (ER+) MCF7 breast 
cancer cell line, similar studies was also carried out in ER- breast cancer cell line, SKBR3 
which is identified by overexpression of HER2 receptor at the cell membrane. 
Furthermore, these cells do not possess hormone receptors (estrogen or progesterone 
receptors), therefore, is also called estrogen receptor negative (ER-) breast cancer cell 
line. As compared to ER+ breast cancer, the ER- breast cancer cells tend to be more 
aggressive and accounts for approximately 18-20% of all breast cancers. Therefore, this 
cellular model of breast cancer can be a good model to study whether CRH can exert 
similar effects as it did in MCF7 cells. 
SKBR3 cells were stimulated with 100nM CRH for 24hrs, before protein and RNA 
extraction followed by western blot and RT-qPCR, respectively. It was found that 
cytoplasmic level of phospho-SRPK1 protein was significantly high in the stimulated cells, 
but was low in the nucleus, as compared to control (Figure 4.7A). In addition, RT-qPCR 
analysis also revealed that CRH can upregulate SRPK1 mRNA expression in this cell line, 
similar to MCF7 (Figure 4.7B). Furthermore, when the cells were treated with Akt 
inhibitor, basal level of pSRPK1 phosphorylation was detected increased, whilst the 
nuclear level was decreased. Even more, inhibition of Akt kinase in the stimulated cells 
seemed to affect the phosphorylation level of SRPK1 protein in the cytoplasm but not in 
the nucleus (Figure 4.7A). In addition, gene expression analysis demonstrated that 
inhibition of Akt kinase did not affect the expression of basal SRPK1 mRNA. However, 
pre-treatment of stimulated cells with Akt inhibitor resulted in the decreased of SRPK1 
expression (Figure 4.7B). These findings suggest that CRH can stimulate SRPK1 
phosphorylation in cytoplasm and upregulate the transcription of SRPK1 mRNA in SKBR3 
cells, both of which are mediated by Akt kinase. However, unlike in MCF7, CRH does not 
stimulate nuclear translocation in these cells.  
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Figure 4.7 (A) Western blot analysis of phospho-SRPK1 in SKBR3 showed that CRH 
stimulated basal phosphorylation of SRPK1 (pSRPK1) in the cytoplasm, but not SRPK1 
nuclear translocation, as nuclear pSRPK1 showed reduced signal. In addition, this 
effect of CRH in the cytoplasm was mediated by Akt kinase, as pre-treatment of the 
stimulated cells with Akt inhibitor (MK2206) has led to reduced pSRPK1 level. 
Reduced Akt activity was shown to increase basal pSRPK1 in the cytoplasm but 
decreased the level of pSRPK1 in the nucleus. (B) Similar finding was also evident at 
mRNA level, in which while CRH upregulated SRPK1 mRNA expression, reduced Akt 
kinase blocked the CRH-driven transcription of SRPK1 mRNA in the cells. 
Furthermore, inhibition of Akt kinase activity did not affect the transcription level of 
SRPK1 mRNA in the untreated cells.  
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4.4 Measurement of E2- and CRH-induced of Serine-Arginine (SR) 
proteins phosphorylation in ER+ and ER- cells 
Serine- arginine proteins (SRp) have broad roles in gene expression, however their most 
essential function is in constitutive and alternative pre-mRNA splicing and mRNA 
translation. In general, the RS domain of SR proteins is extensively phosphorylated by 
protein kinases, from SRPKs and CLKs family, they are predominantly phosphorylated by 
SRPK1 on serine residues, which subsequently influences SR proteins activation state 
and localization in the cells. The SRPK1 kinase role in regulating serine-arginine (SR) 
protein phosphorylation has been well characterized in several studies. Therefore, 
following the demonstration of E2 and CRH effects in modulating SRPK1 protein 
phosphorylation, nuclear translocation and mRNA expression, the effects of SRPK1 
differential phosphorylation in the cells were further interrogated, by examining 
activation state of SR proteins through quantification of their phosphorylation signals in 
cellular fractions. 
 
Analysis of SR protein phosphorylation in ER+ MCF7 cells by estrogen  
MCF7 cells were treated with either E2 (10nM) or CRH (100nM) for 24hrs, before cyto- 
and nuclear protein extraction, followed by immunoblotting against anti-
phosphoepitope SR proteins. It was found that, increased level SRPK1 phosphorylation 
and nuclear translocation in treated cells resulted in differential phosphorylation of SR 
proteins (SRp75, SRp55, SRp40 and SRp30) in the cells.  
In the E2- stimulated cells, it was demonstrated that only signal for phospho-
SRp30 was detected increased as compared to unstimulated cells, whereas no 
statistically significant change was observed on the phosphorylation level of SRp75, 
SRp55 and SRp40 (Figure 4.8). Furthermore, basal level of phospho- SRp55 and – SRp30 
in the nucleus was detected increased when Akt kinase was inhibited, and pre-treatment 
of stimulated cells with Akt kinase inhibitor has led to reduced phosphorylation signal of 
SRp40 and SRp30. 
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Figure 4.8 Immunoblotting results showed increased signal of phospho-SRp30 in the 
stimulated cells, but no significant change was observed in phospho-SRp75, -SRp55 
and -SRp40 level, as compared to unstimulated cells. Inhibition of Akt kinase also 
resulted in increased signal detection of basal phospho- SRp55 and – SRp30 level in 
the nucleus, but reduced Akt kinase in stimulated cells significantly decreased the 
phosphorylation level of SRp40 and SRp30 in the nucleus. Furthermore, E2 was 
shown to induce SRp40 and SRp30 phosphorylation in cells where Akt activity was 
inhibited. Data was normalized to a-tubulin (cytoplasmic control) and Lamin B1 
(nuclear control). n=7, *=p<0.05, **=p<0.01, ***=p<0.001, ns= not significant. 
Representative blots are shown. 
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Analysis of SR protein phosphorylation in ER+ MCF7 cells by CRH  
Furthermore, detection of the subcellular distribution of SR proteins in individual cells in 
response to CRH was monitored by immunofluorescence against anti-phosphoepitope 
SR proteins prior to the detection of phosphorylation level in protein lysate. MCF7 cells 
were stimulated with CRH for 24hrs and the subcellular localization of SR proteins was 
quantified. It was found that stimulated cells showed significantly stronger phospho-SR 
proteins signal in both cytoplasm and nucleus, as compared to untreated cells (Figure 
4.9).  
Following this, the phosphorylation level of SR proteins was measured 
quantitatively in whole cell protein lysate via western blot by using the same anti-
phosphoepitope-SR proteins antibody. Consistent with finding from immunofluorescent 
experiment, Figure 4.10 that quantification of SR proteins phospho-epitope in CRH- 
stimulated cells demonstrated that phospho-SRp55 and- SRp30 level in the nucleus was 
increased, whilst the phosphorylation of SRp75, cytoplasmic SRp55 and SRp40 seemed 
unaffected by the treatment.  
In addition, Akt inhibitor treatment did not change basal phosphorylation status 
of all SR proteins in the cells, but its inhibition in the stimulated cells has resulted in 
significant attenuation of CRH- driven activation of SRp55 and SRp30 in the nucleus, 
suggesting CRH signal transduction was mediated by Akt in this mechanism. In addition, 
although CRH did not induce SRp40 phosphorylation, the phosphorylation signal was 
found reduced when Akt activity was inhibited the CRH-stimulated cells. These results 
further confirm the essential role of Akt in SRPK1-mediated regulation of SR protein 
phosphorylation demonstrated in previous studies (190). Interestingly, it was also 
observed that SRp55 seemed to be hyperphosphorylated in basal state, suggesting that 
its phosphorylation may involve other kinases such as SRPK2. 
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Figure 4.9 Immunostaining results against phospho- SR protein in individual MCF7 
cells stimulated with CRH for 24hrs. Signal quantification using ImageJ (free-form 
shape was drawn around the cyto and nuc region) shows that higher signal of 
phospho-SR proteins was detected in both cytoplasm and nucleus of the stimulated 
cells, as compared to untreated cells. Green = phospho-SR protein, n=5. Scale bar = 
10m.  
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Figure 4.10 Results showed increased signal of phospho- SRp55 and - SRp30 in the 
nucleus of stimulated cells, but no significant change was observed for phospho-
SRp75, cytoplasmic SRp55 and SRp40, as compared to unstimulated cells. Inhibition 
of Akt kinase resulted in no significant change in the basal phosphorylation signal of 
all SR proteins. However, reduced Akt kinase in stimulated cells significantly 
attenuated CRH effects on the phosphorylation level of SRp55 and SRp30 in the 
nucleus. Although CRH did not elevate SR40 phosphorylation, the inhibition of Akt in 
stimulated cells has reduced the phosphorylation signal of this protein. Data was 
normalized to a-tubulin (cytoplasmic control) and Lamin B1 (nuclear control). n=7, 
*=p<0.05, **=p<0.01, ***=p<0.001, ns= not significant. Representative blots are 
shown. 
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Following these differential phosphorylation status of SR proteins, further 
investigation was done to determine whether these changes were due to increased 
expression of SRPK1 in the cells. Therefore, MCF7 cells were pre-treated with 10M 
SRPK1 inhibitor (SRPIN340) for 2hr, followed by stimulation with 100nM CRH for 24hr. It 
was demonstrated that basal phosphorylation signal of all nuclear SR proteins was 
reduced when SRPK1 kinase was inhibited (Figure 4.11). Moreover, when SRPK1 kinase 
was inhibited in the stimulated cells, CRH was shown to no longer able to elevate SRp55 
and SRp30 phosphorylation in the nucleus, suggesting that SRPK1 is indeed involved in 
the CRH-induced phosphorylation of SR proteins in cellular model of ER+ cells. Although 
reduced SRPK1 kinase affected basal SRp75 and SRp55 phosphorylation in the nucleus, 
the signal for phospho-SRp75 and SRp55 was observed increased when SRPK1 activity 
was reduced in stimulated cells. 
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Figure 4.11 Basal phosphorylation of all nuclear SR proteins was found reduced when 
SRPK1 kinase was inhibited, and the effects of CRH on the phosphorylation of SRp55 
and SRp30 was no longer seen when SRPK1 kinase was inhibited in the stimulated 
cells. Although reduced SRPK1 kinase affected basal SRp75 and SRp55 
phosphorylation in the nucleus, the signal for phospho-SRp75 and SRp55 was 
observed increased when SRPK1 activity was inhibited in the stimulated cells. In 
addition, CRH was shown to induce phosphorylation of SRp75, nuc-SRp55 and SRp30 
in cells where SRPK1 activity was inhibited. Data was normalized to a-tubulin 
(cytoplasmic control) and Lamin B1 (nuclear control). n=7, *=p<0.05, **=p<0.01, 
***=p<0.001, ns= not significant. Representative blots are shown. 
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Analysis of SR protein phosphorylation in ER- SKBR3 cells by CRH 
In the analysis of SRPK1 phosphorylation and nuclear translocation in SKBR3 cell line 
(Chapter 4.4.4), it was demonstrated that CRH did induce SRPK1 phosphorylation in the 
cytoplasm, but not nuclear translocation. To investigate the effect of this response to 
phosphorylation status of SR proteins in stimulated cells. Given that SRPK1 is one of the 
key kinases responsible in the regulation of SR protein phosphorylation for the activation 
of splicing program in the nucleus, it was hypothesized that decreased level of phospho-
SR proteins would be detected in the cells, primarily in the nuclear fraction. Therefore, 
SKBR3 cells were stimulated with CRH at 100nM for 24hrs, followed by cyto- nuclear 
protein extraction and western blot.  
The level of phospho-SR proteins was quantified and compared with untreated 
cells, and results showed that CRH significantly reduced basal phosphorylation level of 
SRp55, both in cytoplasm and nucleus, as well as nuclear SRp40 (Figure 4.12). In 
addition, although SRp75 and SRp30 phosphorylation signal seemed decreased as 
compared to untreated cells, the change was not statistically significant. Apparently, 
when Akt kinase was inhibited, none of the basal SR proteins phosphorylation level was 
affected, except the cytoplasmic phospho-SRp55 protein which was reduced as 
compared to unstimulated cells. Similarly, comparing with stimulated cells, inhibition of 
Akt activity in the stimulated cells only significantly affected cyto-SRp55 which was 
shown increased, but the phosphorylation level of the rest of SR proteins was not 
changed. Notably, the phospho- signal for SRp75, SRp55, SRp40 and SRp30 was shown 
decreased in these cells as compared to the cells treated with Akt kinase inhibitor alone, 
suggesting that while CRH signaling in modulating SRPK1-mediated SR protein 
phosphorylation in SKBR3 cell line may not involve Akt, CRH may have inhibitory role on 
SR protein phosphorylation when Akt activity is inhibited. 
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Figure 4.12 Western blot results showed that basal phosphorylation of cyto-SRp55, 
Nuc-SRp55 and SRp40 decreased in the CRH-stimulated cells. In addition, inhibition of 
Akt activity did not change much of SR protein basal phosphorylation, except for 
cyto-SRp55 that was shown reduced. Inhibition of Akt kinase in the stimulated cells 
also has led to similar response on the SRp phosphorylation level, except for cyto-
SRp55 and nuc-SRp40 which was shown increased as compared to CRH-stimulated 
cells. Furthermore, in cells where Akt was inhibited, CRH significantly reduced SRp75, 
nuc- SRp55, SRp40 and SRp30 phosphorylation. Data was normalized to a-tubulin 
(cytoplasmic control) and Lamin B1 (nuclear control). n=7, *=p<0.05, **=p<0.01, 
***=p<0.001, ns= not significant. Representative blots are shown. 
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Next, to examine whether SRPK1 was responsible for the reduced 
phosphorylation signal of SR proteins, SKBR3 cells were pre-treated with the specific 
SRPK1 kinase inhibitor (10M) for 2 hr, before stimulation with CRH at 100nM for 24hrs. 
Results showed that inhibition of SPRK1 kinase has led to significant decrease of basal 
phosphorylation level of cyto-SRp55, SRp40 and SRp30, confirming the key role of SRPK1 
in regulating basal SR protein as previously shown in several studies (171,185). In 
addition, when SRPK1 was inhibited in the stimulated cells, further reduction of 
phospho- SRp55 and SRp40 was detected in the nucleus, suggesting the involvement of 
SRPK1 in the regulation of Sr protein phosphorylation in the CRH- treated cells (Figure 
4.13). Furthermore, phospho-SRp75, cytoplasmic phospho-SRp55 and phospho-SRp30 
level showed no significant change in response to the reduced SRPK1 activity in the 
stimulated cells.  
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Figure 4.13 Basal phosphorylation level of cyto-SRp55, nuc-SRp40 and nuc-SRp30 was 
shown reduced when SRPK1 kinase was inhibited, and the inhibition of SRPK1 activity 
in stimulated cells has led to further reduction of nuc-SRp55 and nuc-SRp40. While 
other SRps showed reduced signals in this cell, however the change was not 
statistically significant. In addition, basal phosphorylation level of SRp75 and nuc-
SRp55 was not affected by the decreased activity of SRPK1 in the cells. Data was 
normalized to a-tubulin (cytoplasmic control) and Lamin B1 (nuclear control). n=6, 
*=p<0.05, **=p<0.01, ***=p<0.001, ns= not significant. Representative blots are 
shown. 
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4.5 Detection of splicing repressor, hnRNPA1 protein and mRNA 
expression in MCF7 and SKBR3 cell lines  
Several studies have demonstrated that splicing repressor protein, hnRNPA1 was found 
to be highly upregulated  in cancer cells as compared to its normal counterpart, and its 
role in the regulation of splicing mechanism has also been well-studied (253,336). 
Therefore, to investigate the expression of hnRNPA1 at both protein and mRNA level in 
response to external stimuli, estrogen (E2) and CRH, MCF7 cells were stimulated with E2 
(10nM) and CRH (100nM) for 24hrs, followed by protein and RNA extraction.  
It was demonstrated that the expression of hnRNPA1 protein and mRNA 
expression were significantly increased by approximately 2-3 folds when MCF7 cells 
were stimulated with either E2 or CRH [Figure 4.14A (i)(ii) and Figure 4.14B (i)(ii)]. 
Furthermore, basal expression of hnRNPA1 protein was shown upregulated when Akt 
kinase was inhibited in the cells. Interestingly, inhibition of Akt kinase activity in E2- or 
CRH- stimulated cells has significantly abolished the effects of E2 and CRH on both 
hnRNPA1 protein and mRNA expression, suggesting that upregulation of hnRNPA1 
protein expression and mRNA transcription by both stimuli were Akt dependent. 
Interestingly, the pattern of hnRNPA1 expression in response to E2 and CRH seemed 
similar with that of SRPK1 expression, as shown in Chapter 4.3.2 and Chapter 4.4.2.  
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Figure 4.14 MCF7 cells were stimulated with (A) 10nM estrogen (E2), and (B) 100nM 
CRH, both for 24hrs. Both A(i) & B(i) hnRNPA1 protein expression and A(ii) & B(ii) 
mRNA expression increased when cells were stimulated with either E2 or CRH. 
Inhibition of Akt kinase resulted in increased basal expression of hnRNPA1, however, 
reduced Akt kinase in the stimulated cells has attenuated E2 and CRH effects on 
hnRNPA1 protein and mRNA expression.  
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To investigate whether SRPK1 plays role in this signaling pathway that led to 
upregulation of hnRNPA1 expression in MCF7 cell line, cells were pre-treated with SRPK1 
kinase inhibitor at 10M for 2hr, before stimulation with CRH at 100nM for 24hrs. Figure 
4.15 (i)(ii) shows that while reduced SRPK1 kinase did not significantly affect hnRNPA1 
protein and mRNA expression, the inhibition of SRPK1 activity in CRH stimulated cells 
resulted in significant downregulation of nearly 2-fold of hnRNPA1 protein, and ~1.5-fold 
of its mRNA expression, suggesting that SRPK1 may not involve in basal regulation of 
hnRNPA1 expression, but it plays essential role in the regulation of hnRNPA1 expression 
in stimulated cells.  
 
 
 
 
Figure 4.15 MCF7 cells were pre-treated with the specific SRPK1 inhibitor (SRPIN340) 
for 2hr, before stimulation with 100nM CRH for 24hrs. Results showed that inhibition 
of SRPK1 activity has no significant effect on hnRNPA1 (i) protein, and (ii) mRNA 
expression in the cells. However, reduced SRPK1 kinase in the stimulated cells has 
significantly abolished CRH effects on hnRNPA1 expression both at protein and mRNA 
level.  
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Furthermore, the effects of CRH on the regulation of hnRNPA1 expression was 
also investigated in SKBR3 cell line. Cells were treated with CRH at 100nM for 24hrs, 
before protein and mRNA extraction, followed by western blot and RT-qPCR for the 
analysis of hnRNPA1 protein and mRNA transcript, respectively. Results showed that 
CRH has no effect on basal hnRNPA1 expression at both protein and mRNA level, in 
SKBR3 cells [Figure 4.16 (i)(ii)]. Interestingly, in cells where Akt was inhibited, CRH was 
shown to have no effect on hnRNPA1 protein and mRNA expression. 
 
 
Figure 4.16 SKBR3 cells were stimulated with 100nM CRH for 24hrs. Results showed that 
CRH did not affect basal expression of hnRNPA1 (i) protein, and (ii)mRNA. In addition, 
inhibition of Akt kinase upregulated mRNA expression of hnRNPA1 in untreated cells, 
and reduced Akt kinase in stimulated cells also led to increased hnRNPA1 mRNA 
transcription. Furthermore, CRH has shown no effect on hnRNPA1 in cells where Akt is 
inhibited. 
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4.6 Effects of differential splicing factors expression on CD44 
mRNA splicing  
Following the activation of SRPK1 by E2 and CRH, which directly or indirectly led to 
differential expression of splicing factors, Serine- Arginine proteins (SRp) and hnRNPA1, 
the effects of these SRPK1-mediated changes on the choice of mRNA transcript splice 
site was examined in both cell lines, MCF7 and SKBR3. Previous studies reported that 
apart from nuclear SRPK1 translocation, differential phosphorylation and distribution of 
SR proteins and hnRNPA1 can trigger alternative splicing event and contribute to the re-
programing of pre-mRNA splicing resulting in the accumulation of abnormal splice 
isoform in cells (171). In addition, hnRNPA1 has been shown to be involved in the 
splicing regulation of CD44, a cell adhesion molecule important in cell-to-cell junction 
(337). CD44 splice isoform, CD44v6 and CD44s were observed to be overexpressed in 
invasive breast tumours and have been associated with the cancer metastasis process 
(145,260,338).  
Therefore, using CD44 as a splicing reporter of altered splicing event in response 
to the activation of SRPK1 splicing kinase and splicing factors in the stimulated cells, 
MCF7 cell lines were stimulated with E2 (10nM) and CRH (100nM) for 24hrs before RNA 
extraction followed by RT-qPCR to analyze the splicing pattern of CD44 mRNA and the 
production of its splice variants, CD44s and CD44v6. Primers specific for total CD44, 
CD44s and CD44v6 sequences were used to quantify the level of these transcripts in the 
cells (Figure 4.17).  
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Figure 4.17 Map of CD44, CD44s and CD44v6 mRNA transcript showing the primer 
pairs (red arrow) used in the RT-qPCR analysis of mRNA level in this study. CD44 total 
primer sequence covered the regions in constant exon 5 and exon 16. CD44s was 
based on the exon 5 sequence (forward) and 14 nucleotides of 5’ of exon 16 + 7 
nucleotides of 3’ of exon 5 sequence (Reverse), while CD44v6 primers were based on 
the sequence specific to exon 11.   
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Results from MCF7 cells stimulated with E2 showed that basal level of CD44s 
was increased by 50% as compared to unstimulated cells, but there was no significant 
change in CD44v6 (Figure 4.18A). Furthermore, when the stimulated cells were pre-
treated with Akt inhibitor, the level of CD44s and CD44v6 was further increased, 
suggesting that Akt attenuates E2 effects in inducing CD44 splice variants production. In 
addition, although reduced Akt activity has led to decreased basal CD44s level only, 
however Akt kinase inhibition in stimulated cells has caused nearly 3-fold increase in 
CD44s, and 2-fold increase of CD44v6 mRNA transcript, suggesting that while the 
production of CD44s is dependent on Akt, E2 effects on both CD44s and CD44v6 is 
enhanced when Akt activity was inhibited in cells.  
In CRH- stimulated cells, it was demonstrated that inhibition of Akt kinase did 
not affect the production of both CD44s and CD44v6 as compared to untreated cell 
(Figure 4.18B). Furthermore, results from stimulated cells showed that CRH showed no 
effect on CD44s but upregulated the expression of CD44v6. However, inhibiting Akt 
activity in the stimulated cells resulted in marked increase of CD44s, by nearly 10 times, 
and CD44v6 by 4 times, suggesting that CRH effect in inducing aberrant CD44 pre-mRNA 
splicing is amplified when Akt kinase is inhibited in the cells. Overall, this abnormal 
accumulation of alternatively spliced CD44 mRNA transcript was observed to occur in a 
manner that correlated with increased SRPK1 nuclear translocation in E2- and CRH-
stimulated cells, and with reduced hnRNPA1 expression in stimulated cells when Akt was 
inhibited, suggesting that splicing repressor effect of hnRNPA1 is Akt dependent, and 
can only be seen when it is activated by either E2 or CRH in the MCF7 cells. These 
findings also suggest that decision for splice site selection during pre-mRNA splicing 
involves interactions of multiple molecular factors such as splicing kinase and both 
splicing promoters (e.g. SR proteins) and splicing repressor (hnRNPA1). 
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Figure 4.18 CD44 splice variants analysis in MCF7 cell line. (A) Cells were stimulated 
with E2 (10nM) for 24hrs. Results showed that E2 induced CD44s production, but not 
CD44v6. Meanwhile, inhibition of Akt kinase reduced basal level CD44s, and 
inhibition of Akt in the stimulated cells resulted in significant increase of both CD44s 
and CD44v6 in the cells, suggesting the E2 effect on CD44s and CD44v6 was enhanced 
in the presence of Akt inhibitor. (B) Stimulation of MCF7 cells with CRH (100nM) for 
24hrs did not affect basal level of CD44s but has slightly increased the level of 
CD44v6. In addition, while inhibition of Akt showed no effect on basal level of both 
CD44 isoforms, its inhibition in the stimulated cells has resulted in significant increase 
of CD44s and CD44v6 mRNA transcript.  
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The effect of reduced SRPK1 activity in the production of CD44 splice isoforms 
was also investigated. MCF7 cells were pre-treated with the specific SRPK1 inhibitor 
(10M) for 2hr, before stimulation with CRH (100nM) for 24hrs, followed by RNA 
extraction for RT-qPCR analysis of CD44 splice variants level. Results showed that 
reduced SRPK1 kinase has significantly reduced basal level of CD44v6, but not CD44s 
(Figure 4.19). Interestingly, reduced SRPK1 in the stimulated cells resulted in the 
increased of CD44s mRNA transcript, but significantly decreased the level of CD44v6. In 
addition, CRH was shown to induce CD44s production in cells where SRPK1 was 
inhibited, suggesting that CD44s production can only be induced by CRH when SRPK1 is 
reduced. Overall, these results suggest that SRPK1 may involve in the signaling 
mechanism leading to the production of CD44v6, and that the accumulation of CD44s 
might require the action of other factors as well. Similar findings was shown in other 
studies (171), in which depleting SRPK1 alone in cell has little effect but knocking down 
both SRPK1 and SRPK2 kinases resulted in reduced accumulation of stress-induced 
mRNA isoform in cells. 
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Figure 4.19 CD44 splice variants analysis in MCF7 cell line. Inhibition of SRPK1 
reduced basal CD44v6 level, but inhibition of this kinase in CRH-stimulated cells 
resulted in significant increase of CD44s, but significant decrease in CD44v6 level in 
the cells. 
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Following the demonstration of CD44 splice isoforms accumulation in MCF7 cell 
line, similar study was investigated in SKBR3 cell line. Cells were treated with CRH 
(100nM) for 24hrs, followed by RNA extraction and RT-qPCR analysis of CD44 isoforms 
mRNA transcript. Results showed that reduced Akt kinase did not affect much of the 
CD44s and CD44v6 level in untreated cells (Figure 4.20A). In addition, CRH was found to 
reduce basal level of CD44s mRNA by 50%, but significantly induced the production of 
CD44v6 by 4-fold in the cells. Interestingly, inhibiting Akt in these stimulated cells 
resulted in increased CD44s level, but 4-fold decreased of CD44v6, suggesting that CRH 
effect on the CD44v6 production was via Akt. In addition, this finding also suggests that 
Akt inhibitor reversed CRH effect on the CD44s mRNA transcript production in SKBR3 cell 
line.  
Furthermore, basal level of both CD44s and CD44v6 was shown decreased when 
SKBR3 cells were treated with SRPK1 kinase inhibitor (10M) for 2hr (Figure 4.20B). It 
was also found that inhibiting the SRPK1 kinase in the stimulated cells resulted in 
increased CD44s production, but marked decrease of CD44v6, suggesting that CRH effect 
on CD44v6 production was mediated by SRPK1, and similar to Akt, SRPK1 inhibitor was 
also shown to reverse CRH effect on CD44s. Altogether, these results showed that CRH 
affect SKBR3 cells, a model for ER- cells, differently, in which CD44v6 expression showed 
positive correlation with hnRNPA1 expression, while CD44s expression was regulated in 
an opposite way, where it was negatively correlated with hnRNPA1 level in cells. The 
summary of CD44s and CD44v6 production in both MCF7 and SKBR3 cell line is shown in 
Table 4.1. 
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Figure 4.20 CD44 splice variants analysis in SKBR3 cell line. (A) Stimulation of SKBR3 
cells with CRH (100nM) for 24hrs reduced basal CD44s mRNA level, but significantly 
induced CD44v6. While inhibition of Akt did not affect basal CD44s and CD44v6 level, 
its inhibition in the stimulated cells has resulted in increased CD44s level, but 
reduced CD44v6 mRNA transcript in the cells. (B) Inhibition of SRPK1 reduced basal 
level of both CD44 isoforms, however inhibition of this kinase in CRH-stimulated cells 
resulted in significant increase in CD44s and significant decrease in CD44v6 level in 
the cells. 
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Table 4.1 Summary of differential level of CD44s and CD44v6 in MCF7 cell line (ER+ 
cells) and SKBR3 cell line (ER- cells) in response to various treatments. 
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Discussion  
 
In the present study, the potential role of hormones (estrogen and CRH) in regulating 
alternative splicing event in ER+ and ER- breast cancer cells was investigated, following 
the preliminary finding that estrogen could trigger overexpression of splicing kinase, 
SRPK1 in the ER+ cells. Interrogation on the hormone-driven upregulation of SRPK1 on 
the targets downstream of SRPK1 was carried out. This was done by analysing the 
phosphorylation level of serine-arginine (SR) proteins in cytoplasmic and nuclear 
compartments, the expression of splicing repressor, hnRNPA1 and the mRNA expression 
of CD44 splice variants as reporter genes for alternative pre-mRNA splicing process 
induced by estrogen and corticotrophin-releasing hormone, CRH in the cells.  
 
Estrogen-driven alternative splicing (AS) in ER+ breast cancer cells 
The analysis of phospho-SRPK1 in cytoplasmic and nuclear compartments 
demonstrated that most of SRPK1 proteins were predominantly found in the nuclear 
compartment of the cells, suggesting that E2 does not only induce SRPK1 expression but 
also its translocation from cytoplasm to the nucleus. This finding fit with current 
understanding of SRPK1 action, in which it phosphorylates SR proteins in the nucleus 
and triggers the assembly of spliceosome units for the initiation of mRNA splicing events. 
In addition, studies have shown that nuclear level of SRPK1 protein induces 
accumulation of SR proteins and changes in the level of splicing factors are frequently 
found to correlate with alternative splicing events in malignant tumor cells (339–341). 
 
Notably, uninterrupted activity of SRPK1 kinase is important to ensure precise 
regulation of SR proteins phosphorylation for an accurate mRNA splicing to take place in 
the cells. Previous studies have shown that altered cellular distribution of SRPK1 in 
response to osmotic stress resulted in differential phosphorylation of SR proteins, thus 
leading to altered splicing of E1A gene (171). The analysis of phosphorylation level of 
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several SR proteins (SRp75, 55, 40 and 30) in this study demonstrated that E2-induced 
SRPK1 protein nuclear translocation led to increased level of phospho- SRp 30, whilst the 
phosphorylation level of SRp75, 55 and 40 remained unaffected. Of note, apart from SR 
proteins, which are also called splicing inducers, the mechanism of alternative splicing is 
also depends on various other factors, such as the activity of splicing repressors. One of 
the best studied is hnRNPA1, whose expression is found to be differentially regulated in 
several cancers (337,342–345). Although proteome analysis showed that E2 treatment 
led to the downregulation of one of the hnRNPs family proteins (i.e. PTPB1), protein and 
gene expression analysis demonstrated that estrogen significantly increased both 
hnRNPA1 protein and mRNA expression which was also positively correlated with SRPK1 
pattern of expression, indicating that hnRNPA1 is one of E2 signaling targets and E2 can 
stimulate hnRNPA1 transcription in breast cancer cells. In parallel with this, a recent 
study showed that estrogen can elevate the expression of hnRNPA1 in skin cancer, 
resulting in the reduction of oncogene, MDM2 expression and thus inhibiting 
carcinogenesis in melanoma (346).  
 
Following the upregulated activity of splicing kinase and the above-mentioned 
splicing factors, the effects of altered splicing molecules on the production of CD44 
splice variants, CD44s and CD44v6, which are generated as a result of aberrant 
alternative splicing of CD44 in cells were investigated. This study found that, CD44s level 
was increased in response to E2 treatment suggesting positive correlation between 
increased SRPK1 expression and CD44s production as shown in Figure 4.21. In addition, 
increased level of hnRNPA1 did not seem to repress this alteration in CD44 splicing, 
suggesting that its action in the cells may not directly involved in CD44 splicing, but it 
may activate or block other molecules during the event that causes an increase level of 
CD44s and CD44v6. 
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Figure 4.21 Illustration of E2 effects on splicing factors and CD44 pre-mRNA splicing 
in ER+ cells. 
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Previous studies have suggested that ER signaling in cells is also controlled by 
post- translational modifications such as phosphorylation. Changes in phosphorylation 
status of ER and ER by kinases such as MAPK and AKT/PKB can lead to ER 
dysfunction in the pathogenesis of breast cancer (327). Furthermore, Akt has also been 
demonstrated to regulate SRPK1 activity in the cells, and this connection between 
activated AKT and SRPKs (AKT-SRPKs-SR pathway) is demonstrated to play a central role 
in most of the induced splicing events in EGF-treated cells (169,170,190). In addition, 
other studies also showed AKT act as one of SRPKs effectors. For example, SRPK1 has 
been demonstrated to mediate TGF-induced proliferation by regulating Akt and JNK 
phosphorylation in oesophageal carcinomas (347). Moreover, overexpression of SRPK1 
in hepatocellular carcinoma was demonstrated to induce concurrent phosphorylation of 
PI3K (p110a subunit), indicating functional link between SRPK1 and PI3K/AKT signaling 
(172,348). In addition to this, studies also suggested that abnormal expression of SRPK1 
will interfere with PHLPP-mediated dephosphorylation of AKT, thus leading to 
constitutive activation of AKT (186). These bidirectional relationships between SRPKs 
and AKT, and the ability of estrogen to modulate SRPK1 activity suggests that E2 
signaling can cross-talk with SRPK1 signaling pathway, hence triggering activation of 
molecules important for cellular functions.  
 
Therefore, to determine the role and position of AKT in this E2- mediated SRPK1 
signaling activation, stimulated cells were pre-treated with Akt inhibitor, MK2206. 
Notably, it was found that reduced AKT kinase activity significantly dampened the 
effects of E2 on SRPK1 activation (measured by phospho-SRPK1 protein antibody), which 
subsequently resulted in reduced detection of phospho-SR proteins signals in the cells, 
especially SRp40 and SRp30, as illustrated in Figure 4.22. Interestingly, both hnRNPA1 
protein and mRNA expression were also found significantly decreased, which may 
suggest AKT-SRPK1-hnRNPA1 network in this E2- induced splicing signaling event in ER+ 
breast cancer cells. Previous studies showed that E2 can upregulate hnRNPA1 expression 
resulting in the prevention of carcinogenesis in melanoma (346). Furthermore, studies in 
endometrial cells demonstrated that E2 may indirectly upregulated hnRNPA1 by 
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inducing the expression of Pyruvate Kinase M splice variant, PKM2 via c-Myc-hnRNPA1 
axis (349), as c-Myc has been shown to induce the transcription of hnRNPA1 in lung, 
pancreatic and breast cancer (350–353). In other studies, down-regulation of hnRNPA1 
has also been found to promote breast cancer progression from non- malignant to the 
malignant type (345). Furthermore, degradation of hnRNPA1 together with activation of 
SRPK1 has been to affect pre-mRNA splicing in HeLa cells, and subsequently contribute 
to enhanced cell migration (354). Therefore, results from this study regarding the 
pattern of hnRNPA1 expression suggests that E2 may induce hnRNPA1 expression 
through signaling mechanism involving Akt.  
 
Interestingly, reduced level of key splicing event regulator SRPK1 in these cells 
did not lead to reduced accumulation of CD44 splice isoform as hypothesized, instead, 
the expression of both CD44s and CD44v6 was found further increased, although Akt 
was initially shown to play a role only in the production of basal CD44s. This may 
probably be due to the decreased level of hnRNPA1, which acts by antagonizing the 
function of serine-arginine (SR) proteins. Therefore, more SRps can bind to splicing 
enhancer motif and trigger the assembly of spliceosome for the splicing event to initiate. 
In addition, the inhibition of Akt may affect hnRNPA1 activity, thus affect its splicing 
repressor function in the cells, as Akt has also previously been shown to indirectly 
involve in modulating hnRNPA1 activation (355). This finding somehow suggests that any 
shifting in the E2-induced AKT-SRPK1-hnRNPA1 network may cause more detrimental 
effects to the cells, which in this case, higher level of CD44 splice isoforms was 
generated in the cells.  
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Figure 4.22 Illustration of differential expression of splicing factors and CD44s and 
CD44v6 splice variants when E2- stimulated cells were pre-treated with Akt inhibitor 
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CRH-driven alternative splicing (AS) in ER+ and ER- breast cancer cells 
Following the finding that estrogen (E2) can regulate the SRPK1- mediated alternative 
splicing mechanism in ER+ MCF7 breast cancer cells, further investigations were carried 
out to assess the impact of one of stress-molecules, Corticotrophin- releasing hormone 
(CRH) in the pathogenesis of cancer via AS mechanism in the cells. In addition, Akt, 
which was shown to regulate SRPK1 phosphorylation is also regulated by CRH. 
Therefore, CRH was used as extracellular stimulus to investigate its effect on SRPK1 
status in ER+ and ER- cells. The actions of CRH have been shown to be involved in 
tumorigenesis since the presence of CRH family peptides and their receptors were 
detected in several cancer cells, including breast cancer (101,103,137,356). To date, 
studies have reported the role of CRH receptors (137,356) and the alternatively spliced 
CRHR1 receptors (141) in cancer, but the mechanism by which CRH can potentially 
facilitate cancer progression by regulating the activity of splicing molecules is not yet 
explored. In addition, as it was shown that AKT can regulate SRPK1 phosphorylation, and 
AKT is one of the kinases regulated by CRH, the effects of CRH on SRPK1 status in MCF7 
cell line, a cellular model for ER+ cell were investigated. Furthermore, as aberrant 
splicing is frequently found in estrogen-responsive breast cancers, and for comparison, 
this study was also conducted in estrogen receptor- negative (ER-) breast cancer cell line 
SKBR3.  
 
As illustrated in Figure 4.23, this study found that CRH can upregulate SRPK1 
phosphorylation in a similar fashion as estrogen did in ER+ MCF7 cell line. The analysis of 
phospho- SRPK1 proteins in cytoplasm and nuclear compartments of the cells showed 
that signals for SRPK1 proteins were mostly detected in the nucleus, suggesting that CRH 
may also stimulate nuclear translocation of SRPK1 protein. This also suggests that CRH 
and E2 uses similar pathway in modulating SRPK1 activity in ER+ cells. In addition, 
immunostaining of phospho- SRPK1 also demonstrated that phospho-SRPK1 were 
distributed more in the nucleus of the cell treated with CRH, as compared to untreated 
cells.  
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However, illustration in Figure 4.23 shows that although CRH was found to 
upregulate SRPK1 activity in ER- SKBR3 cells, cyto-nuclear protein determination showed 
that most of the phosho-SRPK1 signals were detected in the cytoplasm, rather than the 
nucleus. As cytoplasmic SRPK1 functions mainly in re-phosphorylation of cytoplasmic SR 
proteins back into the nucleus for the next round of splicing, nuclear level of SRPK1 is 
one of the factors that activates splicing event by facilitating  the release of fully 
functioning SR proteins from CLKs through additional phosphorylation (177,179), this 
finding demonstrates that CRH actions may impact molecular subtypes of breast cancers 
differently, and that this result suggests that it can potentially regulate the mechanism 
of SRPK1-mediated alternative splicing in ER+, but not in ER- cells.  
 
Following this, the analysis of splicing proteins activity in ER+ cells via 
immunoblotting and immunostaining showed that in agreement with elevated level of 
nuclear SRPK1 proteins, the phosphorylation signals of SRp55, 40 and 30 were detected 
increased and the expression of splicing repressor, hnRNPA1 was also upregulated in the 
nucleus. In contrast, phospho-epitope signals of these SR proteins and hnRNPA1 
expression in ER- cells were found lower than basal level, which further highlight the 
potential of CRH to differentially regulate the activity of splicing factors in different types 
of cells.  
 
Furthermore, when mRNA splicing activity was assessed by the level of CD44s 
and CD44v6 splice isoforms through mRNA expression analysis, it was found that both 
CD44 splice variants were found slightly increased in ER+ cells. This result suggests that 
CRH can induce alternative splicing of CD44 mRNA via SRPK1-mediated regulation of 
splicing proteins in the ER+ cells. In ER- cells, CD44s level was shown significantly 
decreased and CD44v6 was particularly elevated nearly 5-fold in the stimulated cells. 
Although this result in ER- was not anticipated as CRH initially was not shown to induce 
SRPK1 activity in the nucleus, this finding suggests that CRH may modulate splicing 
mechanism in ER- breast cancer cells, but via other pathways that is may probably not 
mediated by SRPK1 kinase, and it requires the involvement other factors, unlike that in 
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ER+ cells. In fact, in addition to SRPK1, there are other protein kinases known to be 
involved in the regulation of splicing mechanism and in splicing proteins phosphorylation 
such as SRPK2, cdc2- like kinase (CLK/STY) and DNA topoisomerase 1 (335,357). 
Furthermore, studies also demonstrated that Akt1 and Akt2 can directly target the RS 
domain of SR proteins with distinct specificity than SRPK1 (358), and cyclic AMP (cAMP)-
dependent PKA can phosphorylate splicing protein ASF/SF2 at Serine 119; which this 
phosphorylation could potentially be involved in the regulation of RNA binding (359). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23 Illustration of differential expression of splicing factors and CD44s and 
CD44v6 splice variants when cells were treated with CRH in MCF7 and SKBR3. 
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Previous studies have demonstrated the potential of CRH receptors in 
modulating various intracellular protein kinases such as protein kinase A (PKA), protein 
kinase B (PKB/AKT) and p42/p44 and p38 mitogen activated protein kinases in various 
cells such as in rat Leydig cells, endothelial cells and in human epidermoid carcinoma cell 
line (MAPKs) (reviewed in (109)). Therefore, to investigate the involvement of AKT in 
CRH- induced regulation of SRPK1 activity, CRH- stimulated cells were treated with AKT 
kinase inhibitor (MK2206). The results in ER+ cells demonstrated although the reduced 
activity of Akt did not affect basal nuclear SRPK1 protein and mRNA level, both protein 
and mRNA level were significantly decreased when the AKT was inhibited in the 
stimulated cells (Figure 4.24). As predicted, signal detection for SR proteins, primarily 
SRp40 and SRp30, and hnRNPA1 protein and mRNA expression level were decreased in 
the cells. This finding shows that CRH induction in ER+ breast cancer cells seems to 
follow the proposed AKT-SRPK1-hnRNPA1 network above. In addition, findings from 
splicing assay show that inhibition of Akt in the stimulated cells resulted in 9-fold 
increase of CD44s mRNA, and 3-fold increase in CD44v6 mRNA. This finding is consistent 
with the finding previously found in E2-stimulated cells where Akt was inhibited, 
suggesting that Akt inhibitor enhances the effects of E2 and CRH in inducing CD44s and 
CD44v6 mRNA transcription in ER+ cells.   
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Furthermore, Figure 4.24 also illustrates that reduced AKT kinase in ER- cells has 
no effect on the basal level of SRPK1 mRNA level but led to slightly lower level of 
phopsho-SRPK1 protein in the nucleus. Interestingly, although pre-treatment of CRH-
stimulated cells with Akt inhibitor downregulated SRPK1 mRNA expression, no change 
was detected in the level of nuclear phospho-SRPK1, suggesting that Akt mediates the 
effect of CRH on SRPK1 at mRNA level only. Likewise, generally no changes were 
demonstrated in the basal level of nuclear SR proteins phosphorylation and hnRNPA1 
protein expression when Akt was reduced, as well as in CRH-stimulated cells where Akt 
was inhibited. However, as opposed to ER+ cells, hnRNPA1 mRNA expression remained 
upregulated in these cells. Previous studies have shown that other than Akt, hnRNPs can 
be regulated by cellular signaling pathways involving kinases such as Protein kinase A 
which phosphorylates hnRNPA1 at Ser-16, and Mitogen- activated protein kinase 
(MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) via the activation of p38 MAPK 
signaling cascades (360,361). Therefore, the mRNA expression results in ER- SKBR3 cells 
Figure 4.24 Illustration of differential expression of splicing factors and CD44s and 
CD44v6 splice variants in stimulated cells in the presence of Akt Inhibitor, MK-2206. 
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reflects that, Akt may play inhibitory role the transcriptional activity of CRH on hnRNPA1, 
in which this transcriptional effect of CRH may potentially be mediated by either of the 
kinases mentioned above. Furthermore, although Akt was not shown to play role in the 
transcription of basal CD44s and CD44v6 mRNA level, its inhibition in the stimulated cells 
resulted in increased production of CD44s, but reduced production of CD44v6, 
suggesting that the transcription of CD44v6 by CRH is Akt dependent in ER- cells.  
 
Further investigations on the role of SRPK1 in CRH- induced activation of splicing 
factors, ER+ and ER- cells were examined by simultaneously treating the cells with 
SRPK1-kinase inhibitor, SRPIN340. The finding demonstrated that the inhibition of SRPK1 
kinase in MCF7 cells resulted in decreased signal detection of phospho- SRp55, 40 and 
30 in the nucleus, and it was also shown to have inhibitory effect on hnRNPA1 
transcription in the cells. This subsequently led to reduced accumulation of only CD44v6 
splicing isoform, but not CD44s mRNA (Figure 4.25). In contrast, although CRH did not 
have a major effect on the regulation of SRPK1-mediated splicing proteins in ER- SKBR3 
cell line, decreased SRPK1 kinase activity was demonstrated to further reduce the 
phosphorylation level of SR proteins, suggesting the important role of SRPK1 kinase in 
regulating SR protein phosphorylation in cells. This is in line with findings from previous 
studies in which knocking down of SRPKs resulted in the failure to elevate SR protein 
phosphorylation in HeLa cells (171). Furthermore, the inhibition of SRPK1 kinase in CRH-
stimulated ER- cells resulted in a slight increase of CD44s mRNA level, but CD44v6 mRNA 
was shown significantly reduced, a finding similar to that in ER+ MCF7 cell line. Overall, 
the results from splicing assay in both cell types suggest that the production of CD44s 
splice variants may not be entirely dependent on SRPK1 kinase only, whereas, CD44v6 
isoform production is shown to be highly dependent on intact activity of SRPK1 kinase, 
especially in ER- cells (Figure 4.25). 
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In summary, the results show that E2 and CRH can regulate SRPK1-mediated 
splicing factors activity through similar signaling mechanism via Akt in ER+ MCF7 cell 
line, and splicing results suggest that Akt plays inhibitory role in E2- and CRH- induction 
of CD44s and CD44v6 mRNA transcription. Meanwhile in ER- SKBR3 cell line, CRH did not 
exert similar effects on SRPK1 activity and splicing factors activation, and these effects of 
CRH were independent of Akt activity in the cells, and the production of CRH- induced 
CD44 splice isoforms was differentially dependent on Akt, in which Akt inhibitor reverses 
inhibitory effect of CRH on CD44s mRNA transcription but it plays role in the processes 
leading to accumulation of CD44v6 in ER- cells.  
 
 
 
 
 
Figure 4.25 Illustration of differential expression of splicing factors and CD44s and 
CD44v6 splice variants when cells were treated with CRH either in the presence or 
absence of SRPK1 inhibitor, in both cell lines, MCF7 and SKBR3. 
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CHAPTER 5 
Effects of altered pre-mRNA alternative 
splicing event in triggering epithelial-to-
mesenchymal transition (EMT) in breast 
cancer cell lines 
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Introduction  
Alterations in splicing activity is one of the common signatures in cancer cells, in 
which the resulting splice isoforms can encode proteins that promote cell proliferation, 
inhibit apoptosis and stimulate uncontrollable cell growth by triggering cellular 
processes such as epithelial-to-mesenchymal transition (EMT) event in the cells. The 
alterations in alternative pre-mRNA splicing (AS) was first connected with EMT was when 
splice variants of CD44, a cell surface protein were identified in metastatic pancreatic 
cancer cells that was not present in the primary tumor (252). In addition, apart from 
changes in cells morphology, the occurrence of EMT is evident at the molecular level, 
through the activation of signaling pathways leading to the change in the expression of 
such as transcription factors, microRNA and various genes that play role in cellular 
functions such as cytoskeletal re-organisation, cell motility, immune response cell 
growth (362). 
 
Therefore, this chapter was aimed to analyse the impact of hormone- driven 
aberrant alternative splicing process on the metastatic potential of ER+ and ER- cells by 
measuring the expression level of EMT-associated gene markers and the cell invasion 
and migration properties by using real-time PCR and Xcelligence real-time cell 
monitoring assay. In addition, a study using EMT profiler PCR array was also carried out 
to elucidate the transcriptional effects of Akt and SRPK1 kinase on EMT genes, as well as 
the potential diversion of CRH signaling mechanism when either of these two kinases 
were inhibited in the cells.  
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5.1 Correlation between altered pre-mRNA alternative splicing and 
activation of Epithelial-to-Mesenchymal Transition (EMT) in cells  
Previous studies have demonstrated that CD44, CD44s and CD44v6 were linked 
to EMT process by regulating downstream targets, transcription factor Snail1 (SNAI1) 
and membrane bound metalloproteinase (MMP), both of which are known regulators of 
EMT program (363). Therefore, the expression of EMT markers, Twist, Snail and 
Vimentin were examined to investigate whether differential expression of CD44s and 
CD44v6 lead to changes in EMT associated genes in both cell lines.  
MCF7 cells were treated with E2 (10nM) or CRH (100nM) for 24hrs, followed by 
RNA extraction and RT-qPCR analysis of Twist, Snail, and Vimentin mRNA expression. 
Results showed that E2 did not significant upregulate Twist and Snail expression, but the 
expression of these EMT genes were increased in CRH-stimulated cells. Furthermore, 
basal expression of Twist and Snail was shown decreased in cells where Akt was 
inhibited. Interestingly, when Akt activity was inhibited  using Akt inhibitor (5M) for 2hr 
in either E2- or CRH- stimulated cells, the Twist and Snail mRNA level was found 
significantly increased, similar to the pattern of CD44s and CD44v6 expression previously 
found in these cells, suggesting that while Akt involves in the transcriptional activity of 
Twist and Snail, it however attenuates the potential effects of E2- or CRH- in modulating 
Twist and Snail mRNA expression in the cells (Figure 5.1A and Figure 5.1B).  
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Figure 5.1 The analysis of EMT- associated mRNA expression, Twist and Snail in MCF7 
cell line. (A) The treatment of MCF7 cells with E2 (10nM,24hrs) showed no effect on 
basal Twist and Snail mRNA expression, but inhibition of Akt in the stimulated cells 
led to upregulation of both mRNA. In addition, reduced Akt activity significantly 
reduced the transcription of Twist but has no effect on Snail. (B) Stimulation with 
100nM CRH for 24hrs resulted in increased Twist and Snail mRNA expression but 
inhibiting Akt activity in the stimulated cells further enhanced the CRH effect on both 
mRNA transcripts. Meanwhile, treatment with Akt inhibitor alone (5M) for 2hr has 
no effect on basal Snail expression but reduced basal Twist mRNA expression.  
181 
 
In addition, the effect of modulating SRPK1 activity by using the specific SRPK1 
inhibitor was also investigated. Basal expression of Twist mRNA was shown decreased 
when cells were treated with SRPK1 inhibitor at 10M for 2hr, but Snail mRNA 
expression remained unaffected suggesting that SRPK1 involves in the transcription of 
Twist (Figure 5.2). However, inhibiting SRPK1 activity has no effect on CRH-induced Twist 
and Snail mRNA expression, which further suggests that transcriptional effect of CRH on 
Twist and Snail does not dependent on SRPK1 activity. In addition, in cells where SRPK1 
was inhibited, CRH was shown to upregulate Twist and Snail mRNA expression, 
suggesting the potential involvements of other kinases in mediating CRH effect on the 
induction of EMT gene expression in MCF7 cells. 
 
 
 
 
 
 
 
 
Figure 5.2 The treatment with SRPK1 inhibitor (10M) for 2hr reduced basal Twist 
mRNA level but has no effect on Snail mRNA, and its inhibition in CRH- stimulated 
cells did not affect both mRNA expression. In cells where SRPK1 was inhibited, CRH 
was shown to induce Twist and Snail mRNA expression. 
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Furthermore, the expression of Twist and Snail was also investigated in SKBR3 
cell line. Cells were treated with CRH (100nM) for 24hrs, followed by RNA extraction and 
RT-qPCR analysis of Twist and Snail mRNA expression. Results showed that although CRH 
did not affect basal expression of both Twist and Snail mRNA, pre-treatment of the 
stimulated cells with Akt inhibitor (5M) for 2hr has led to nearly 3-fold increase of Twist 
and 1-fold increase of Snail mRNA expression in the cells suggesting that although Akt 
was not shown to be involved in the regulation of basal Twist expression, its activity 
restrains CRH effect on the transcriptional activity of Twist. In addition, this finding also 
suggests that Akt not only plays inhibitory role in the regulation of basal Snail mRNA 
expression, but also in the CRH-stimulated cells (Figure 5.3).  
Overall, these results demonstrated that while CRH has no effect on the basal expression 
of Twist and Snail in SKBR3 cell line, as compared to that in MCF7 cell line, the 
transcriptional activity of both Twist and Snail was upregulated when Akt was inhibited 
in stimulated cells of both cell lines, suggesting that Akt masks the role of either E2 or 
CRH in the regulation of EMT gene expression, Twist and Snail in MCF7 and SKBR3 cell 
lines. 
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Figure 5.3 The expression of EMT- associated gene, Twist and Snail mRNA in SKBR3 cell 
line. Cells were stimulated with CRH (100nM) for 24hrs, followed by RNA extraction and 
RT-qPCR. Results showed that CRH has no effect on basal transcriptional activity of Twist 
and Snail, however when the stimulated cells pre-treated with Akt inhibitor (5M, 2hr), 
the expression of Twist and Snail increased significantly. In addition, inhibition of Akt 
activity has no effect on basal Twist expression but has increased Snail mRNA expression 
by 1-fold. 
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5.2 Transcriptional regulation of Epithelial-Mesenchymal Transition 
(EMT) genes by CRH using EMT RT2 Profiler PCR Array 
Results so far have demonstrated that CRH and E2 can potential alter the 
expression of splicing factors; SR proteins and hnRNPA1, by modulating SRPK1 activity 
via Akt. This subsequently induces the production of CD44 splice variants, CD44s and 
CD44v6 and upregulates the expression of EMT genes, Twist and Snail, both of which 
signaling pathways are differentially dependent on Akt or SRPK1 kinase in MCF7 cell line 
(ER+ cells). Whereas in SKBR3 cell line (ER- cells), CRH was not shown to exert similar 
effect on the modulation of SRPK1 and splicing factors; SR proteins and hnRNPA1. 
However, the accumulation of both CD44 mRNA isoforms and differential expression of 
Twist and Snail in response to CRH were still observed. This suggests that CRH probably 
exerts it effect via different signaling route in this cell line, which eventually affecting 
CD44 splicing and promoting EMT gene expression, similar to that in MCF7 cell line. 
Therefore, having established the potential of CRH and E2 in inducing altered 
splicing event leading to elevated expression of known EMT-associated genes in the 
MCF7 cell line, the expression of other genes known to be involved in processes 
promoting EMT such as in cell adhesion, cytoskeletal remodeling and cell motility were 
further investigated in stimulated cells. In addition, as the transcription of Twist and 
Snail was demonstrated to be either unaffected or enhanced when either Akt or SRPK1 
was inhibited in CRH- stimulated cells, the impact of specific kinase inhibition on CRH 
signal transduction was also investigated. Therefore, MCF7 cells were treated with CRH 
(100nM) for 24hrs, with or without the presence of Akt (5M) or SRPK1 inhibitor (10M) 
before 500g of RNA was extracted, followed by qRT-PCR using the RT2 Epithelial- to- 
Mesenchymal Transition (EMT) Profiler PCR Array plate, consisting of 84 EMT-associated 
target genes. Changes were considered significant when p-value <0.05, and fold-change 
was greater than two. 
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Table 5.1 shows that out of 84 genes, three of them (MAP1B, OCLN, RGS2) were 
upregulated by two-fold following the treatment with CRH, as compared to untreated 
cells. These genes, especially MAP1B (Microtubule Associated Protein 1B) and RGS2 
(Regulator of G protein-coupled receptor signaling) have been demonstrated to be part 
of MAPK signaling pathway and were found overexpressed in the majority of breast 
cancers (364,365).  
 
 
 
 
 
 
 
 
 
 
 
Table 5.1 Untreated vs CRH. List of upregulated genes in the qRT-PCR analysis 84 
EMT-associated genes in ER+ breast cancer cells.  
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Additional experiment showed that inhibition of Akt activity in control cells led 
to significant increase of six (7%) of EMT-associated genes expression (VCAN, MMP3, 
MMP9, TFPI2, PTP4A1, ITGA5), while 20 genes (24%) were found significantly 
downregulated (Table 5.2), indicating a key role of Akt in numerous cellular signaling 
networks in the cells.  
 
 
 
Table 5.2 Untreated vs Akt Inhibitor. List of upregulated genes (Blue) and 
downregulated genes (Orange) in the qRT-PCR analysis 84 EMT-associated genes in ER+ 
breast cancer cells.  
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These results led to investigation on the actions of CRH in cells in the presence 
of Akt inhibitor. Table 5.3 shows the significant changes in EMT gene expression in 
response to the treatment, and the pie-chart displays percentages of genes affected 
with as much as 44% of them (37 out of 84) were found significantly high which mostly 
were the most representative markers known to be involved in the processes leading to 
EMT in cancer cells such as TGFB1, SNAI3, CTNBB1, NOTCH1 and WNT5A. Studies have 
shown that while TGFB plays role in growth inhibition and apoptosis, it can also 
contribute to tumor progression and metastasis through the induction of EMT once cells 
overcome the TGFB-induced anti-oncogenic responses (366). Notably, TGFB signaling 
can regulate and crosstalk with other signaling pathways such as Wnt/b-catenin and 
NOTCH pathway that leads to TGFB target genes such as Snail and MMP9, causing 
increased cell invasion and trans- endothelial migration (245,367). In addition, the role 
of Notch signaling has been known in inducing EMT, where elevated expression of Notch 
and its ligand Jagged-1 have been demonstrated in various cancers including breast 
cancer and the Notch receptor, NICD can activate the expression of genes such as Twist, 
Snail and ZEB1/2 that promote tumor development via NF-kB and Akt signaling (250). 
Furthermore, Twist expression has been reported to play role in the activation of 
WNT5A gene expression and subsequently leads to WNT5A-mediated EMT process in 
breast cancer cells (368).   
Furthermore, the results also showed that only 6% (5 out of 84) namely ITGA5, 
MMP3, MMP9, PTP4A1, VCAN was shown markedly suppressed under the treatment 
and apparently, these pattern of EMT gene expression were opposite with the pattern of 
expression when cells were treated with Akt inhibitor alone. This also indicates the 
change of direction in CRH signal transduction which probably involves other kinases, as 
studies on kinome proposed the existence of kinases network and their interplay that 
contributed to poor clinical outcome in ER+ breast cancer (57). Based on this data, we 
investigated potential interactions among the significantly altered genes by introducing 
these 42 up- and down-regulated genes into a molecular tool, STRING. The STRING 
analysis revealed that 34 out of 42 genes are closely connected in a single network, 
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demonstrating the tight relationship among the molecules (Figure 5.4). The interaction 
between each factor during the multiple signaling crosstalk can create feedback loops in 
the cells that either supports the EMT states or inhibit the process. For example, 
overexpression of Tissue Inhibitor of Metalloproteinases (TIMP1) and E-cadherin (CDH1) 
when Akt was inhibited in the stimulated cells might contribute to decreased expression 
of MMP-3 and MMP-9, which play role in the degradation of both matrix and non-matrix 
proteins in the extracellular matrix (ECM) during EMT and contribute to tumor cell 
migration (369). However, increased expression of TGFB can lead to the formation of 
heterodimeric complex via SMAD2, which then binds to DNA-sequence-specific 
transcription factors and activate the transcription of target gene such as SNAIL3 (370), 
which has been shown to repress E-cadherin (CDH1) expression in cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
189 
 
 
 
 
 
Table 5.3 Akt Inh. vs Akt Inh./CRH. List of upregulated genes (Blue) and 
downregulated genes (Orange) in the qRT-PCR analysis 84 EMT-associated genes in 
ER+ breast cancer cells.  
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Figure 5.4 STRING analysis of known and predicted protein interactions existing 
among the 42 significantly altered gene expression in cells simultaneously treated 
with Akt inhibitor and CRH as compared against cells treated with Akt Inhibitor only. 
The analysis shows that 34 out of 42 altered EMT gene signatures expression are 
closely connected in a single network. 
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Table 5.4 summarises and compares the results from EMT gene profiler array 
experiment between untreated cells, Akt inhibited cells and CRH-stimulated cells. 
Overall, these findings suggest that basal expression of most EMT-associated genes was 
not much affected by CRH. However, the inhibition of Akt kinase led to up- and down-
regulation of numerous EMT gene transcription, suggesting its key role in EMT-related 
intracellular signaling pathways such as Wnt/-catenin and TGF pathways. This finding 
suggests that Akt blocked the CRH-driven upregulation of EMT genes such as GSK33b, 
SNAI3 and SMAD2. Interestingly, CRH was demonstrated to reverse the effects of Akt 
inhibition on basal expression of VCAN, MMP3, PTP4A1 and ITGA5. 
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Table 5.4 Summary of the EMT gene expression pattern in response to various 
treatments in MCF7 cells. Blue represents Increased expression, while Red represents 
Decreased expression.  
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Additionally, the impact of inhibiting SRPK1 on the transcriptional activity of 
EMT-associated genes was also investigated. Table 5.5 shows that reduced SRPK1 
activity resulted mainly in reduced level of nine EMT genes (11%); BMP7, CAV2, COL3A1, 
EGFR, KRT19, NOTCH1, TGFB2, VPS13A and WNT5A. Previous studies have shown that 
some of these genes such as BMP7, EGFR, NOTCH1 and WNT5A are targets of TGF 
signaling pathway, or they are part of signaling pathways that is directly or indirectly 
associated with TGF pathway. BMP7 is a member of bone morphogenic proteins 
(BMPs) family that can function as TGF ligand, and activate TGF signaling pathway by 
binding to TGF receptors (371). Furthermore, genes such as NOTCH1, TGFB and WNT5A 
represent the most well-established signaling pathways involved in processes that 
promote EMT, suggesting that SRPK1 kinase play role in the induction of these pathways 
in ER+ cells.  
Comparison between the impact of inhibiting either Akt or SRPK1 in the cells 
demonstrated that Akt regulates 26 of 84 EMT, whereas SRPK1 regulates 9 of them 
(Table 5.6). Interestingly, some of the genes from both group are overlapping which 
includes CAV2, COL3A1, KRT19, NOTCH1, TGFB2, and WNT5A, suggesting that the 
transcriptional regulation of these EMT genes involves both kinases. 
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Table 5.6 Comparison between the pattern of expression when cells were treated 
with either Akt or SRPK1 inhibitor vs untreated cells.  Blue represents Increased 
expression, while Red represents Decreased expression. 
Table 5.5 Untreated vs SRPK1 Inhibitor. List of downregulated genes in the qRT-PCR 
analysis 84 EMT-associated genes in ER+ breast cancer cells.  
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Moreover, when SRPK1 was inhibited in CRH- stimulated cells, 27 EMT genes 
were upregulated, including the nine genes that were downregulated in cells treated 
with SRPK1 inhibitor alone. This result suggests that CRH can reverse the effect of SRPK1 
inhibitor, and CRH can potentially divert its signal through other kinase and thus 
modulating transcriptional activity of various other EMT genes, as lister in Table 5.7.   
 
 
 
 
Table 5.7 SRPK1 Inh. vs SRPK1 Inh/CRH. List of upregulated genes (Blue) and 
downregulated genes (Orange) in the qRT-PCR analysis 84 EMT-associated genes 
in ER+ breast cancer cells.  
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5.3 Analysis of cell invasion and migration properties in stimulated 
cells  
In addition to altered expression pattern of EMT signatures, we determined the change 
in cell motility, another functional characteristic of EMT to determine whether the 
changes in gene expression were translated into altered biological responses. Cell 
proliferation and invasion were determined by using Xcelligence system, as described in 
Chapter Method 2.10. This is a label-free and real-time impedance-based assay systems 
with the plates designed to contain inter-digited gold microelectrodes to monitor the 
viability of cultured cells (372).  The electrical impedance of the cell population was 
measured by electrodes in each well, and this measurement provides quantitative 
information about the status of the cells. Seeding concentration was determined prior to 
experiment and we determined that the optimum cell seeding density to monitor cell 
behavior of both MCF7 and SKBR3 cells is 40,000 cells/well.  
For cell proliferation study, cells were seeded in E-plate 16 and the cells were 
automatically monitored every 15min over 24hr before stimulants were added and the 
cell behavior in response to the treatments was monitored continuously using RTCA for 
another 24hr and expressed as CI (Cell Index) value. Likewise, for the invasion study, 
cells were treated with stimulant in serum-free media (SFM) 24h prior to experiment 
and 4x104 cells were seeded in a 10% (v/v) Matrigel-coated (to simulate extracellular 
matrix in tissues and to provide layer which the cells would have to invade) CIM-plated 
16. Epidermal Growth Factor (EGF) in SFM was used as chemoattractant in the lower 
chamber and the cells were monitored from 0-8 hr with untreated cells served as control 
(in all experiments). 
 In line with previous findings on the role of E2 in promoting cancer cell 
proliferation (373–376), our MCF7 results in Figure 5.5A shows a slight increase in 
proliferation when treated with  E2 at 10nM. In addition, the treatment with Akt 
inhibitor alone led to the reduction of cell proliferation, and inhibition of Akt kinase was 
also shown to reduce the cell proliferation in E2- and CRH- stimulated MCF7 cells (Figure 
5.5B and 5.5C). In addition, CRH was shown to promote cell proliferation properties via 
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Akt in SKBR3 cells (Figure 5.5D). Overall, these findings suggest that E2 promote MCF7 
cell proliferation properties, and the presence of Akt inhibitor blocks the effect of E2 on 
cell proliferation, whilst CRH via Akt, promotes cell proliferation in ER- cells but not ER+ 
cells. 
 
 
 
 
 
 
 
Figure 5.5 (A) MCF7 cells were stimulated with E2 or CRH alone at 10nm and 100nm 
for 24hr respectively and cell proliferation was determined by using Xcelligence 
system. (B) & (C) Stimulated MCF7 cells were co-treated with Akt-inhibitor, MK-2206 
at 5M for 2hrs (D) SKBR3 were treated with CRH, 100nM in the presence or absence 
of Akt Inhibitor and cells index were measured. 
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Next, we investigated the potential of CRH in promoting breast cancer invasion 
following their potent effect in regulating the transcriptional activity of various EMT-
associated genes. Figure 5.6 shows that, consistent with non-invasive property of MCF7 
cells, the untreated MCF7 cells shows limited invasive potential which gradually 
decreasing over time. Consistent with previous report (104), our data shows that CRH 
promotes the invasion of MCF7 cells in vitro, possibly by inducing the expression of 
matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9)(139). This effect is somewhat 
different from earlier finding by Lal et.al (141) which could be explained by different 
experimental conditions used and variability in the cell passage number. In addition, as 
reduced Akt kinase in CRH-stimulated triggered the transcription of several EMT genes, 
our data shows that it resulted in increased cell migration properties but showed no 
effect on the invasion properties of the stimulated cells (Figure 5.7). Meanwhile, 
reduced SRPK1 kinase dampened CRH effect on cell migration and invasion (Figure 5.6 
and Figure 5.7), an observation that agrees with reports regarding the role of SRPK1 as 
one of  cancer metastasis  determinants (193,377).  
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Figure 5.6 Cell Invasion assay measured with xCELLigence system.  MCF7 cells were 
treated with 100nM CRH for 24hr, in the presence or absence of either Akt inhibitor 
(5M) or SRPK1 inhibitor (10M). Data represent mean ±SEM of at least two 
independent biological replicates measured in triplicates. 
200 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 Cell migration assay of MCF7 treated with 100nM CRH for 24hr, in the 
presence or absence of either Akt inhibitor (5M) or SRPK1 inhibitor (10M).  
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Additionally, slightly different pattern of cell invasion property was observed in 
ER- cells SKBR3, in which CRH did not potentiate the invasive properties of cells, and 
inhibition of Akt kinase in the stimulated cells seemed showed no effect on the invasive 
properties of the cells (Figure 5.8).  Notably, inhibition of SRPK1 significantly decreased 
the cell invasion in CRH-induced cells, consistent with the finding from Roosmalen etc al 
which demonstrated that depleting the SRPK1 activity in ER- mammary carcinoma 
(mouse) completely abolished the metastatic potential of the cells (193).  
 
 
 
Figure 5.8 Cell Invasion assay measured with xCELLigence system.  SKBR3 cells were 
treated with 100nM CRH for 24hr, in the presence or absence of either Akt inhibitor 
(5M) or SRPK1 inhibitor (10M). Data represent mean ±SEM of at least two 
independent biological replicates measured in triplicates 
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In addition, the action of CRH was further investigated by pre-treatment with 
either CRH-R1 antagonist (NBI 27914) or CRH-R2 antagonist (Asstressin-2B) in ER+ MCF7 
cell line. Results showed that blocking the CRH-R1 resulted in significantly reduced cell 
invasion as compared to the invasion properties when MCF7 cells were pre-treated with 
CRH-R2 inhibitor (Figure 5.9), suggesting that CRH may promote invasive properties of 
ER+ cells via CRHR1.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9 Cell Invasion assay measured with xCELLigence system. MCF7 cells were 
pre-treated with either CRH-R1 inhibitor (NBI 27914) or CRH-R2 inhibitor (Asstressin-
2B) before stimulation with 100nM CRH for 24hr. Data represents mean ±SEM of at 
least two independent biological replicates measured in triplicates. 
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Discussion  
 
The association between increased CD44 splice variants and EMT induction in breast 
cancer cells 
One of the types of Epithelial-to- mesenchymal transition (EMT) in organism 
involves the conversion of epithelial cells to migratory and invasive cells. Growing 
evidence also reveal that EMT event can be supported by three regulatory events; small 
non-coding RNAs, differential splicing and translational and post-translational control 
which influence protein stabilisation and localisation (378). Studies have shown evidence 
on how splicing can trigger EMT through post- transcriptional mechanism such as 
alternative pre-mRNA splicing. Examples of the target genes that have been identified to 
be affected by altered splicing hence producing oncogenic variants that can trigger EMT 
are CD44, FGFR2, RON, and CTNND1.  
 
Therefore, this study investigated the possibility of hormone- induced alteration 
of splicing factors activity leading to accumulation of CD44s and CD44v6 splice variants 
and activation of processes leading to EMT by examining the expression of selected 
known EMT markers i.e. Twist and Snail in cellular models of ER+ and ER- breast cancer 
cells. Previously, it was shown that while both splice isoforms contribute to cancer 
progression, CD44s expression was found to be more strongly linked with breast cancer 
metastasis, as this isoform was found highly expressed in TGF-induced EMT and 
showed positive correlation with EMT marker, ZEB1, and ALDH1, one of the malignant 
stem cells biomarkers (164,260). Meanwhile, high level CD44v6 has been demonstrated 
to play crucial role in the acquisition of metastatic features in human carcinoma cells 
such as colorectal and pancreatic carcinoma (256–258,262), and in the promotion of cell 
motility in breast cancer cells (379).  
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This thesis found that the expression of Twist and Snail were positively 
correlated with the level of CD44s and CD44v6 in ER+ cells, in which the expression of 
these EMT markers were increased in stimulated cells, especially in cells treated with 
CRH, and Twist and Snail mRNA expression was enhanced when the stimulated cells 
were pre-treated with AKT kinase inhibitor. Akt kinase is a downstream target of the 
PI3K/AKT pathway, and plays important role in cancer cell survival, cell cycle entry and 
glucose metabolism, and  alterations in this signaling route are frequently found in 
cancer such as breast cancer (83,85,380). The PI3K/AKT pathway is activated often by 
signals from extracellular stimuli that activate receptor tyrosine kinases (RTKs) and G 
protein-coupled receptors (GPCRs) (381). The regulation of signaling downstream this 
pathway is highly complex and multifaceted, in which Akt regulates its downstream 
effectors by two general mechanisms; acute regulation through post-translational 
modification by phosphorylating its substrates, thus controlling their activity and 
localization, and through long-term changes in cellular behaviour by phosphorylation, 
hence affecting the activity of various transcription factors (381). Therefore, while Akt 
was shown to play a role in the transcription of basal Twist expression, this result from 
this study shows that it may not involve in the E2- and CRH- induced signaling 
mechanism that leads to increased transcriptional activity of Twist and Snail mRNA. This 
reflects that there probably be a convergence of signaling machinery in stimulated cells 
where Akt is inhibited in ER+ cells.  
 
This finding supports the hypothesis made from earlier finding in CD44 splicing 
assay that, whilst Akt was demonstrated to play major part in this signaling pathway 
leading to cancer progression and activation of EMT- associated genes, this study 
somehow shows that blockade of its signaling cascade  may lead to similar or a more 
unfavourable effect due to potential signal diversion or the presence of compensatory 
loops that may trigger activation of various other protein effectors or signaling networks 
in the cells. The difference in Twist and Snail mRNA expression in response to each 
treatment in MCF7 cells was as illustrated in Figure 5.10. 
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Figure 5.10 Illustration of differential expression of splicing factors, CD44s and CD44v6 
splice variants, and Twist/Snail mRNA expression when cells were treated with either E2 
or CRH, in the presence or absence of Akt inhibitor in MCF7 cells. 
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Interestingly, although reduced SRPK1 activity in the stimulated cells resulted in 
significantly reduced level of CD44v6 variant, this did not affect the expression of Twist 
and Snail as illustrated in Figure 5.11, which may further suggest that the upregulation of 
Twist and Snail previously found in the stimulated cells was due to the increased amount 
of CD44s in the cells, but not CD44v6. This finding is therefore consistent with growing 
evidence that CD44s plays more significant role in the cancer metastasis, as it was 
revealed that isoform switching from CD44v to CD44s and increased ratio of 
CD44s/CD44v mRNA is required to accelerate EMT in breast cancer cells (145). The 
demonstrated higher level of CD44s than CD44v6 mRNA in stimulated cells with reduced 
AKT or SRPK1 kinase, may also indicate that isoform switching was taking place in the 
cells, and that cells were stimulated towards becoming more mesenchymal type than 
the non-stimulated counterparts in the ER+ breast cancer cells. In addition, the 
comparison between estrogen and CRH mechanism of action in regulating splicing 
proteins in MCF7 is as shown in Table 5.8. 
 
Figure 5.11 Illustration of differential expression of splicing factors, CD44s and CD44v6 
splice variants, and Twist/Snail mRNA expression when cells were treated with CRH, in 
the presence of SRPK1 inhibitor in MCF7 cells. 
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Table 5.8 Comparison between E2 and CRH action in MCF7 cells. 
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Furthermore, in the CRH- stimulated ER- SKBR3 cells, similar finding was also 
observed regarding the correlation between CD44s level and the induction of EMT gene 
expression, Twist and Snail, in which, the expression of these EMT markers was 
positively correlated with CD44s level, but not CD44v6, regardless of AKT kinase activity 
(Figure 5.12). The correlation between CD44s and Snail expression has also been 
described in previous studies, in which Snail was shown as one of CD44s targets in 
cancer cells (363).   This result may also suggest that CD44v6 does not influence the 
transcriptional activity of Twist and Snail in ER- cells. Additionally, the difference in CRH 
actions in MCF7 and SKBR3 is compared in Table 5.9. 
 
  
 
 
 
 
 
Figure 5.12 Illustration of differential expression of splicing factors, CD44s and 
CD44v6 splice variants, and Twist/Snail mRNA expression when cells were treated 
with CRH, in the presence or absence of Akt inhibitor in SKBR3 cells. 
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Table 5.9 Comparison of CRH action in MCF7 cells and SKBR3 cells. 
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Profiling of 84 EMT gene transcription regulated by CRH in MCF7 cells 
As CRH has been demonstrated to potentially induce EMT genes expression in 
breast cancer cells, the effects of CRH as well as the impact of inhibiting either Akt or 
SRPK1 kinase in the stimulated cells on the transcriptional regulation of 84 selected EMT 
signature genes were further interrogated using human EMT genes profiling PCR array. 
This can provide information about the expression of groups of EMT genes that may be 
co-ordinately regulated in ER+ cells. This assay can also reveal the correlation between 
differential expression of these genes and the change in cells behaviour undergoing EMT 
such as increased proliferation, migration or invasion.  
In this study, using fold change of >2.0 and p-value <0.05 to determine 
significant differences in mRNA expression between two groups, it was found that 
untreated cells showed increased transcription of VCAN, MMP3, MMP9, TFPI2, PTP4A1 
and ITGA5 when AKT was inhibited in the cells. These genes such as VCAN and MMPs 
involve in extracellular matrix (ECM) for example in the regulation of intercellular 
signaling and cells communication with ECM, as well as in the proteolysis of ECM, 
respectively. Increased expression of these genes has been found to correlate with 
increased cancer cells growth, differentiation, and migration. As expected, many more 
EMT genes were found downregulated, some of which were the most representative 
markers of EMT such as TIMP1, TGFB2, NOTCH1, KRT19, ERBB3, CTNNB1, and WNT5A 
suggesting the important role of Akt in signaling pathways leading to activation of these 
genes in cells. In addition, while NOTCH1 and WNT5A overexpression is well known 
driver in metastasis, decreased expression of KRT19 has been found to be strongly 
associated with the promotion of metastasis, whereas the mesenchymal phenotype of 
some cancer cells were shown to have loss ERBB3 leading to increased tumour survival 
(365). This finding indicates the major role of AKT in various cell signaling pathways 
leading to cancer progression and a potential presence of feedback loops that leads to 
the activation of alternative signaling pathways, when AKT kinase was inhibited.  
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In addition, growing evidence has demonstrated the central role of SRPK1 in the 
regulation of splicing mechanism in cells. Alterations in its expression can lead to 
pathogenesis of many diseases such as cancer and cancer metastasis, for examples, its 
overexpression has been shown to inhibit apoptosis in breast cancer cells through 
aberrant splicing of RBM4 mRNA (192), and increased SRPK1 expression is also 
correlated with angiogenesis, through aberrant splicing of VEGF (187). In addition, other 
than cancer, upregulation of SRPK1 activity has also been shown to promote alternative 
splicing of Tau gene, resulting in the pathogenesis of Alzheimer disease (183).  The 
profiling of EMT- associated gene expression from this study demonstrated that while 
none of the EMT gene expression were found upregulated, basal expression of COL3A1, 
TGFB2, CAV2, BMP7, KRT19, WNT5A, NOTCH1, EGFR and VPS13A were reduced when 
SRPK1 kinase was inhibited, suggesting that SRPK1 directly or indirectly involves in the 
transcription of these genes in the cells. Interestingly, some of these downregulated 
genes namely CAV2, COL3A1, KRT19, NOTCH1, TGFB2 and WNT5A were found 
commonly downregulated in cells where Akt was inhibited (Figure 5.13), suggesting that 
the activation of these gene expression probably follows the Akt-SRPK1 axis, a network 
proposed in previous studies (190). In addition, this finding also suggests that 
transcriptional effect of SRPK1 on BMP7, EGFR and VPS13A is independent of Akt in ER+ 
cells.   
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Figure 5.13 Diagram shows the list of downregulated EMT genes in response to the 
treatment with Akt inhibitor or SRPK1 inhibitor in MCF7 cells, each was compared to 
untreated cells. Commonly downregulated genes are shown in the overlapped 
region. 
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Furthermore, the expression of Occludin, OCLN (2.007-fold), RGS2 (2.0019-fold), 
and MAP1B (2.0019-fold) was found upregulated in response to CRH treatment. 
Occludin is a tight junction transmembrane protein and plays a role in the formation and 
regulation of the tight junction permeability barrier. In addition, gene encodes for the 
regulator of G protein- coupled receptor, RGS2 and gene important in the regulation of 
cytoskeletal re-organisation in the cells, MAP1B were also increased. Notably, when Akt 
was inhibited in these stimulated cells, the expression of VCAN (30.7-fold), MMP3 (15.4-
fold), MMP9 (3.74-fold), PTP4A1 (2.64-fold) and ITGA5 (2.62-fold) was found 
downregulated. Interestingly, the fact that these genes were found upregulated when 
Akt was inhibited in control cells suggests that CRH can reverse the effects of Akt 
inhibitor on the activation of these gene expression. In addition, NOTCH1, KRT19, ERBB3, 
WNT5A and 33 other EMT markers such as ILK, TGFB1, IL1RN, CTNNB1 (-catenin) and 
GSK3B were found upregulated in these cells. This finding suggests that while CRH alone 
was shown not able to modulate GSK3B and -catenin gene expression, inhibiting the 
activity of AKT kinase in the cells resulted in significant increased expression of both 
genes, suggesting that Akt masks the transcriptional effect of CRH, through CRH- 
receptors (CRH-R), on the above-mentioned mRNA transcripts.  
This gene expression result is in line with findings from previous student in this 
group, which showed that at protein level, AKT was demonstrated to restrain the 
inhibitory effects of CRH, through CRHR1, on -catenin though a  potential converging 
mechanism involving AKT, GSKB and the Wnt signaling pathway in ER+ breast cancer 
cells (141). In addition, as the expression of these upregulated genes were not found 
increased in CRH- stimulated cells, it also suggests that CRH can drive the transcriptional 
regulation of these genes, but its effect was blocked by Akt in the cells. As illustrated in 
Figure 5.14, among other upregulated genes found when Akt was inhibited in stimulated 
cells were the MAP1B, OCLN, and RGS2, which suggests that the transcription of these 
three genes by CRH is independent of Akt activity in the cells.  
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Figure 5.14 Comparison between upregulated and downregulated EMT genes 
between cells treated with Akt inhibitor alone and in CRH-stimulated cells when Akt 
was inhibited.  
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Moreover, when SRPK1 was inhibited in the stimulated cells, 27 genes such as 
VIM, STAT3, and MMP9 were found upregulated. Vimentin (VIM) is a widely used 
marker for cells undergoing EMTs that take place during embryogenesis and metastasis 
(382), whilst STAT3 activation has been shown to contribute to resistance to apoptosis in 
breast cancer cells though the NF-kB pathway activation (383). Apparently, these 
upregulated genes also included all the genes that were found downregulated when 
SRPK1 was inhibited in the control cells. This result suggests that CRH can reverse the 
inhibitory effects of SRPK1 inhibitor on the transcription of those genes in the ER+ cells. 
Notably, results from this experiment showed that the expression of most of the EMT 
genes were significantly affected when Akt or SRPK1 was inhibited in the cells, as shown 
in Table 5.10, suggesting the direct or indirect roles of these kinases in regulating cellular 
processes leading to the transcription of various EMT genes in the cells.  
 
 
 
 
Table 5.10 Comparison in EMT gene expression profile when stimulated cells were 
treated with either Akt inhibitor or SRPK1 inhibitor. 
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Impacts of differential expression of EMT genes on cell migration and invasion 
properties 
In addition to EMT profiling, functional assays to monitor the association of 
cancer cells behaviour with the expression of various EMT genes studied were 
performed. In line with previous findings, this study demonstrated that E2 promoted 
MCF7 cell proliferation, but CRH has no proliferative effect in MCF7 cells (384). In 
addition,  consistent with the downregulation of the majority of EMT genes in basal cells 
when Akt was inhibited, which some of them play roles in cell growth and proliferation 
such as ERBB3 and KRT19 (365), reduced cell proliferation ability was displayed in these 
cells, as well as in the stimulated cells with reduced Akt activity.  
 
Previous studies have demonstrated discrepancies in CRH role in tumor 
progression, which some have shown that CRH induces colon cell survival and 
proliferation via NF-kB and STAT3 pathway (137), and it was also revealed to promote 
cell migration and invasion in breast cancer and prostate cancer via CRHR1 
(103,104,138). In other studies, CRH was found to inhibit invasion in breast cancer (291), 
and cell growth and proliferation in human endometrial carcinoma (101), hepatocellular 
carcinoma (106) and in dermal fibroblast (107). This thesis has demonstrated that in 
agreement with findings from Androulidaki et.al (104), that while CRH via Akt, did not 
promote breast cancer cells proliferation, it was shown to induce cell migration and 
invasion in ER+ MCF7 cells. Notably, the increased in cell migration and invasion 
observed in the stimulated cells might be explained by the elevated level of Snail which 
was shown to contribute to tumor cell migration and invasion via NF-kB pathway in 
cancer cells (385).   
 
Furthermore, a slightly different effect of CRH was observed in ER- SKBR3 cells, 
in which CRH via Akt was shown to promote cell proliferation. However, it showed no 
effect on SKBR3 cells invasion, which again correlated with unaffected expression of 
Snail in the cells. 
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Previous studies have revealed that SRPK1 is one of the key determinants in cancer 
metastasis, as it was shown to promote cell proliferation, migration and invasion in 
ovarian cancer, prostate cancer and breast cancer (193,386,387). Follow up experiment 
on cellular behaviour in cells where SRPK1 was inhibited showed that the cell migration 
and invasion properties was decreased in MCF7 cells. This observation might be 
associated with downregulation of EMT genes, such as KRT19, BMP7, NOTCH1, and 
TGFB2 which were shown to be positively correlated with growth and invasive ability of 
cancer cells (365,388,389). This finding may suggest that SRPK1 may enable cancer cells 
to acquire invasive ability through the activation of EMT-associated signaling pathways 
such as TGF, NOTCH and Wnt signaling whose role in cell motility has been widely 
demonstrated in various cancers.  In addition, in cells where SRPK1 was inhibited, CRH 
was shown to reverse the effect of SRPK1 inhibitor, leading to the upregulation of 
KRT19, BMP7, and MMP3 and subsequently resulted in a slight increase of cell invasion 
index. Notably, reduced invasion property was also demonstrated in SKBR3 cells when 
SRPK1 was inhibited in stimulated cells suggesting that SRPK1 can promote cell invasion 
in both ER+ and ER- cells. 
Additionally, when the action of CRH was further investigated by pre-treating 
stimulated cells with CRH receptors inhibitors, CRH-R1 inhibitor (NBI 27914) or CRH-R2 
inhibitor (Asstressin-2B), it was found that cell invasion was reduced when CRHR1 was 
blocked, as compared to cells where CRHR2 was inhibited, in both breast cancer 
subtypes.  Interestingly, proteome analysis using Nano-flow UltraHPLC in cells depleted 
with SRPK1 kinase showed that GNAS2, a protein important in the activation of 
adenylate cyclase activity by G protein signaling pathway was found downregulated 
(data not shown). Furthermore, phosphosite analysis in these cells also demonstrated 
reduced detection of signal specific for phosphorylation site of corticotropin- releasing 
hormone receptor (CRH-R1/R2) at Tyrosine 208 position (data not shown). These 
findings may possibly suggest that SRPK1 kinase might potentially regulate the activity of 
CRH receptors, in which reduced phosphorylation of these receptors might lead 
attenuation of the receptors signaling activity, and thus leading to reduced pro- 
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migration and invasion effects of CRH in breast cancer cells. However, further studies are 
needed to verify this finding. 
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CHAPTER 6 
Discussion  
Recent studies have found that pre-mRNA splicing patterns are frequently 
altered in cancer, and in addition to mutations that alter mRNA splicing, altered 
expression of splicing-regulating proteins can also promote oncogenesis. In addition, 
alterations in alternative splicing are also evident in cells undergoing epithelial- to- 
mesenchymal transition (EMT) program. Notably in breast cancer, the role of hormones 
such as estrogen in the pathogenesis of the disease has been well- established. 
Additionally, hormonal stress response is also associated with cancer biology and studies 
on the role of stress hormones, such as corticotropin-releasing hormone (CRH) in breast 
cancer show the complexity of its actions in cancer development. Therefore, this study 
was set out to assess the potential role of key hormones (Estrogen and CRH) and their 
key molecular pathways in promoting cancer progression through the mechanism of 
pre-mRNA alternative splicing and epithelial-to-mesenchymal transition EMT) event in 
cellular models of breast cancer.  
 
This study has demonstrated that estrogen (E2) and CRH can potentially alter 
proteome profiles in ER+ MCF7 cell line, through the modulation of a key kinase in 
mRNA splicing mechanism, Serine- Arginine Protein Kinase 1(SRPK1). The effects of both 
hormones on SRPK1 activity and nuclear translocation resulted in increased 
phosphorylation level of serine- arginine (SR) proteins and hnRNPA1 expression, leading 
to altered CD44 mRNA splicing hence increased production of CD44 splice isoforms, 
CD44s and CD44v6 in ER+ cells. Furthermore, increased level of CD44 splice variants, 
particularly CD44v6 in CRH-stimulated cells correlated with upregulation of epithelial-to- 
mesenchymal transition (EMT)-associated gene expression Twist/Snail and increased cell 
migration and invasion properties in the stimulated cells.  
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Additionally, EMT gene profiling analysis revealed that in addition to Twist and 
Snail, CRH was able to enhance the transcriptional activity of several other prominent 
EMT markers such as VIM, TGFB1/2, NOTCH1, MMP9 and Wnt5A when either Akt or 
SRPK1 kinase was inhibited in the cells, potentially due to convergence in signaling 
mechanism in the cells. In the ER- SKBR3, CRH has no effect on SRPK1 nuclear 
translocation thus leading to unchanged level of SR proteins phosphorylation and 
hnRNPA1 expression. Notably, differential expression of CD44 splice isoforms were still 
demonstrated in the cells, and increased cell invasion was also observed, indicating that 
CRH exerted its effect in these cells via different signaling mechanism that enabled the 
cells to acquire invasive properties, one of the hallmarks of EMT. 
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Conclusions and future works 
Accumulating evidence suggests that aberrant alternative splicing is linked to 
various diseases including cancer. Mutations or alterations in the activity of splicing-
related proteins can influence the splicing pattern of susceptible target genes, hence 
producing oncogenic gene isoforms. It has been reported that altered pre-mRNA splicing 
accounts for at least 15% of human diseases such as cystic fibrosis, spinal muscular 
atrophy, as well as it can induce proliferative and invasive properties in cancer cells 
(390,391).  
This thesis explored the possibility of a female sex hormone, estrogen and 
stress-associated hormone, CRH to trigger aberrant splicing event and EMT program in 
breast cancer cells. One of the main contributions of this work is to discover that both 
hormones can upregulate splicing kinase, SRPK1, which is one of the central switches in 
alternative pre-mRNA splicing program. This finding has therefore led to deeper 
investigation on the processes and the key molecular factors involved that lead to 
alteration in pre-mRNA splicing by using CD44 as reporter gene. The relationship 
between hormone-induced alternative splicing and activation of epithelial-to-
mesenchymal transition (EMT) program was also addressed, in which, accumulation of 
CD44 splice variants positively correlated with EMT gene expression. Another 
contribution of this study is the fact that CRH can potentially divert its signaling pathway 
during the transcriptional regulation of EMT gene whenever Akt or SRPK1 kinase activity 
was inhibited. This emphasizes the complexity of CRH signaling in cancer cells, which 
may probably involve cross-talks with several other molecular networks and eventually 
trigger the transcription of various other EMT signature genes in breast cancer cells.  
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Future works 
Findings from this study were obtained from experiments using breast cancer cell lines 
as models to investigate the potential role of hormones (estrogen and CRH) in 
promoting cancer progression via alternative pre-mRNA splicing event and EMT program 
in the cells. Therefore, for the future works, animal models (in vivo) could be used to 
strengthen and complement these findings. In addition, a recently-developed and 
improved molecular biology tool such as CRISPR/Cas9 system can be utilized for targeted 
genome editing to ensure more efficient downregulation/silencing (time-wise, 
reversible, more than one targets at a time) of genes of interest.  
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